20-F

As filed with the Securities and Exchange Commission on June 18, 2009

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 20-F

o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2008

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to

o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 1-14398

SHAMIR OPTICAL INDUSTRY LTD.
(Exact name of registrant as specified in its charter)

N/A		Israel
(Translation of registrant's		(Jurisdiction of incorporation
name into English)		or organization)
	Kibbutz Shamir Upper Galilee 12135 Israel (Address of principal executive offices)

Mr. David Bar-Yosef, General Counsel
Telephone Number: +972-4-6947810; E-Mail: davidby@shamir.co.il,
(Name, Telephone, E-mail and/or Facsimile number and Address of the Registrant's Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each class:	Name of each exchange on which registered:
Ordinary Shares, par value NIS 0.01 each	NASDAQ Global Market

Securities registered or to be registered pursuant to Section 12(g) of the Act: None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: 16,423,740 Ordinary Shares, 0.01 NIS par value each.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes o No x

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes o No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o Accelerated filer o Non-accelerated filer x

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP x International Financing Reporting Standards as issued by the International Accounting
Standards Board o
Other o

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow :

Item 17 o Item 18 o

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

TABLE OF CONTENTS

CERTAIN DEFINED TERMS			1
FORWARD-LOOKING STATEMENTS			1
PART I			2
	ITEM 1.	IDENTITY OF DIRECTORS; SENIOR MANAGEMENT AND ADVISERS	2
	ITEM 2.	OFFER STATISTICS AND EXPECTED TIMETABLE	2
	ITEM 3.	KEY INFORMATION	2
	ITEM 4.	INFORMATION ON THE COMPANY	18
	ITEM 4A.	UNRESOLVED STAFF COMMENTS	33
	ITEM 5.	OPERATING AND FINANCIAL REVIEW AND PROSPECTS	34
	ITEM 6.	DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES	48
	ITEM 7.	MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS	58
	ITEM 8.	FINANCIAL INFORMATION	66
	ITEM 9.	THE LISTING	67
	ITEM 10.	ADDITIONAL INFORMATION	69
	ITEM 11.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	82
	ITEM 12.	DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES	82
PART II			83
	ITEM 13.	DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES	83
	ITEM 14.	MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS	83
	ITEM 15T.	CONTROLS AND PROCEDURES	84
	ITEM 16.	[RESERVED]	85
	ITEM 16A.	AUDIT COMMITTEE FINANCIAL EXPERT	85
	ITEM 16B.	CODE OF ETHICS	85
	ITEM 16C.	PRINCIPAL ACCOUNTANT FEES AND SERVICES	85
	ITEM 16D.	EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES	86
	ITEM 16E.	PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS	86
	ITEM 16F.	CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT	86
	ITEM 16G.	CORPORATE GOVERNANCE	86
PART III			87
	ITEM 17.	FINANCIAL STATEMENTS	87
	ITEM 18.	FINANCIAL STATEMENTS	87
	ITEM 19.	EXHIBITS	87

CERTAIN DEFINED TERMS

        In this annual report, unless otherwise provided, references to “Shamir,” “we,” “us” and “our” refer to Shamir Optical Industry Ltd. (or its predecessor or successor entities) and its subsidiaries, and references to our company refer to Shamir Optical Industry Ltd. (or its predecessor or successor entities) without its consolidated subsidiaries. The terms “Euro,” “EUR” or “€” refer to the common currency of the member states of the European Union, “NIS” refers to New Israeli shekel, and “dollar,” “USD” or “$” refers to U.S. dollars.

        We own rights directly or through our subsidiary Shamir Insight Inc. (“Shamir Insight”), in the following trademarks in various jurisdictions world-wide: Shamir™, Shamir logo, Shamir Genesis™, Genesis™, Shamir Piccolo™, Piccolo™, Shamir Office™, Shamir Creation™, Shamir Autograph™, Autograph™, Shamir Attitude™, Attitude™, Prescriptor™, Eye Point Technology™, Freeform™, Freeform Lenses™, Freeform Technology™, Freeform Software Protocol™ Panorama™, Eye Point™, Direct Lens Technology™, Autograph Golf™, Autograph Short™, Autograph Everyday™, Piccolo Wrap™, The Progressive Lens Experts™, Titan Hardcoat™, Deskvision™, Individual Eyes™, Recreating Perfect Vision™, Multispace™, Shamir Nano™, Piccolo Nano™, Autograph Nano™, Shamir Relax™, Autograph Relax™, Sport Attitude™, Shamir Smart Office™, Shamir Smart Attitude™, Shamir Smart Single Vision™, Shamir Freeform Geometry™ and Shamir Freeform Cosmetics™. Our main trademarks are registered or are in the process of being registered in the U.S., the European Union, Canada and additional countries. All other trademarks or brand names referred to in this annual report are the property of their respective owners.

FORWARD-LOOKING STATEMENTS

        This annual report includes forward-looking statements. Forward-looking statements may be, but are not necessarily, identified by words like “believe,” “anticipate,” “intend,” “target,” “estimate,” “plan,” “assume,” “may,” “will,” “should,” “could” and similar expressions. Forward-looking statements also include statements containing a projection of revenues, earnings or losses, capital expenditures, dividends, capital structure or other financial terms.

        The forward-looking statements in this annual report are based upon our management’s beliefs, assumptions and expectations of our future operations and economic performance, taking into account currently available information. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known to us, that may cause our actual results, performance or financial condition to be materially different from the expectations of future results, performance of financial condition we express or imply in any forward-looking statements. Some of the important factors that could cause our actual results, performance or financial condition to differ materially from expectations are:

— the effects of competition in our industry, and changes in our relationships with optical laboratories, distributors, research and development partners and other third parties;

— the effects of the international expansion of our operations and our ability to manage our growth, including our ability to manage potential future acquisitions;

— the political, economic, trade restriction, staffing, contract enforcement, tax and other risks associated with international operations;

— the effects of the worldwide economic conditions;

— the effects of exchange rate fluctuations;

— our ability to timely develop and market new or enhanced products and the effects of developments in alternative technologies and treatments in our industry;

— our ability to protect our proprietary technology and intellectual property rights;

— our ability to capitalize on our research and development capabilities;

— our ability to retain or recruit key personnel;

— our relationship with Kibbutz Shamir;

— the political, military and economic conditions in Israel;

— our success at managing the risks of the foregoing; and

— the other factors referenced in this annual report, including, without limitation, in the sections entitled “Item 3. Key Information–Risk Factors,” “Item 5. Operating and Financial Review and Prospect” and “Item 4. Information on the Company.”

        We undertake no obligation to update forward-looking statements or risk factors in this annual report to reflect new information, future events or otherwise, except as may be required under applicable securities laws and regulations.

1

PART I

ITEM 1. IDENTITY OF DIRECTORS; SENIOR MANAGEMENT AND ADVISERS

Not applicable.

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE

Not applicable.

ITEM 3. KEY INFORMATION

Introduction – Corporate Reorganization

        In March 2005, we conducted an initial public offering (“IPO”) and concurrent listing on the NASDAQ National Market (currently known as NASDAQ Global Market) of our ordinary shares. Our ordinary shares have also been listed on the Tel Aviv Stock Exchange since May 2, 2005. Prior to the IPO, we were organized as an agricultural co-operative society (A.C.S.), which is a corporate entity organized under Israeli law with shares and limited liability for its members. The principal distinction between an Israeli corporation, our current corporate form, and an A.C.S. is that an A.C.S. is a pass-through tax entity and all the profits and losses of the A.C.S. are attributed to its shareholders pro rata to their shareholding. Historically, the Articles of Association of our A.C.S. reflected the laws and regulations applicable to such an entity.

        On March 6, 2005, we changed the structure of our company from an A.C.S. into an Israeli corporation. To do so, we relied on a provision of the Israeli Companies Law that allows such reorganization without having to transfer any assets, rights or liabilities into a new entity and by using the same entity of the A.C.S. in order to change its form into a corporation, which is not considered as a taxable event. As part of this reorganization and in preparation for the March 2005 offering, we adopted new Articles of Association and restructured our share capital by splitting the 105,506 existing shares so that each share with a par value of NIS 1.00 was divided into 100 ordinary shares with a par value of NIS 0.01 each. In addition, we distributed to our shareholders out of our equity 2,160,732 new ordinary shares with a par value of NIS 0.01 each. With this distribution, the old shares of the A.C.S. were in effect split at a ratio of 120.48-to-one, and our total issued and outstanding share capital then amounted to NIS 127,113 consisting of 12,711,332 ordinary shares with a par value of NIS 0.01 each. We also created authorized share capital of 100,000,000 ordinary shares with a par value of NIS 0.01 each. As part of the IPO, which closed on March 16, 2005, we issued 3,400,000 new ordinary shares with a par value of NIS 0.01 each. In addition on July 31, 2005, we allocated 145,182 ordinary shares to Severn Confirmers & Forwarders, Ltd. As of the date of this annual report we have 16,423,740 ordinary shares outstanding. See also “Item 10. Additional Information–Share Capital.”

3.A SELECTED FINANCIAL DATA

        The following selected consolidated financial data as of December 31, 2007 and 2008 and for the years ended December 31, 2006, 2007 and 2008 have been derived from our audited consolidated financial statements. These financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, and audited by Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global. The selected consolidated statement of income data as of December 31, 2004, 2005 and 2006, and the selected consolidated balance sheet data for the years ended December 31, 2004 and 2005, have been derived from other consolidated financial statements not included in this annual report and have also been prepared in accordance with U.S. GAAP and audited by Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global.

        The selected consolidated financial data set forth below should be read in conjunction with and are qualified by reference to Item 5, “Operating and Financial Review and Prospects” and the Consolidated Financial Statements and notes thereto and other financial information included elsewhere in this annual report.

2

	Year Ended December 31,
	2004			2005		2006			2007			2008
(Dollars in thousands, except per share data)
STATEMENT OF OPERATIONS DATA:
Revenues, net	$	71,269		$	80,364	$	97,280		$	120,419		$	140,326
Cost of revenues(1)		33,414			36,030		44,038			55,856			64,415
Gross profit		37,855			44,334		53,242			64,563			75,911
Operating expenses:
Research and development(1)		1,842			1,688		2,372			2,564			3,368
Selling and marketing(1)		18,915			23,663		32,798			36,552			42,374
General and administrative(1)		4,571			6,887		10,986			13,549			16,793
Total operating expenses		25,328			32,238		46,156			52,665			62,535
Operating income		12,527			12,096		7,086			11,898			13,376
Financial income (expenses) and other, net		(864	)		401		(159	)		(239	)		(2,142	)
Income before taxes on income		11,663			12,497		6,927			11,659			11,234
Taxes on income		1,549			4,504		2,179			5,013			2,216
Income after taxes on income		10,114			7,993		4,748			6,646			9,018
Equity in gain (losses) of affiliates, net		(48	)		-		(245	)		46			44
Minority interest in losses (earnings) of subsidiaries		(1,254	)		112		1,957			1,509			16
Net income	$	8,812		$	8,105	$	6,460		$	8,201		$	9,078
Pro forma data (unaudited)(2):
Pro forma-additional taxes on income	$	1,707
Pro forma net income(2)	$	7,105
Net earnings per share:
Basic	$	0.70		$	0.52	$	0.40		$	0.50		$	0.55
Diluted	$	0.68		$	0.51	$	0.39		$	0.50		$	0.55
Pro forma earnings per share (unaudited)(2) :
Basic	$	0.56
Diluted	$	0.55
Weighted average number of shares (in thousands)
Basic		12,625			15,449		16,257			16,339			16,424
Diluted		12,961			15,869		16,548			16,552			16,522
Weighted average shares used for pro forma (in thousands)(2):
Basic		12,625
Diluted		12,961

3

	As of December 31,
	2004		2005		2006		2007		2008
(Dollars in thousands)
FINANCIAL POSITION DATA:
Cash and cash equivalents	$	6,235	$	27,502	$	23,205	$	18,953	$	18,276
Short term investment		-		14,474		16,911		14,375		7,187
Working capital		8,256		54,671		59,028		52,316		47,770
Total assets		65,344		116,661		146,996		160,491		149,496
Total liabilities		43,146		41,697		64,970		74,468		61,477
Temporary equity(3)		3,000		-		-		-		-
Total debt		23,020		21,487		40,381		45,433		35,193
Total shareholders' equity		14,630		71,388		79,803		85,223		86,769

(1) Operating expenses includes the following stock-based compensation:

	Year Ended December 31,
	2004		2005		2006		2007		2008
(Dollars in thousands)
Cost of revenues		-		-		-	$	23	$	40
Research and development		-		-		247		226		149
Selling and marketing		13		343		260		86		63
General and administrative		69		265		919		695		481
Total	$	82	$	608	$	1,426	$	1,030	$	733

(2) The pro forma adjustments give effect to our reorganization into an Israeli corporation (see “–Corporate Reorganization,” above), pursuant to which 105,506 shares in our original corporate entity, an Israeli agricultural co-operative society (A.C.S.) were converted into 12,711,332 ordinary shares of Shamir Optical Industry Ltd. As the A.C.S. was a pass-through tax entity, the tax liability was not charged to our company but to the owners, pro rata to their holding in the A.C.S. For comparison purposes, we have included in the selected consolidated financial data in this annual report our pro forma net income, which reflects the additional income taxes we would have paid during the historical periods presented, assuming we had been an Israeli corporation during that time.

(3) Represents shares of the company owned by Kibbutz Eyal for which Kibbutz Eyal had a right to put the shares to us. This put option expired upon the reorganization of our company from an A.C.S. to an Israeli corporation.

Exchange Rate Data

        Our reporting currency is the U.S. dollar. We generate revenues and incur expenses principally in dollars, Euros and NIS. See also “Item 5. Operating and Financial Review and Prospects–Functional Currency and Exchange Rate Fluctuations.”

        The following table sets out the average exchange rates for these currencies per $1.00 for the past five fiscal years, based on the exchange rates published by the Bank of Israel:

Currency	2004		2005		2006		2007		2008
EUR		0.794		0.804		0.797		0.730		0.682
NIS		4.482		4.488		4.457		4.108		3.588

        On June 15, 2009, the exchange rate was NIS 3.965 per $1.00 and €0.722 per $1.00, as reported by the Bank of Israel.

4

3.B CAPITALIZATION AND INDEBTEDNESS

Not applicable

3.C REASONS FOR THE OFFER AND USE OF PROCEEDS

Not applicable.

3.D RISK FACTORS

        The following risk factors should be read carefully in connection with evaluating our business and the forward-looking statements contained in this Form 20-F. Any of the following risks could materially adversely affect our business, our operating results, our financial condition and the actual outcome of matters as to which forward-looking statements are made in this report. The risks described below do not purport to be exhaustive and these risks do not constitute the only risks to which we are exposed. The order in which the individual risks are presented does not provide an indication of the likelihood of their occurrence nor of the severity or significance of the individual risks.

Risks Relating to Our Business and the Ophthalmic Industry

The industry in which we operate is highly competitive, and these competitive pressures may harm demand for our products.

        Competition in our industry is intense, and we expect competition to increase. New products are introduced frequently, and we compete primarily on the basis of innovation, quality and breadth of product offerings, customer service and price.

        Many of our main competitors are significantly larger than we are and have significantly greater financial and human resources than we do. They also have greater technical, product development and marketing resources and are more established and enjoy greater market recognition than we do. As a result, these competitors benefit from greater economies of scale and may be able to develop products or services that are more effective than ours and to respond more quickly to new or emerging technologies or changes in customer requirements. They compete with us in some cases by offering lower prices or devoting greater resources to product marketing than we do. Price competition in our industry is often severe and may result in lower prices or reduced demand for our products and a corresponding reduction in our gross margins, which would, in turn, impair our ability to maintain profitability.

        Certain of our competitors also have more developed and substantial direct customer bases than we have and may be able to fund significant direct sale efforts as well as more product development and acquisition efforts. A number of our principal competitors are vertically integrated with optical laboratories to a greater extent than we are. This integration may limit the number of independent optical laboratories to which we can market our products and may limit the amount of purchases of our products by these laboratories. In addition, within a particular market, certain of our competitors may enjoy a “home-country” advantage over foreign competition, and we may also face additional competition if new participants enter the markets in which we operate. The development and successful introduction by a competitor of products or services that are superior in performance to or lower in price than ours could adversely affect our ability to effectively compete in the marketplace for optical lenses.

We rely on optical laboratories in various geographic markets to purchase, market and sell our products worldwide. If we are unable to maintain or expand our relationships with these laboratories, it could have a material adverse effect on the sales and distribution of our products.

        We rely on optical laboratories in the different geographic markets in which we operate to purchase our products from us or to distribute our products to the end-user on our behalf. The number, size, business strategy and operations of these laboratories vary widely from market to market. The success of our sales and distribution channels depends heavily on our successful cooperation with these laboratories in each of our various markets.

5

        The U.S. ophthalmic market is characterized by a large number of laboratories, independent and non-independent, as well as large national retail chains and buying groups, some of which own their own laboratories. We distribute our products to independent and non-independent laboratories, which distribute our products to the ophthalmic market. The laboratories in the U.S. sell both their own products as well as products of other manufacturers like us. If a large number of non-independent laboratories, buying groups or retail chains cease to purchase our products due to a change in internal purchasing policies, or if the number of independent laboratories decreases, it could have an adverse impact on our sales and our results of operations in the U.S.

        The European ophthalmic market, relative to the U.S. market, has a smaller number of optical laboratories. Non-independent laboratories control a major share of the European market, and sell mainly their own products. We sell our products in Europe mainly through our own laboratories and distribution channels to opticians and retail chains.

         In the rest of the world we sell our products through our laboratories to opticians or to independent or non-independent laboratories. If one or more of such laboratories cease to purchase our products due to a change in internal purchasing policies, it could have an impact on our sales and our results.

A significant portion of our business is conducted outside of Israel and the United States, and we intend to continue to expand our operations internationally. As a result, we are subject to a number of risks associated with our foreign operations.

        We derive substantial revenues from sales outside of Israel, and a significant majority from sales outside of Israel and the United States. During 2008, we generated approximately 68.6% of our revenues from sales outside of Israel and the United States, including 50.1% in Europe. We also sell our products in Australia, Canada, South Africa, Central and South America, China and several additional countries. An integral part of our expansion strategy is to enter new foreign markets, principally in Central and South America and Asia, and to further penetrate those foreign markets in which we are currently active. Our ability to penetrate certain international markets may be limited, and our international sales and operations and our expansion strategy are subject to numerous risks inherent in international business activities, including:

— developments in the political and economic environment of some foreign countries, primarily in Asia, Central and South America, that have an adverse effect on our operations in those countries, including the fact that customers in some jurisdictions may not do business with an Israeli company;

— the imposition of tariffs or exchange controls, technology export license requirements or other trade restrictions;

— difficulty in managing a large organization spread through various countries, including staffing and managing foreign operations;

— difficulty in enforcing agreements and collecting receivables through certain foreign legal systems, in particular in developing markets in Asia, Central and South America;

— longer payment cycles for foreign customers than for customers in the United States;

— currency exchange risks, in particular between the U.S. dollar and local foreign currencies;

— difficulties in complying with a variety of foreign laws and regulations;

— tax rates in certain foreign countries that exceed those in Israel, withholding requirements on foreign earnings and local import or export taxes; and

— greater difficulty in safeguarding intellectual property in certain jurisdictions, in particular in China and other Asian countries.

6

        These and other factors could have a material adverse effect on our international operations or our business as a whole. As we continue to expand our business globally, our success will increasingly depend on our ability to effectively manage these risks.

Current economic conditions may adversely affect our industry, business and results of operations.

        The global economy is currently undergoing a period of substantial contraction, and the future economic environment is likely to be less favorable than that of recent years. This has led to reduced consumer and governmental spending, which may drive to decrease prices in the ophthalmic market. These events may have an adverse effect on our revenues, as well as on our ability to raise capital or debt at an attractive cost of capital.

        We conduct our operations in Israel and throughout the world, including in Europe and in the U.S. In 2008, our sales to customers in Europe constituted approximately 50.1% of our revenues, while our sales to customers in the U.S. constituted approximately 29.1% of our revenues. A continued economic slowdown, recession or sustained loss of consumer confidence in the markets in which we sell our products, especially in the European and U.S. markets, could trigger a decline in demand for our products that may adversely affect our results of operations.

We generate a significant portion of our revenues and expenses in currencies other than the dollar. As a result, our results of operations may be adversely affected by currency fluctuations.

        We operate globally, and our financial results are subject to both transaction and translation effects resulting from fluctuations in currency exchange rates. We generate our revenues primarily in Euros and dollars, and we incur a significant portion of our expenses, principally salaries and related expenses of our staff in Israel, in NIS. In 2008 we generated approximately 31.5% of our revenues in dollars and 48.3% in Euros, and we incurred approximately 18.0% of our operating expenses in NIS, 32.2% in dollars and 38.6% in Euros. Exchange rate fluctuations between the dollar and the Euro and between the dollar and the NIS may impact our revenues, cost of revenues and other operating expenses. See “Item 5. Operating and Financial Review and Prospects–Functional Currency and Exchange Rate Fluctuations.” We currently do not significantly hedge our currency exposure through financial instruments.

        One currency exchange risk we face is translation risk. In preparing our consolidated financial statements, we convert the results from operations outside the U.S. dollar zone into dollars at the average rate for each reporting period. As a result, a strong decline in the value of the Euro compared to the dollar will have a negative impact on our sales revenues, while an increase in the value of the NIS or Euro to the U.S. dollar will have a negative impact on our expenses. As of December 31, 2007, the NIS exchange rate appreciated against the dollar by 9.0% and the Euro exchange rate appreciated against the dollar by 10.5%. As of December 31, 2008, the NIS exchange rate appreciated against the dollar by 1.1% and the Euro exchange rate devaluated against the dollar by 5.6%.

        The NIS annual average rate in 2007 and 2008 appreciated against the dollar by 7.8% and 12.7% respectively, and the Euro annual average rate appreciated against the dollar by 8.3% and 6.6%, respectively, which had an adverse effect on our results of operations.

        Another currency exchange risk we face is translation risk in companies were the measurement of taxable income is in a different currency than the functional currency. When coming to measure our taxable income in these companies, we translate the operating results from the functional currency to the currency in which the taxable income is measured. Therefore, translation differences in the financial statements may differ from those recognized for tax purposes. This exchange risk may dramatically affect our effective income tax rate.

7

        We are also exposed to transaction risk when our sales are denominated in currencies that are different from those in which we purchase raw materials or incur production costs. If the value of the currency in which the purchase price is denominated declines relative to the currency in which we incur our costs, the profit margin for the transaction will be reduced.

If we do not continually enhance our existing products and develop and market new products, our product portfolio may become obsolete and we may not achieve broad market acceptance and brand recognition.

The market for spectacle lenses and lens designs is characterized by:

— rapid technological change;

— short product life cycles and frequent product introductions and enhancements;

— evolving industry performance standards; and

— changes in customer and end-user requirements.

        Any one of these factors could reduce the demand for our products or require us to expend substantial resources for research, design and development of new products and technologies to avoid technological or market obsolescence. Our success will depend on our ability to continually enhance our existing products and develop or acquire and market new products in an effort to maintain and increase sales and to improve our gross margins. We cannot assure you that we will have sufficient financial resources or otherwise be able to develop the technological advances necessary for us to remain competitive or that any new products that we develop will be accepted in the marketplace, either at all or on a timely basis or at competitive prices. Any delay or failure by us to respond to these market conditions or to technological advances by our competitors would have a material adverse effect on our business, operating results and financial condition.

We compete against alternative technologies and treatments that provide a substitute for spectacle lenses.

        Spectacle lenses compete with other methods of vision correction, including laser surgery and contact lenses. Some of these technologies currently offer limited competition to our progressive lens products, our most significant products in terms of sales. See “Item 4. Information on the Company–Industry Overview–Lenses and Alternatives.” As alternative technologies evolve in the future, they may decrease demand for spectacle lenses, which would have a material adverse effect on our sales and results of operations.

Our main manufacturing facilities are located in Israel and Portugal. An interruption of manufacturing at these facilities for any reason could have a material adverse effect on our results of operations.

        A significant portion of the development and manufacturing of our products is concentrated at our manufacturing facilities in Israel and in Portugal. Raw materials and finished product inventories are also stored at these facilities. Although these facilities are in several separate locations, a disruption of our operations or damage to any of these facilities, whether as a result of fire, natural disaster, act of war, terrorist attack, plague or otherwise, could materially affect our ability to deliver products on a timely basis and could materially adversely affect our results of operations. We have insured the portion of our product inventories stored in these facilities against loss from any such disruption or damage. For risks relating to our facilities in Israel, see also “–Risks Relating to our Operations in Israel.”

        In addition, we have some additional manufacturing facilities in Turkey and Mexico, that are smaller and less significant than those that are mentioned above. Nevertheless, a disruption of our operations or damage to any of these facilities, whether as a result of fire, natural disaster, act of war, terrorist attack, plague or otherwise, could affect our ability to deliver products on a timely basis and could affect our results of operations.

8

Our proprietary technology is difficult to protect. Unauthorized use of our proprietary technology by third parties may impair our ability to compete effectively.

        Our success and ability to compete within the ophthalmic industry depend in large part on our ability to protect our proprietary technology. To do so, we currently rely on a combination of patent protection for our technologies and products, trade secret and intellectual property laws, nondisclosure and other contractual agreements, and other technical measures to protect our proprietary rights and maintain the confidentiality of key business and manufacturing processes. We seek to defend and enforce our rights against infringement and to operate without infringing the proprietary rights of others.

        The validity and breadth of claims in patent applications for ophthalmic technology or processes involve complex legal and factual questions and may therefore be highly uncertain. We cannot assure you that:

— patent authorities will not grant patents based on applications our competitors have filed or may file;

— the scope of any patent protection we receive will exclude competitors or provide us with competitive advantages;

— any of the patents that have been or may be issued to us will be held valid if subsequently challenged; or

— others will not claim rights in or ownership of the patents and other proprietary rights that we hold.

        Furthermore, we can not assure that others have not developed or will not develop similar products or technologies, duplicate any of our products or technologies, or design around any patents that have been or may be issued to us. In many countries patent applications remain confidential until the issuance of a patent. We cannot be certain, therefore, that others have not filed earlier applications for inventions covered by our pending patent applications, nor can we be certain that we will not infringe any patents that may be issued to others on such applications.

        Certain of our employees and consultants are subject to confidentiality undertakings in favor of the company, and we also seek these undertakings from some suppliers and customers. However, not all of our employees or suppliers and customers are subject to these undertakings, and even where they are, these measures may not be sufficient to protect our technology from third-party infringement or misappropriation. There can be no assurance that our counterparties will not breach these agreements, and we may not have adequate remedies for such breaches. In addition, our competitors may learn of our trade secrets through other methods. Intellectual property law protection may be insufficient to safeguard our proprietary information, and our products may be sold in countries that provide less protection to intellectual property than the United States, Europe or Israel, or no protection at all. If any third parties infringe our proprietary technology rights, this infringement could have a material adverse effect on our competitive position.

Our business may suffer if we are involved in disputes or protracted negotiations regarding our intellectual property rights or the intellectual property rights of third parties.

        We are subject to the risk of adverse claims and litigation alleging infringement by us on the intellectual property rights of others. There are increasing numbers of patents and patent applications in our industry. Third parties may assert infringement claims in the future, alleging infringement by our current or future products or applications. For example, we have been notified by a large lens manufacturer that certain of our products infringe a patent claimed by such manufacturer. In addition, we have also received notice from a shareholder of one of our subsidiaries claiming unlawful use of such subsidiary’s intellectual property and unjust enrichment. See “Item 8. Financial Information–Legal Proceedings.”

9

        We may institute or otherwise be involved in litigation to protect our registered patents and/or trade secrets or know-how, challenge the validity of proprietary rights of others or defend against alleged infringement by us of proprietary rights of others. This type of litigation is costly and diverts management’s attention from its day-to-day responsibilities of running our business. In addition, an adverse determination in such litigation could:

— limit the value of our trade secrets or know how;

— subject us to significant liabilities to third parties;

— require us to seek licenses from third parties; or

— prevent us from manufacturing and selling products,

any of which could have a material adverse effect on our business, financial condition and results of operations.

We are a company that is focused on research and development, and we cannot assure that our research and development efforts will result in new products or product enhancements that will receive the market acceptance and demand that we expect.

        We are focused on research and development (R&D), and the success of our business depends substantially on the results of our R&D activities. We conduct R&D both to enhance our existing proprietary technologies and to develop new technologies. We cannot assure you that our R&D efforts will result in product enhancements or new products, or that there will be a market for products related to or based on these new concepts. The success of our R&D efforts depends on the availability of funds as well as on the timely completion of our R&D projects. If we fail to provide the necessary funds to complete our various R&D projects or if we miss our target deadlines, we may lose a competitive advantage of being the first to market. In addition, our competitors that have greater financial resources to commit to R&D efforts may be able to “leap frog” our technological innovations with their own technological innovations and make our innovations obsolete even before we introduce them to market. In addition, some of the agreements pursuant to which we provide design services restrict our ability to offer products with certain qualities that exceed those designed for the customer who is party to the agreement, which may limit our ability to market new product developments outside of those relationships. Our investment of human and financial resources in R&D is therefore highly risky with no guarantees of any developmental success or investment return.

        We also provide design and manufacturing services to producers, distributors and wholesalers of lenses in accordance with specifications defined by such producers, distributors and wholesalers. Though we are usually compensated for this development work, this compensation is primarily in the form of royalties and depends on the ability of these producers, distributors and wholesalers to sell these products. Their failure to do so may affect our results.

We have experienced a period of rapid growth, and if we cannot adequately manage our growth, our results of operations will suffer.

        Over the past several years, we have experienced rapid growth in our business. Our anticipated future growth may place a significant strain on our managerial, research and development, technical, administrative, operational, financial and marketing resources. If we continue to experience such rapid growth, we cannot assure you that we will have adequately considered all costs and risks associated with such future expansion, or that our systems, procedures and managerial controls will be adequate to support such expanded operations. If our systems, procedures or controls prove inadequate to support such future extended operations, we may be unable to achieve our goals for growth. Our growth may also require us to hire additional research, engineering, technical support, sales, accounting, administrative and operational personnel and competition for qualified personnel may be intense. We anticipate incurring expenses before realizing a commensurate increase in sales. Failure to manage our future growth effectively could result in higher-than-anticipated costs and lower-than-anticipated sales and could have a material adverse effect on our operating results and financial condition.

10

We intend to continue our policies of acquisitions and of co-operations with local strategic partners. Pursuing these polices could divert our resources, create unanticipated expenses, disrupt our business and adversely affect our financial condition.

        Part of our expansion strategy is to pursue acquisitions of other businesses, in particular laboratories, establish local co-operations and acquire complementary businesses or technologies. Negotiating potential acquisitions or local co-operations as well as integrating newly acquired or jointly developed businesses, products or technologies into our operations could divert our management’s attention from other business matters and could be expensive and time-consuming. We cannot assure that we will be successful in integrating acquired businesses, laboratories or technologies or in establishing local co-operations or that we will be able to realize the intended sales and cost benefits of the acquisition or local co-operations.

        In addition, future acquisitions could require substantial cash expenditures and could result in customer or distributor dissatisfaction, including with respect to independent laboratories that may view our ownership of laboratories in their respective jurisdictions as competitive. We may also experience performance problems with an acquired company, suffer a decrease in our profit margins or incur debt and contingent liabilities from the acquired businesses. In addition, we may issue equity securities in the context of an acquisition that could cause dilution to our existing shareholders at the time, and we may incur impairment charges related to goodwill and amortization of intangibles. Any of these factors could harm our business, financial condition and results of operations.

We have non-wholly-owned subsidiaries for various parts of our business operations, including research and development and sales. If our relationships with these third parties end or deteriorate, it might have an adverse effect on our business and results of operations.

        We have non-wholly-owned subsidiaries for certain parts of our foreign operations. We are also distributing our products to national retail chains, optical retail stores and national retail buying groups who, we believe, will make up a growing part of the distribution of spectacle lenses.

        We have minority partners in some of our foreign subsidiaries that contribute to our sales and profitability. The consent of certain minorities in certain subsidiaries is required for certain matters regarding the subsidiaries operations, including resolutions that contradict specific existing agreements, issuances of shares, and transactions with related parties (including us) or other transactions outside the ordinary course of business. Dividends and other payments to us from subsidiaries in certain jurisdictions are subject to legal restrictions and may have tax consequences to us. In addition, these payments or loans are contingent on the results of operations of the particular subsidiaries and are subject to various business considerations.

We are dependent on a small number of suppliers for raw materials and subcontractors.

        Most of the raw materials used in the manufacture of lenses, including our products, are available from a limited number of suppliers. There are currently less than five suitable suppliers of blanks for glass lenses and a similar number of suitable suppliers of monomers for plastic and polycarbonate lenses. We purchase our raw materials from some of these suppliers. A change of supplier may cause us a high expense.

         A certain part of the production process of our lenses is supplied by a limited number of worldwide subcontractors, some of which own a worldwide recognize trademark for their process and product. In addition, our competitors control some of these subcontractors.

        The loss of any one of these suppliers or subcontractors, would require us to obtain these materials or services elsewhere. Because these markets are dominated by a small number of suppliers or subcontractors, there is the risk of a price cartel or monopoly. Our larger competitors may be able to purchase more supplies or subcontractors at any given time than we are and may therefore achieve lower prices than we do or prevent us from receiving such services. See “–The industry in which we operate is highly competitive, and these competitive pressures may harm demand for our products.” If we are unable to obtain such raw materials or services from our suppliers (or alternative suppliers) or subcontractors at acceptable prices, we may realize lower margins and experience difficulty in meeting our customers’ requirements.

11

We have several large customers to which we sell our products.

        We have five large customers that collectively accounted for approximately 30.3% of our revenues during 2008. In addition, our largest customer accounted for approximately 12.6% of our revenues during 2008. The remaining 69.7% of our revenues are spread across a large number of customers in various geographic locations, and no other customer, other than our five largest customers, accounted for more than 3.5% of our revenues. Nevertheless, if one of our large customers were to cease purchasing our products, partially or entirely, it could cause a decrease in our total revenues.

We may not be able to continually reduce manufacturing costs for our products.

        Prices for certain of our products come under pressure, in particular when such products become available from a comparatively large number of suppliers with little product differentiation. To maintain or strengthen our competitive position for these products within the ophthalmic industry, we must continually reduce our product manufacturing costs. These reductions are necessary to help offset price decreases, inflationary pressures and changes in product and regional mix. To the extent our cost reduction activities are unsuccessful, in part or in full, our ability to compete may be significantly impacted and our profit margin may be reduced.

Our operating results may fluctuate on a periodic basis, which could cause us to fail to meet expectations for a given period and result in a decline in the trading price of our shares.

        Our results of operations may fluctuate significantly in the future on a quarterly and an annual basis due to a number of factors, many of which are beyond our control. These factors include:

— foreign currency exchange rate fluctuations;

— variations in the timing of orders and shipments of our products and services;

— variations in the demand from and the size of orders by our customers;

— the timing and success of new product or technology introductions by us or our competitors;

— the pricing and profitability of our products or the timing of aggressive low-pricing policies by our competitors;

— changes in the availability or cost of raw materials;

— seasonal variations in customer spending in Europe and the United States;

— the timing of technological innovations for our products or those of our competitors;

— our ability to bring new products into volume production efficiently;

— shifts in market and industry emphasis and end-user demands; and

— market conditions in the ophthalmic industry and in the economy as a whole.

        These factors complicate our planning processes and reduce the predictability of our earnings. This problem is particularly acute for us because of our relatively small size and the dynamics of the industry and worldwide markets in which we operate. Fluctuations in our quarterly results could cause us to fail to meet expectations (either our own or those of securities analysts) for the relevant period and could cause the trading price of our shares to decline. Therefore, period-to-period comparisons of our results of operations may not be meaningful, and you should not rely on them as indications of our future performance.

12

We depend on a limited number of key personnel. If we lose the services of these individuals, our business may be adversely affected.

        Our continued growth and success depend to a large extent on the services of, among others, certain of our senior personnel. If any of these key personnel should leave our employ we may be unable to locate and recruit sufficient replacement personnel without undue delay or additional cost or we may be unable to replace them at all. Any such delay or inability could delay or terminate some or all of our development programs or the commercialization of our products. Even if we are able to attract suitable replacement personnel, to the extent that the process of educating new personnel in our technologies, in the needs of the ophthalmic industry and in our company culture requires a certain transition period, we may incur delays with respect to the further developments of our products. The implementation of our business strategy and our future success will also depend in large part on our continued ability to attract and retain other highly qualified scientific, technical, marketing, financial and management personnel.

Risks Related to Our Relationship with Kibbutz Shamir

Kibbutz Shamir is our controlling shareholder, and its interests may conflict with those of other investors.

        As of June 15, 2009, our majority shareholder, Kibbutz Shamir, holds approximately 59.04% of our outstanding ordinary shares. As a result, this single shareholder has sufficient voting power to effectively control all matters concerning our company that require shareholder approval. For example, Kibbutz Shamir may have the power to affect our legal and capital structure; to elect all of our directors; to prevent or effect changes in our control or management; to approve or reject changes to our operations or strategic direction; to amend our Articles of Association and change the rights attached to our shares; and to determine whether we may enter into mergers or other business combination transactions in which shareholders could receive a premium over the prevailing market price for our shares. Kibbutz Shamir has contractually agreed with another shareholder to vote for that shareholder’s nominee for membership on our board. See ” Item 7. Major Shareholders and Related Party Transactions.”

        In addition, we have entered into certain agreements with Kibbutz Shamir pursuant to which Kibbutz Shamir provides us with, among other things, facilities, workers to fill certain positions within our company, administrative services, security and facilities maintenance, and other services. For more information please see “Item 7. Major Shareholders and Related Party Transactions.”

        In these and other circumstances, Kibbutz Shamir’s interests may conflict with those of other investors, and other investors may be unable to prevent Kibbutz Shamir from acting in conflict with their interests.

Our agreements with Kibbutz Shamir may be less favorable to us than if they had been negotiated with unaffiliated third parties.

        Our headquarters and certain manufacturing facilities are located on the premises of Kibbutz Shamir, which is our majority shareholder. In addition, we have entered into certain agreements with Kibbutz Shamir pursuant to which Kibbutz Shamir provides us with the certain services mentioned above. While these agreements have been negotiated on an arms’ length basis, they may contain terms that are different from the terms that would have been included had these agreements been negotiated with unaffiliated third parties. See “Item 7. Major Shareholders and Related Party Transactions .”

13

Our directors and executive officers who are members of Kibbutz Shamir may have conflicts of interest with respect to matters involving the company.

        Certain of our directors, officers and key employees are members of Kibbutz Shamir, which is our majority shareholder. Some of these individuals are also members of the management board of Kibbutz Shamir. These persons will have fiduciary duties to both us and Kibbutz Shamir. As a result, they may have real or apparent conflicts of interest on matters affecting both us and Kibbutz Shamir and in some circumstances may have interests adverse to ours. Currently, two members of our board of directors (including our chairman), and two of our executive officers are members of Kibbutz Shamir and members of Kibbutz Shamir’s management board. In addition, another member of our board of directors, who is not a member of Kibbutz Shamir, also serves on the management board of Kibbutz Shamir. See “Item 6. Directors, Senior Management and Employees.”.

Risks Related to Our Shares

The trading price of our shares may fluctuate substantially.

        The trading price of our shares is likely to be highly volatile and subject to wide fluctuations. Factors that could affect the trading price of our shares include:

— the gain or loss of significant orders or customers;

— actual or anticipated variations in our operating results or a variance in our financial performance from the expectations of market analysts;

— announcements of technological innovations, new products or product enhancements, strategic alliances or significant agreements by us or by our competitors;

— conditions and trends in the end markets we serve and changes in the estimates of the sizes and growth rates of these markets;

— recruitment or departure of key personnel;

— changes in our pricing policies or the pricing policies of our competitors;

— changes in the estimates of our operating results or changes in recommendations by any securities analysts that elect to follow our ordinary shares;

— changes in market valuation or earnings of our competitors;

— changes in legislation;

— the trading volume of our shares; and

— market conditions in our industry, the industries of our customers and the economy as a whole.

        If our future quarterly or annual operating results are below the expectations of securities analysts or investors, the price of our shares would likely decline. Share price fluctuations may be exaggerated if the trading volume of our shares is limited.

        In addition, the stock market in general, and the NASDAQ Global Market in particular, have experienced substantial price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of particular companies affected. These broad market and industry factors may materially harm the market price of our ordinary shares, regardless of our operating performance. In the past, following periods of volatility in the market price of a company’s securities, securities class-action litigation has often been instituted against that company. Such litigation, if instituted against us, could result in substantial costs and a diversion of management’s attention and resources, which could materially harm our business, financial condition, future results and cash flow.

14

Future sales of our shares could adversely affect the market price of our shares.

        Those of our shareholders who held shares prior to the initial public offering of our ordinary shares in March 2005, hold approximately 69.24% of our outstanding shares as of June 15, 2009. These shareholders are not contractually prohibited from transferring our shares. See ” Item 7. Major Shareholders and Related Party Transactions.” Any sale by us or our pre-offering shareholders of our shares into the public market, or the perception that sales could occur, could adversely affect the prevailing market price for our shares.

        All of our current shareholders who held shares prior to the March 2005 offering have the right, subject to some limited conditions, to demand that we file a registration statement on their behalf to register their shares or that we include their shares in a registration statement that we file on our behalf or on behalf of other shareholders. See “Item 10. Additional Information – Shares Eligible for Future Sale – Registration Rights Agreement.”

We may fail to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002.

        The Sarbanes-Oxley Act of 2002 imposes certain duties on us and our executives and directors. Our efforts to comply with the requirements of Section 404, which started in connection with our Annual Report on Form 20-F for the fiscal year ended December 31, 2007, have resulted in increased general and administrative expense and a diversion of management time and attention, and we expect these efforts to require the continued commitment of resources. Section 404 of the Sarbanes-Oxley Act of 2002 requires (i) management’s annual review and evaluation of our internal control over financial reporting and (ii) an attestation report issued by an independent registered public accounting firm on our internal control over financial reporting, in connection with the filing of our Annual Report on Form 20-F for each fiscal year (such requirement is currently expected to be applicable to us starting with our Annual Report on Form 20-F for the fiscal year ending December 31, 2009). We have documented and tested our internal control systems and procedures in order for us to comply with the requirements of Section 404. While our assessment of our internal control over financial reporting resulted in our conclusion that as of December 31, 2008, our internal control over financial reporting was effective, we cannot predict the outcome of our testing in future periods. If we fail to maintain the adequacy of our internal controls, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting. Failure to maintain effective internal control over financial reporting could result in investigation or sanctions by regulatory authorities, and could have a material adverse effect on our operating results, investor confidence in our reported financial information, and the market price of our ordinary shares.

Our shares are listed for trade on more than one stock exchange, and this may result in price variations.

        Our ordinary shares are listed for trading on the Nasdaq Global Market and on the Tel Aviv Stock Exchange. This may result in price variations. Our ordinary shares are traded on these markets in different currencies, U.S. dollars on the Nasdaq Global Market and New Israeli Shekels on the Tel Aviv Stock Exchange. These markets have different opening times and close on different days. Different trading times and differences in exchange rates, among other factors, may result in our shares being traded at a price differential on these two markets. In addition, market influences in one market may influence the price at which our shares are traded on the other.

15

Provisions of our Articles of Association and Israeli law could inhibit our acquisition by others.

        Provisions in our Articles of Association may make it difficult and expensive for a third party to pursue a tender offer or a change in control or takeover attempt that our management and board of directors oppose. Public shareholders that might desire to participate in one of these transactions may not have an opportunity to do so. For example, our Articles of Association contain provisions:

— establishing advance notice requirements for director nominations or other proposals at shareholder meetings;

— generally requiring the affirmative vote of holders of at least 75% of the voting power of our outstanding voting shares to amend any provision in our Articles of Association, which could make it more difficult for a third party to remove the provisions we have included to prevent or delay a change of control; and

— providing for staggered terms for the members of our board of directors.

        These anti-takeover provisions could substantially impede the ability of public shareholders to benefit from a change in control or to change our management and board of directors.

        Some provisions of Israeli corporate law may also have the effect of delaying, preventing or making more difficult a merger with, or acquisition of, us. In addition, Israeli tax law treats some acquisitions, such as stock-for-stock exchanges between an Israeli company and a foreign company, less favorably than U.S. tax laws. See “Item 10. Additional Information–Share Capital” and “–Israeli Taxation.”

Risks Relating to Our Operations in Israel

Conducting business in Israel entails special risks.

        Our headquarters and main research and development department, and part of our manufacturing facilities, are located in the State of Israel, some of our key employees, officers and our directors are residents of Israel. Although most of our sales are made to customers outside Israel, we are nonetheless directly influenced by the political, economic and military conditions affecting Israel. Specifically, we could be materially and adversely affected by:

— any major hostilities involving Israel;

— a full or partial mobilization of the reserve forces of the Israeli army;

— the interruption or curtailment of trade between Israel and its present trading partners; or

— a significant downturn in the economic or financial condition of Israel.

        Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its Arab neighbors, and a state of hostility, varying from time to time in intensity and degree, has led to security and economic problems for Israel. In the summer of 2006, for approximately one month, battles took place between the Israeli military and Lebanese guerilla units, and our northern facilities suffered certain damages for which we were not fully reimbursed. Further, the establishment of a Hamas government in Gaza and the recent battles during January 2009, have created additional unrest and uncertainty in the region. There is no indication as to how long the current hostilities will last or whether there will be any further escalation nor as to how the current negotiations with the Syrian government will develop. Any continuation of or further escalation in these hostilities or any future armed conflict, political instability or violence in the region may have a negative effect on our business condition, harm our results of operations and adversely affect our share price. Furthermore, there are a number of countries, primarily in the Middle East, as well as Malaysia and Indonesia, that restrict business with Israel or Israeli companies, and we are precluded from marketing our products to these countries. Restrictive laws or policies directed toward Israel or Israeli businesses may have an adverse impact on our operations, our financial results or the expansion of our business.

16

Our operations could be disrupted as a result of the obligation of our key personnel in Israel to perform military service.

        Many of our officers and employees in Israel, including certain key employees, are obligated to perform annual reserve duty in the Israeli army and are subject to being called up for reserve duty at any time. The obligation to perform compulsory military reserve service on an annual basis extends up to a maximum age of 45 for most male Israeli citizens. The absence of one or more of our officers and key employees for significant periods of time due to military service could be disruptive to our operations.

The Israeli government programs and tax benefits in which we have participated in the past and in which we currently participate or from which we receive benefits require us to meet several conditions. These programs or benefits may be terminated or reduced in the future, which could increase our costs.

        We benefit from certain Israeli government programs and tax benefits, particularly from tax exemptions and reductions resulting from the status of our manufacturing facilities in Israel (see “Item 10. Additional Information–Taxation–Israeli Taxation.”). To be eligible for these programs and tax benefits, we must continue to meet certain conditions, including making specified investments in fixed assets and equipment and financing a percentage of those investments with our share capital, and deriving a certain level of the revenues related to those facilities from exports outside of Israel. If we fail to meet such conditions in the future, these tax benefits could be cancelled or reduced, and we could be required to refund those tax benefits already received, adjusted for inflation and with interest. These programs and tax benefits may not be continued in the future at their current levels or at all, and our requests for future participation in these programs for any future expansion of our manufacturing facilities may not be approved. In recent years, the Israeli government has reduced the benefits available under these programs (among other things, by shortening the tax moratorium in certain geographic areas of the country), and Israeli governmental authorities have indicated that the government may in the future reduce or eliminate the benefits of these programs. Further changes in the policy of the Israeli Government in general, and the termination or reduction of these programs and tax benefits specifically, could increase our tax rates, thereby reducing our net profits or increasing our net losses, or otherwise materially adversely affect us.

        In addition, in March 2005 the law governing these tax benefits was amended to revise the criteria for investments that qualify for tax benefits as an approved enterprise. See “Item 10. Additional Information–Taxation–Israeli Taxation.”

It may be difficult to enforce a U.S. judgment against us, most of our officers and directors and some of the experts named in this annual report or to assert U.S. securities law claims in Israel.

        We are incorporated in Israel. Most of our executive officers and directors are nonresidents of the United States, and a substantial portion of our assets and the assets of these persons is located outside the United States. Therefore, service of process upon any of our officers or directors may be difficult to effect in the United States. Furthermore, it may be difficult to enforce a judgment obtained in the United States against us or any of these persons, including one based on the civil liability provisions of the U.S. federal securities laws, in both U.S. and non-U.S. courts.

        Additionally, it may be difficult for investors to assert U.S. federal securities laws claims or to enforce civil liabilities under U.S. federal securities laws in actions originally instituted in Israel.

17

ITEM 4. INFORMATION ON THE COMPANY

4.A HISTORY AND DEVELOPMENT OF THE COMPANY

        We began our activity as a limited partnership in the early 1970‘s as a manufacturer of bifocal lenses. During the first half of the 1980‘s, we began to develop our own progressive lens. In the mid-1980‘s, we began to produce and market progressive glass lenses and gradually began to produce glass molds for casting progressive plastic lenses for other manufacturers. In 1994 we established Shamir USA in order to establish a marketing presence in the United States. In 1995 we made a decision to focus on the development and production of progressive lenses. In 1997 we acquired 25% of Eyal Optical Industries (1995) Ltd. (“Eyal”), the manufacturer of Shamir brand plastic progressive lenses. In 1998 we developed the Eye-Point Technology, proprietary software that simulates human vision, as well as mathematical tools for the optimal design of progressive and aspherical lenses. Using these technologies, we developed the Shamir Genesis, Shamir Office and Shamir Piccolo lenses. In 1998 we, along with Eyal and other founders, established Shamir Insight, our U.S. distributor of Shamir lens brands, and we purchased an additional 25% of Eyal. In the fourth quarter of 2001 we acquired our European operation and an additional 1% of Eyal to give us control of Eyal. In November 2003, we acquired an additional 47% of Eyal, and in May 2004, we acquired the remaining 2% of Eyal’s shares. In July 2004, we purchased Interoptic S.A.R.L., a local French distributor. In September 2004, we purchased the Cambridge Optical Group, through which we gained control in Shamir UK Limited.

        In March 2005, we conducted an IPO and concurrent listing on the NASDAQ National Market (currently known as NASDAQ Global Market) of our ordinary shares. Our ordinary shares have also been listed on the Tel Aviv Stock Exchange since May 2, 2005. Prior to the IPO, we were organized as an agricultural co-operative society (A.C.S.), which is a corporate entity organized under Israeli law with shares and limited liability for its members. The principal distinction between an Israeli corporation, our current corporate form, and an A.C.S. is that an A.C.S. is a pass-through tax entity and all the profits and losses of the A.C.S. are attributed to its shareholders pro rata to their shareholding. Historically, the Articles of Association of our A.C.S. reflected the laws and regulations applicable to such an entity.

        On March 6, 2005, we changed the structure of our company from an A.C.S. into an Israeli corporation. To do so, we relied on a provision of the Israeli Companies Law that allows such reorganization without having to transfer any assets, rights or liabilities into a new entity and by using the same entity of the A.C.S. in order to change its form into a corporation, which is not considered as a taxable event.

        On June 27, 2005, we established a laboratory facility in Turkey, Altra Optik Sanayi ve Ticaret A.S. In establishing this facility, our subsidiary acquired the assets of the laboratory from another laboratory in Turkey.

        On September 30, 2005, we completed the purchase of an additional 31.3% stake in Shamir Insight from Severn Confirmers & Forwarders, Ltd. In April 2005, we purchased 2% of Shamir Insight from one of its minority shareholders, and in July 2007, we purchased the remaining 10% from an additional minority shareholder, following which we are the sole shareholder of Shamir Insight.

        On December 1, 2005, we formed a subsidiary in France, Shamir France S.A.R.L., in order to establish and operate sales and distribution platform.

        In December 2005, we established a subsidiary in Kibbutz Shamir, Israel, Shamir Special Optical Products Ltd. (“SSOP”), which manufactures and develops polycarbonate and finished lenses.

        In January 2006, we purchased 51% of Spherical Optics (PTY) Ltd., a local distributor in South Africa, through which we distribute our lens brands in the South African market.

        In January 2006, SSOP and Einit Ltd., a well known local distributor of lens and frames in the Israeli market, established a subsidiary, Shamir Einit Ltd., to distribute Shamir’s lenses in the Israeli market. In August 2007, in two separate transactions, we purchased both Einit’s as well as SSOP’s holdings in Shamir Einit following which we are the sole shareholder of Shamir Einit. In addition, on July 31, 2007, Shamir Einit changed its name to Shamir Israel Optical Marketing Ltd. (“Shamir Israel”).

18

        On July 2, 2006, we purchased the remaining holdings of the outstanding shares in our R&D Israeli based subsidiary Shamir Or Ltd. following which we are the sole shareholder of Shamir Or Ltd.

        On August 15, 2006, we purchased 26% in Centro Integral Optico S.A. de C.V. (“CIO”), a local laboratory and distributor in Mexico. In addition, On November 1, 2006, we established a distribution company, Shalens S.A. de C.V. (“Shalens”), with local strategic partners. On February 20, 2008, we exercised our option to purchase an additional 25% of each of CIO and Shalens, following which we currently hold 51% of the outstanding shares of each of CIO and Shalens.

        In January 2007, we finalized a purchase of 25.8% in Siam Optical Technology Company Ltd. (“SOT”), through which we operate a local laboratory in Thailand. On July 26, 2008, we executed an amendment to the SOT share acquisition agreement following which we increased our holdings in SOT to 40.4%.

        On July 1, 2008, we executed an agreement following which we purchased the remaining 49% of Shamir Optic GmbH (formally know as “Altra Trading GmbH”) and gained full control of our European subsidiaries.

        On November 1, 2008, we have executed an agreement following which we purchased through Spherical Optics (PTY) Ltd. holdings in a local laboratory in South Africa, Optispeed Laboratory (PTY) Ltd.

        During the fourth quarter of 2008 we executed several internal changes in the structure of our European holdings following which we gained direct holdings in Shamir UK Limited and in our Turkish operation, and Shamir UK became the holding company of the remaining European subsidiaries.

        We financed our acquisitions and purchases of significant fixed assets through loans, capital leases and working capital, including the proceeds from the March 2005 offering of our shares.

        Our main office and production facilities are located at Kibbutz Shamir, Upper Galilee, 12135 Israel. Our telephone number at our main office is +972 (4) 6947810. Our agent for service of process in the United States is Shamir USA, 29800 Agoura Rd., Suite 102, Agoura Hills, CA, 91301-2559.

4.B BUSINESS OVERVIEW

Introduction

        We are a leading provider of innovative products and technology to the spectacle lens market, with a particular focus on the progressive and sophisticated lens market. Utilizing our proprietary technology, we develop, design, manufacture and market progressive lenses that we sell to the ophthalmic market. In addition, we sell finished lenses (stock and prescriptions) to opticians, and utilize our capabilities to provide design services to optical lens manufacturers under service, royalty agreements. Progressive lenses, also known as progressive addition lenses or PALs, combine several optical strengths in a single lens to provide a gradual and seamless transition from near to intermediate to distant vision.

        We differentiate our products from those of our competitors primarily through lens design. We have successfully pursued a strategy of focusing on higher value product categories, and several of our lenses are recognized by industry and research sources for their superior design and quality. Our leading lenses are marketed under a variety of brand names, including Shamir Genesis, Shamir Piccolo, Shamir Office, Shamir Autograph, Shamir Creation, Shamir Smart and Shamir Attitude.

        We believe that we have one of the world’s preeminent research and development teams for progressive lenses, molds and complementary technologies and tools. Through our research and development team, we have continually enhanced our capabilities and resources to develop new, innovative products and design tools with superior characteristics.

19

        We have developed software dedicated to the design of progressive lenses. This software is based on our proprietary mathematical algorithms that optimize designs of progressive lenses for a variety of activities and environments. We have also created software tools specifically designed for our research and development and production requirements, including our Eye Point Technology software that simulates human vision. We believe that these proprietary tools provide us with a competitive advantage in our market. To maintain this advantage, we have pursued investments in new technologies in the ophthalmic field and are developing product technologies in fields such as lens development, lens production and optical measurement and simulation.

The Markets in which we Operate

        The global ophthalmic retail market consists of various type of products, including frames, spectacle lenses, contact lenses ,optical accessories, medical and military products. For a breakdown of our total revenues by category of activity and geographic market, see “Item 5. Operating and Financial Review and Prospects– Operating Results.”

Lenses and Alternatives

        The spectacle lens market consists of three primary types of lenses.

— Single Vision Lenses. Single vision lenses have only one optical power and are primarily used to correct deficiencies in either near or distant vision. As they are essentially simple magnifying glasses when used to treat near-sightedness, single vision lenses tend to be cheaper than other types of lenses and are readily available in most markets in the world.

— Bifocal Lenses. Bifocal lenses have two optical powers and are used to correct deficiencies in both near and distant vision. The surface of the bifocal lens is typically divided into two parts, the upper portion for distant vision and part of the lower portion for near vision. The division between the two parts of the lens is clearly visible and forces the eyes to make an abrupt transition.

— Progressive Lenses. Progressive lenses utilize complex designs to combine several optical powers for different viewing distances, with the optical power gradually increasing from the upper portion of the lens to the lower portion of the lens. The transition between powers is gradual and seamless, thereby eliminating distracting lines between the different vision areas and allowing the user to see at various distances without an image jump, restrictive focal lengths or demarcation lines, although some users have difficulty adapting to the distortion areas of progressive lenses. Progressive lenses are generally the most expensive type of lenses and are less frequently covered by insurance than single vision or bifocal lenses. Progressive lenses are used to treat Presbyopia, a vision condition where the crystalline lens of the eye loses its flexibility and the eye muscles become less powerful causing the eye to lose its ability to focus on close objects. Presbyopia is part of the normal aging process and develops gradually over an extended period of time and affects almost everyone over the age of 45, regardless of whether they have previously had normal vision or have suffered from myopia, astigmatism or other vision conditions. Presbyopia is a degenerative condition that worsens and often requires progressively stronger lenses over time. Presbyopia cannot currently be cured but is treated with lenses that generate optical power assisting the eye to focus on both close and distant objects.

        Contact lenses and surgical procedures, including laser surgery, represent the primary alternatives to spectacles for the visually impaired. Both contact lenses and surgical procedures provide solutions for near-sightedness, far-sightedness and astigmatism, but we believe that they are inferior to progressive lenses as remedies to treat Presbyopia. With progressive lenses, as the wearer naturally shifts his eyes downward or upward when focusing on near or far objects, his eyes move gradually through the different optical powers of the lens. Contact lenses can have multifocal properties, but they are unable to take into account this natural movement of the eyes. Current applications of laser surgery to treat Presbyopia seek to modify the optical power of one eye for near distances and that of the other eye for far distances, thereby reducing overall flexibility and quality of vision relative to other treatments. In addition, surgical procedures are invasive and irreversible, can be painful and involve some recuperation time, and do not address the degenerative nature of Presbyopia.

20

        We believe that most users choose progressive spectacle lenses due to the benefits of these lenses over alternative treatments for Presbyopia. While these other techniques may evolve to be better suited for the treatment of Presbyopia (see “Item 3. Key Information–Risk Factors–We compete against alternative technologies and treatments that provide a substitute for spectacle lenses.”), we do not believe that they currently represent a significant alternative to progressive lenses.

Market Growth

        We believe the following factors will stimulate growth in the progressive lens market:

— Increased Awareness. Over the past few years, there has been an increasing number of advertising, marketing, promotional and educational programs supported by progressive lens manufacturers and optical chains to increase public awareness of progressive lenses and their advantages. We expect the progressive lens market to continue to benefit from these programs.

— Shift From Bifocal Lenses. Progressive lenses will continue to benefit from the shift in demand away from bifocal lenses to progressive lenses as a superior treatment for Presbyopia. As technologies evolve and more people begin to require treatment for Presbyopia, we expect that the market shift from bifocal to progressive lenses will accelerate.

— Favorable Demographic Trends. Multifocal lenses, which include bifocal and progressive lenses, are currently the most satisfactory treatments for Presbyopia. Because Presbyopia generally becomes symptomatic for individuals in their early forties, the primary market for progressive lenses is people over the age of 45. We expect that the world population over the age of 45 will grow.

— Advancements in Lens Technologies. Over the past five years, there have been significant technological advances in lens quality due to the development of design and manufacturing processes, anti-reflective coatings, improved raw materials and other factors. We believe that the continuous introduction of improved technology will also encourage customers to upgrade and replace their lenses.

— Fashion Trends. Leading companies in fashion, cosmetics and athletics are promoting multiple spectacle frames of different styles for different activities. We believe this trend will result in increased purchases of spectacles, as fashion-conscious customers will choose a different frame for each specific activity. In addition, we believe that these customers will prefer progressive to bifocal lenses for the lack of visible lines marking the shift in prescription strengths.

— Maturing of New Markets. We believe that currently approximately half of all people suffering from Presbyopia are left untreated. A significant part of these potential customers reside in China and India. We believe that, as these countries develop and health care becomes more readily accessible, the demand for progressive lenses as a solution to Presbyopia will expand as well.

        We believe that we are well positioned to benefit from these trends, especially due to our proprietary technology created by our research and development team, which we believe will enable us to continue to design and manufacture top quality lenses, and due to our marketing capabilities.

21

Market Structure

        The following graphic shows the flow of orders and goods in the market for optical lenses.

Patient

Optical Doctor &
Optometrist

Optical Laboratory

Manufacturer/
Research &
Development

        The current progressive lens market is driven by the eye correction needs of the patient. A patient undergoes an eye examination in which an optical doctor or an optometrist determines the proper prescription and sends it to an optical laboratory. To complete the prescription, the optical laboratory uses semi-finished progressive lens blanks that are supplied by lens manufacturers. Semi-finished progressive lens blanks are lenses that contain the progressive surface on one side and are unfinished on the other. The optical laboratories finish the progressive lenses by surfacing the other side of the lens blanks according to the prescription and may add coating or tinting that the customer may request. The finished lenses are finally cut, edged and mounted onto the frame by the optical laboratory or the optical shop and delivered to the patient.

Basis for Statements about our Competitive Position

        We compete primarily with manufacturers and distributors of spectacle lenses. Our main competitors include Essilor, Zeiss (merged with Sola), Hoya, Younger and Rodenstock for the production and marketing of spectacle lenses. Many of our competitors have significantly greater resources than we do and may benefit from greater economies of scale. See “Item 3. Key Information–Risk Factors–The industry in which we operate is highly competitive, and these competitive pressures may harm demand for our products”. In Europe our competitors’ primary distribution channels are the optical laboratories and distribution centers that that they own. We compete with these laboratories, as well as with other distributors in Europe that do not own their own labs, through our optical laboratories and distribution centers in Germany, France, Spain, Turkey, Portugal and the United Kingdom.

        Competition in our industry is based primarily on technological innovation and product quality, as well as on breadth of product offerings, customer service, marketing and price. Price competition can be severe in the spectacle lens industry, especially in certain geographic markets and for high-volume, standardized products. We attempt to counter this competition to the extent possible by offering what we believe are among the highest quality progressive lenses in the market. We believe that our sales of progressive lenses constituted less than 5% of the global progressive lens market in 2008. We also believe that our research and development services gives us a competitive advantage over other progressive lens manufacturers.

        For additional information about our competitive position, see “–Products” below.

        We believe that we have a number of competitive strengths that allow us to capitalize on the prevailing trends in our industry. These strengths include:

Research and Development

        We believe that we are a technological leader in the progressive spectacle lens market. Through our research and development efforts, we believe that we possess expertise in developing a variety of new progressive lens designs and production techniques. Our proprietary Eye Point Technology is based on mathematical algorithms that simulate the vision of the human eye in order to calculate the optical performance of the lens. This technology has become the cornerstone of our research and development approach and enables us to minimize distortions inherent in the design of progressive lenses.

        We believe that the quality of our research and development efforts has been validated by independent industry publications, as well as by our ability to sell exclusively designed progressive lenses and molds to other leading progressive lens manufacturers for the production or sale of their own branded lenses.

Products for the Progressive Lens Market

        When we began operations in the progressive lens field, we were among the first companies in the world engaged in the design, development and marketing of progressive lenses, and we have focused on progressive lenses since 1995. Our concentration on progressive lenses has enabled us to develop lens designs and technologies to produce lenses that are considered among the best-performing lenses in the industry. Our leading product portfolio includes Shamir Genesis, our general purpose lens, Shamir Piccolo for use in small frames, Shamir Office for viewing distances common to an office environment, Shamir Creation, optician cosmetic fit for the newest line of frames, Shamir Attitude, lenses especially designed for wrap around frames, and Shamir Autograph, which is based on our Direct Lens Technology to allow greater customization of the lens.

22

Distribution Channels

        We have currently two separate distribution platforms for our two principal markets, the United States and Europe, which are specifically tailored to our target customers in each market. Our sales via our European subsidiaries, mainly to European based operations, accounted for $71.9 million, or 51.2%, of our revenues in 2008, and sales mainly in the United States, via Shamir Insight, accounted for $27.6 million, or 19.7% during the same period.

        In Europe, we sell our products directly to retail optical shops through our vertically integrated optical laboratories in Portugal, and Turkey, as well as through our distribution centers in Spain, France, Germany and the United Kingdom. In addition, we sell our products through our European subsidiaries and clients from other parts of the world.

        In the United States, we distribute our products to opticians through laboratories. Laboratories in the U.S. sell their own products as well as the products of different manufactures, like us. There are currently more than 300 laboratories in the U.S. As of today, we have not yet established or acquired an optical laboratory in the United States. We have expanded our U.S. sales via Shamir Insight from approximately $8.7 million in 2003 to approximately $24.7 million in 2008, representing a compound annual growth rate of 23.2%.

Ability to Leverage Resources

        We apply our research and development expertise and resources to making our own lenses and to providing design services to third party lens companies. By providing these services, we are able to generate revenues and further expand our intellectual property base. Through our design services to third party lens manufacturers, we have successfully introduced our technology to the market without having to bear the cost of marketing. As a result, we are able to generate design service revenues, including royalties, by leveraging our proprietary intellectual property across a broad spectrum of customers in our established markets.

        In addition, we believe that the implementation of our Freeform Technology and the ability of optical laboratories to produce custom-made progressive lenses to specification, using our innovative software and based on our mathematical algorithms, have the potential to increase our revenues and to enhance our financial results. As laboratories adopt the Freeform Technology and use this technology to produce lenses, we are able to generate revenues without incurring the cost of manufacturing. Moreover, as we expand into developing markets, we will further leverage our proven technology across a broader geographic base.

Strong Ownership and Dedicated Workforce and Management Team

        Kibbutz Shamir is our largest shareholder and holds approximately 59.04% of our outstanding shares as of June 15, 2009. Kibbutz Shamir was founded in 1944 and is a small communal society of approximately 300 members, including approximately 42 of our employees in Israel. As with most kibbutzim, each member of Kibbutz Shamir owns an equal part of the assets of Kibbutz Shamir. Kibbutz Shamir has been successful in developing and encouraging a creative and dedicated managerial and entrepreneurial team to manage the businesses located in Kibbutz Shamir, including Shalag Industries Ltd., a company that is listed on the Tel Aviv Stock Exchange.

        Our management team supports a particularly creative and dynamic culture, which we believe enhances our ability to innovate. Our executive management group has completed a number of key strategic initiatives, improved our financial performance, successfully completed and integrated acquisitions, strengthened sales and marketing, and enhanced our focus on research and new product development. Three of our directors, including the chairman of our board, and an additional two executive officers, are members of the management board of Kibbutz Shamir.

23

Growth Strategy

        The following plans are the focal points of our strategy to grow our business and increase our revenues.

Maintain Technological Leadership

        We plan to further strengthen our research and development efforts to continue to develop innovative optical design tools, which will be used to design new optical products. We plan to maintain our position among the leading designers and developers of new innovative products that we will utilize for our own production and distribution and sell to third parties. We also plan to continue to invest in promising technologies both directly and through our subsidiaries. We believe that the technologies we are developing will enable us to maintain our technical leadership and create innovative premium products, services and technologies into the future.

Capitalize on Positive Demographic Trends and Increase Penetration

        Given our strategic focus on progressive lenses, we believe that we are well positioned to benefit from the positive demographic trends in developed countries and the increased penetration of progressive lenses in developed and developing regions. Because Presbyopia is an age-related process that affects almost all individuals above the age of 45, we believe demand for progressive lenses will continue to benefit from the aging of the population. In addition, the multifocal lens market continues to experience a positive transition to progressive lenses as a superior alternative to bifocal lenses. We intend to capitalize on our design and manufacturing capabilities in order to take advantage of these demographic and market trends.

Increase Share in Key Markets

        We plan to expand our sales in Europe by acquiring or establishing additional optical laboratories and marketing platforms, and also plan to implement new sales and marketing programs to further leverage our existing optical laboratories and distribution centers in Germany, Spain, Portugal, France, Turkey and the United Kingdom. We plan to significantly increase our presence in the United States by expanding our sales force and increasing our marketing programs. We plan to increase awareness and brand recognition world-wide by participating in trade shows, seminars and conventions, and hosting presentations for optometrists, opticians and ophthalmologists. We believe that greater brand recognition, combined with the quality of our products, will enable us to expand our business with existing laboratory customers and generate additional business from potential new customers.

Expand into New Geographic Markets

        Given the population demographics of Australia, Central and South America, China, India, other Asian countries and Eastern Europe, and the low current penetration in these areas, we believe these markets provide significant growth opportunities for our products. In each of these markets, we have established relationships with optical laboratories and distributors with whom we intend to develop agreements so that they expand distribution of our products, as we have done in other parts of the world. In addition, we plan to explore vertical acquisitions of optical laboratories or to establish new laboratories or distribution platforms with local strategic partners where appropriate to maintain and increase our market share. By developing new and existing distribution relationships and expanding our sales of technology solutions and design molds into developing markets, we believe that we will be able to further leverage our proven technology across a broader geographic base, deriving even more value from our existing resources.

24

Implement New Approach of Designing and Manufacturing Personal Lenses

        We were among the first progressive lens manufacturers to provide optical laboratories with a newly developed Freeform production method. Our Freeform production method, known as our Direct Lens Technology, is an advanced surfacing technology for creating premium lenses customized for the unique needs of each patient. By combining the patient’s exact vision requirements with our proprietary Eye Point Technology, a personal file for a customized progressive lens is created and transferred to advanced cutting and polishing machinery for production. We believe that over time Freeform production methods will redefine the traditional ophthalmic business model on an industry-wide basis. We are currently utilizing our Direct Lens Technology in optical laboratories and we intend to increase the number of laboratories to whom we provide this production technology.

Focus on Value-Added Materials

        Our lenses are available in a variety of materials, including standard plastics and high refraction index plastics that allow for thinner lenses. We plan to continue to increase our offerings of lenses made from plastic and high index material. We believe that they represent the fastest growing segment for progressive lenses and provide enhanced profit margins. We believe this strategy will improve the performance of our products and generate increased sales.

Products

        Our products consist of lenses that we sell to optical laboratories and opticians, and design services, including molds, which we sell to optical lens manufacturers under service and royalty agreements. During the year 2008, revenues from our sales of lenses accounted for 96.4% of our total revenues, while revenues from our sales of design services and other accounted for 3.6% of our total revenues.

Lenses

        Premium Lenses. We believe that we have been one of the market leaders in manufacturing premium progressive lenses in a wide range of materials over the past several years. These lenses are sold under our own brand names as well as private labels. We currently produce over 50 principal types of progressive lenses, which differ from one another in design, color and lens material, as well as in size and shape.

        Freeform Lenses. In addition to our premium lens offerings described above, we also produce lenses under the Shamir Autograph and Shamir Smart brands using our proprietary Freeform production method known as Direct Lens Technology, a technology which we released in 2004. Our Direct Lens Technology creates a unique personal computer file for a customized progressive lens by combining the patient’s exact vision requirements with our proprietary Eye Point Technology. This file can be transferred to advanced cutting and polishing machinery for mold-free lens production. This single process yields a finished lens that contains both the progressive and prescription characteristics and does not require any further surfacing. In addition, this process allows the optical laboratory to place both the progressive and prescription characteristics on the back surface of the lens, which is closer to the patient’s eye, thereby enhancing the field of view. By taking into account the patient’s personal prescription, measured or traced frame data and the exact pupil position for specifically chosen frames, the Shamir Autograph is a finished, customized progressive lens that is ready for edging and framing in every type of frame. In addition to producing these lenses ourselves, we are also currently providing this technology to selected laboratory customers to allow them to produce these advanced lenses tailored to meet their patients’ unique requirements, for which we receive fees according to usage.

25

        The following table shows our primary brands of lenses.

Brand	Characteristics	Available Materials
Shamir Genesis	All-purpose progressive lens.	Plastic, Glass, Trivex
Shamir Office	Designed for visual clarity from 1.3 ft. to 10	Plastic, Glass,
	ft. Allows comfort for people working in closed	Polycarbonate
	environments.
Shamir Piccolo	Designed to fit into any small frame.	Plastic, Glass,
		Polycarbonate
Shamir Attitude	Designed to fit "Wrap - Around" frames.	Plastic, Polycarbonate
Shamir Creation	Flat lens fit for fashionable frames.	Plastic, Glass,
		Polycarbonate
Shamir Autograph	Customized back surface progressive lens.	Plastic Polycarbonate
	Produced using Freeform Technology.
Shamir Smart	Customized back surface aspheric single vision	Plastic, Trivex,
	lens. Produced using Freeform Technology.	Polycarbonate

Design Services

        Research and Development Services. We provide third party lens manufacturers with research and development services in which we develop new optical designs and related software tools designed for the production processes of lenses and for which we receive ongoing payments and future revenues from royalties. As such we operate as an outsourced research and development arm for third parties. See also “–Research and Development.”

        Molds.We specialize in the design and manufacture of sophisticated progressive lens molds for use by plastic lens manufacturers. We believe our customers value our ability to design tailor-made optical molds to satisfy precise requirements regarding size, base curves, markings and other properties. We design and produce several different molds that can be easily adapted to customer needs by changing characteristics including invisible markings, edge configuration and thickness.

Research and Development

        Our research and development group, which includes approximately 49 engineers, mathematicians, physicists, chemists, programmers and optical technicians, is in our opinion one of the world’s preeminent research and development teams for development of progressive lenses, molds, and complementary technologies and tools. We constantly enhance our capabilities and invest resources in order to develop new innovative products and related tools designed to optimize the production processes. Innovation, technological sophistication and rigorous quality assurance practices have enabled us to position ourselves as a clear technology leader in the progressive lens segment of the lens market and contributed to our growth.

        In addition to pure optical tools, we have developed complementary software tools specifically designed for our research and development requirements, including proprietary software that simulates human vision, and mathematical tools that optimize the design of progressive and aspheric lenses. These proprietary tools, and in particular our Eye Point Technology, enable us to maintain a competitive advantage.

Research and Development Teams

        Our technologies are developed through a cooperative process among our integrated research and development teams that follow the generation of a new concept through to the completion of a new lens or mold design that is ready for production.

26

        Algorithm and Software. Our algorithm and software team works to generate mathematical algorithms aimed to optimize lens design and integrate these algorithms into the optical design software that we build for creating our optical products.

        Optical Design. Our optical design team uses our proprietary software to create innovative progressive lens and mold designs for us and our design services customers.

        R&D Optical Laboratory. Our R&D optical laboratory team generates prototypes for experimentation and testing of each lens and mold designed by our optical design team, using similar manufacturing systems to those that are in place in our mass production facilities.

        Optical Measurement. Our optical measurement team utilizes our advanced measurement capabilities to analyze the prototype and provide our optical designers with detailed information from the prototype that our optical laboratory team has produced.

Proprietary Technologies

        Optical Design Technology. We have developed a unique family of optical design software tools that enable us to create our lenses using unique mathematical algorithms to optimize the optical characteristics of the lens and minimize distortion. These algorithms are continually reviewed and improved to take into account new production methods and advances in raw materials to enable us to quickly integrate new technologies into our design and manufacturing operations.

        Eye Point Technology. Our Eye Point Technology utilizes a dedicated ray-tracing program that we developed to compute optical properties and simulate human vision. Capable of calculating the optical performance of thousands of locations covering the surface of a lens, the ray-tracing program takes into account numerous vision parameters essential for developing progressive lenses. We believe this technology represents a significant departure from conventional lens analysis tools and enables us to optimally develop every lens point in order to create progressive lenses meeting precise individual requirements.

        Direct Lens Technology. Direct Lens Technology is our Freeform production technology that uses dedicated optical machines that are capable of forming a uniquely designed optical lens by processing the raw material to meet the desired geometrical and surface characteristics. Our Direct Lens Technology creates a unique personal electronic file for a customized progressive lens by using our proprietary Prescriptor software to combine the patient’s exact vision requirements with our proprietary Eye Point Technology. This electronic file can be transferred to advanced cutting and polishing machinery for mold-free lens production. This single process yields a finished lens that contains both the progressive and prescription characteristics and does not require any further surfacing. In addition, this process allows the optical laboratory to place both the progressive and prescription characteristics on the back surface of the lens, which is closer to the patient’s eye, thereby enhancing the field of view.

Marketing and Distribution

        Our marketing efforts focus on lenses and design services. Our progressive lenses are marketed to optical laboratories, retail chains, buying groups and opticians. Our research and development services, which include molds designed for the production of progressive lenses, are marketed primarily to other manufactures and designers of plastic lenses. We believe we have gained a reputation in the design services market as a quality leader.

Lenses

        Our marketing strategy in the United States differs from our marketing strategy in Europe and the rest of the world. In the United States it is a customary practice for optical shops to determine for their patients the type of lens to be generated whereas in Europe and the rest of the world the optical laboratories generally make such determinations. Therefore, marketing semi finished progressive lenses in the United States requires a larger marketing force and greater presence in order to reach as many optical shops as possible.

27

        United States. The U.S. ophthalmic market is characterized by a large number of laboratories, independent and non-independent, as well as large national retail chains and buying groups, some of which own their own laboratories. We currently market and distribute our products in the United States directly to laboratories, using our marketing subsidiary Shamir Insight. Our marketing platform aims to build brand recognition for our lenses through its focus on progressive lenses and sponsorship of industry seminars attended by optometrists, opticians and ophthalmologists. To support our marketing efforts and further educate the market on progressive lenses, we developed our “ReCreating Perfect Vision” promotional campaign, in which more than 300 laboratories have joined into a special marketing effort urging customers to use Shamir lenses while presenting the “Eye-View” software, a proprietary program that illustrates differences in lens quality and design.

        Europe. We market and sell our products through our European subsidiaries. Our European subsidiaries rely on two primary distribution channels. The first channel is comprised of our distribution centers and optical laboratories in Germany, Portugal and Turkey. From these locations, we distribute prescription, single vision, and progressive lenses and offer a variety of stock lenses that we source from other manufacturers in order to provide the market with a comprehensive offering of optical lenses. In each of our locations, we employ a professional, well trained sales force that builds our brand name through direct sales efforts and attendance at conventions, presentations and trade shows. Our distribution center in Germany maintains an inventory of several thousand varieties of semi-finished progressive, bifocal and single vision lenses and finished single vision lenses, has significant capacity, and enables us to provide just-in-time deliveries of nearly any size order to anywhere in Europe. The second channel we pursue consists of optical laboratories, chains and buying groups that market our products primarily under a private label. Due to our delivery capabilities, variety of finished and semi-finished lenses, and customer service provided by our laboratories and distribution centers, we believe we can increase our business with our existing customers while simultaneously obtaining business from new opticians, optical laboratories, retail chains and buying groups.

        The Rest of the World and Other Lens Manufacturers. We sell our lenses to other lens manufacturers through our U.S. based subsidiary, Shamir USA. We market and sell our products in the rest of the world through distributor relationships or directly to optical laboratories. We have established relationships with distributors in several markets, which we intend to develop so that they distribute only our products as we have done in Europe and the U.S. We also plan to explore opportunities for vertical acquisitions of optical laboratories or for establishing new laboratories or distribution platforms together with local strategic partners where appropriate to maintain and increase our market share. An example of this strategy was our purchase, in January 2006, of 51% of Spherical Optics (PTY) Ltd., a local distributor in South Africa, through which we distribute our lens brands in the South African market. Recently, we established similar relationships by purchasing approximately 40.4% of a local laboratory and distributor in Thailand, and 51% of a local laboratory and distributor in Mexico. In addition, we participate in many international optical trade shows, such as OLA and Vision Expo in the United States, Silmo in Paris, Mido in Milan, and also local trade shows in China, India, South Africa, Brazil, Spain, Portugal and the United Kingdom.

Design Services

        We have established close technological relationships with other lens manufacturers worldwide for whom we design and to whom we sell molds and design services. We maintain these relationships through ongoing contacts between our research and development teams and the engineering departments of the lens manufacturers.

        In 1994, we established Shamir USA as our marketing channel and distributor of research and development services in the United States. Since then, we have developed supplier-customer relationships with many lens manufacturers in the United States.

28

Customers

        Our customers are optical laboratories, national retail chains, retail buying groups and opticians for spectacle lenses and third-party lens manufacturers for design services. During 2008, our five largest customers collectively accounted for 30.3% of our revenues. Our largest customer accounted for approximately 12.6% of our revenues during 2008. The remaining 69.7% of our revenues are spread across a large number of customers in various geographic locations, and no other customer, other than our five largest customers, accounted for more than 3.5% of our revenues.

Manufacturing Operations

        We operate manufacturing and research and development facilities in Kibbutz Shamir in northern Israel and a manufacturing facility in Kibbutz Eyal in central Israel. These facilities produce molds and semi-finished lenses. We also produce finished lenses at our optical laboratories in Portugal, Israel, Mexico and Turkey.

Raw Materials

        The primary raw materials that we use in our production operations are glass blanks and monomers. The supply market for these raw materials is dominated by a small number of suppliers. See “Item 3. Key Information–Risk Factors–We are dependent on a small number of suppliers for raw materials.”

Production of Semi-Finished Plastic Lenses

        Initial Processing of the Raw Material. We initially combine a mixture of raw materials to prepare the plastic for casting.

        Mold Assembly. Two glass molds, one for forming the convex progressive surface of the lens and one for forming the concave surface of the lens are assembled in a plastic ring or tape. The volume between the two molds is sealed by this plastic ring or tape.

        Casting. The volume between the two molds is filled with the plastic raw material and the two molds are inserted into an oven for polymerization, or hardening, after which time the molds are removed and separated leaving the plastic lens formed by the molds. Following each use, the glass molds are inspected and rinsed with specially designed detergents and chemicals to treat them for re-use.

        Curing and Coating. After the lens is formed by the molds, it undergoes a curing process in order to alleviate internal stress and is coated in accordance with the customer’s request. In some cases, we use a third party subcontractor in order to turn the lens into a photo-chromatic lens, per clients request.

        Marking and Quality Assurance. Once the plastic lens is formed and coated, it is subjected to marking and quality assurance procedures similar to those utilized for glass lenses.

Production of Semi-Finished Polycarbonate Lenses

        Raw Material. We purchase raw material from leading manufacturers of polycarbonate.

        Process. The polycarbonate raw material is injected after heating into dedicated molds that are assembled in an injection machine. The material is cooled down in the mold and once it achieves a desired temperature, the molds are opened and the lenses are pulled out and transferred to a cleaning and hard coating system.

        Marking and Quality Assurance. Once the polycarbonate lens is formed and coated, it is subjected to marking and quality assurance procedures similar to those utilized for plastic lenses.

29

Production of Finished Lenses by Freeform Technology

        Freeform Technology refers to a new lens production technology that incorporates special optical machines that are capable of accurately forming an optical surface defined by a computer data file. Using this technology, we surface lenses so that the lenses are made according to the prescription requested by the optometrist. We also provide this production method to several optical laboratory customers to allow the production of customized lenses with greater optical accuracy. Using this technology, a spherical semi-finished lens blank is processed on its concave side by a computer-controlled Freeform optical lathe. The lathe computer is loaded with a surface data file. The surface data file is specifically computed by our proprietary Prescriptor software to meet a desired prescription. After forming the surface topography by the lathe, the lens is polished by a Freeform polishing machine to achieve optical surface quality. Using a laser engraving system, we etch reference marks on the concave surface to enable the optician to properly fit the lens into the frame.

Production of Glass Molds and Semi-Finished Glass Lenses

        Initial Processing of the Raw Material. We receive raw material in the form of glass round blanks, which are then ground, lapped and polished in order to give them an accurate form and high optical quality surface.

        Rinsing. The blanks are rinsed thorough a series of ultrasonic tanks to remove production residues from the surface and then dried.

        Imprinting the Progressive Attributes. Each blank is laid on a ceramic block for imprinting the progressive attributes and passed through a special heating oven in order to relax its form. We produce the ceramic blocks using computerized milling equipment, which imprints topography of the progressive surface on the ceramic block using our proprietary software. When the glass softens, the ceramic block structure is copied onto the blank and the progressive attributes are retained on the surface.

        Marking. Each lens is etched with semi visible and visible marks to aid with the precise adjusting and mounting of the lens in the eyeglass frame and other marks requested by customers, such as a customer’s logo.

        Quality Assurance and Control. Lenses and molds undergo rigorous quality control for cosmetics, such as cracks or nicks, and optics, such as power and geometry.

        The process for producing glass progressive lenses and molds is similar, but the production of molds involves additional edge processing to shape the mold’s edge so that it will fit the manufacturing systems of the customer to whom we sell the mold.

Freeform Production of Glass Molds

        In addition to the traditional production methods described above, we use our Freeform production method for our internal glass molds production process. In this Freeform production method, advanced grinding and polishing machines are used to surface the mold in accordance with the topography of a surface that was computed by our optical design software. This production technology enables us to create a desired multifocal surface topography of the mold by machining the glass surface instead of forming it by heat. We grind a glass blank with a computer-controlled Freeform grinding machine. This process creates the needed surface topography. We then polish the lens with dedicated computer-controlled Freeform polishing machines. This production technology involves fewer steps and results in higher surface accuracy than traditional production.

30

Freeform Lens Calculation Software (Prescriptor), Writing and Distributing

        Our software team, which is part of the R&D team, is writing a Freeform lens calculation software that computes a surface for processing a Freeform lens. The software gets as an input the prescription of lens as ordered by the optometrist as well as the frame shape that the customer selected. The software computes a file that represents the surface that needs to be formed on the lens and transfer it to a Freeform manufacturing line. A lens having the exact prescription and optimal optical and geometrical characteristics is produced by the Freeform line, using this file. We installed and keep installing this software at our customer’s facilities and we get paid based on usage of this technology, which is monitored and reported by the software.

Extent of Dependency on Patents/Licenses

        We seek to protect our intellectual property through patents, trademarks, trade secrets and other appropriate protective measures in the primary markets in which we are active. As of December 31, 2008, we hold seven patents and two pending patent applications owned by us, one patent and three pending patent applications owned by SSOP, and five patents owned by our partially owned subsidiary Inray Ltd. These patents cover various aspects of our innovative algorithms, devices, and methods of designing multifocal surfaces.

        We own rights directly or through our subsidiary Shamir Insight Inc., in the following trademarks in various jurisdictions world-wide: Shamir™, Shamir logo, Shamir Genesis™, Genesis™, Shamir Piccolo™, Piccolo™, Shamir Office™, Shamir Creation™, Shamir Autograph™, Autograph™, Shamir Attitude™, Attitude™, Prescriptor™, Eye Point Technology™, Freeform™, Freeform Lenses™, Freeform Technology™, Freeform Software Protocol™, Panorama™, Eye Point™, Direct Lens Technology™, Autograph Golf™, Autograph Short™, Autograph Everyday™, Piccolo Wrap™, The Progressive Lens Experts™, Titan Hardcoat™, Deskvision™, Individual Eyes™, Recreating Perfect Vision™, Multispace™, Nano™, Piccolo Nano™, Autograph Nano™, Shamir Relax™, Autograph Relax™, Sport Attitude™, Shamir Smart Office™, Shamir Smart Attitude™, Shamir Smart Single Vision™, Shamir Freeform Geometry™ and Shamir Freeform Cosmetics™. Our main trademarks are registered or are in the process of being registered in the United States, the European Union, Canada and additional countries. We do not believe that our viability or profitability substantially depends on any single patent, trademark, trade secret or other piece of intellectual property.

Material Effects of Government Regulations

        We are subject to regulatory requirements governing the manufacture and sale of spectacle lenses in all of the markets in which we operate. For example, in the United States our lenses–like those of our competitors–must comply with the so-called “drop-ball impact test” to satisfy the safety requirements of the U.S. Food and Drug Administration for the sale of lenses. The drop-ball impact test involves dropping a steel ball of specified size from a specified height onto the center of a lens with a specific size. The lens passes the test if it does not break.

        In Europe our lenses must obtain certifications within the requirements of the Medical Device Directive 93/42 EEC. These certifications relate primarily to the adequacy of the procedures used in the manufacture, testing and sale of spectacle lenses.

        In addition, our operations are subject to stringent environmental regulations throughout the world concerning, in particular, air emissions, waste water discharge and the generation, handling, storage, transport and disposal of hazardous wastes. These laws and regulations have for the most part become increasingly stringent over the years. In order to comply with these laws and regulations, we use non-hazardous materials and chemicals in our manufacturing processes where feasible. Certain of our processes, including cleaning lenses, assembling molds and coating lenses, require a variety of volatile and hazardous substances. Where use of these substances or other hazardous materials is essential, we develop manufacturing processes in compliance with relevant local, national and international environmental and safety standards.

        Our policy is to meet or exceed all applicable environmental and health and safety laws and regulations. We believe that we possess all material permits and licenses necessary for the continuing operation of our business and that our operations are in substantial compliance with the terms of all applicable environmental laws and regulations. We cannot predict the impact of any new environmental laws or regulations or of changes in current environmental laws or regulations on our operations.

31

4.C ORGANIZATIONAL STRUCTURE

        In furtherance of our focus on innovative research and development projects, we have acquired equity interests in companies in the optical field. The following chart shows the names and locations of our direct and indirect subsidiaries and equity investments, along with our ownership interest in each relevant subsidiary.

Shamir Optical Industry LTD.

Kibbutz Shamir, Israel

Eyal Optical Ind. Ltd.

K. Eyal, Is.

100%

Shamir Special
Optical Products Ltd.

K. Shamir, Is.

100%

Spherical Optics
(Pty) Ltd.

Joh., South Africa

51%

Shamir USA

Agora Hills, CA

100%

e-Vision LLC

Roanoke, VA

17.52%

Siam Optical

Technology

Company Ltd.

Bangkok, Thailand

40.4%

Inray Ltd.

K. Shamir, Is.

50%

(1)

Shamir Optic GmbH

Niederau, Ger.

100%

Shamir
Insight, Inc.

San Diego, CA

100%

Shamir UK Limited
Cambridge, UK

100%

Shamir Portugal, LDA

Vilar, Portugal

100%

Shamir Optical Espana, SL

Madrid,  Spain

100%

Interoptic SARL

Paris, France

100%

Altra Optik Sanayi
ve Ticaret A.S.

Istanbul, Turkey

100%

Shamir France SARL

Paris, France

100%

Shamir Israel Optical
Marketing Ltd.

K. Shamir, Is.

100%

Shamir Or Ltd.

K. Shamir, Is.

100%

Centro Integral
Optico

S.A. de C.V.

Mexico City, Mex.
51%

Shalens S.A. C.V.

Mexico City, Mex.

51%

(1) Shamir has a 50.03% ownership interest and holds 50% of the voting rights in Inray Ltd.

The subsidiaries and equity investments shown in the chart above engage in the following business activities:

— Eyal Optical Industries (1995) Ltd. manufactures Shamir plastic progressive and other lenses.

— Shamir Or Ltd. is a research and development company.

— Shamir USA, is one of our marketing and distribution companies in the U.S.

— Shamir Insight, Inc. is our main marketing and distribution company in the U.S.

— Shamir Optic GmbH is a distribution company located in Germany. We hold 100% ownership of Shamir Optic GmbH.

— Inray Ltd. is a research and development company jointly owned by us, the Technion Israel Institute of Technology and two of its researchers.

— e-Vision, LLC, through its partially owned subsidiaries PixelOptics, Inc., Ocular Optics, Inc. and SolBeam, Inc., is developing and marketing lenses.

— Interoptic S.A.R.L. is one of our distributors in France.

— Shamir Optical Espana, S.L. is our distributor in Spain.

— Altra Optik Sanayi ve Ticaret A.S. is our laboratory facility and distributor in Turkey.

— Shamir France S.A.R.L. is one of our distributors in France.

— Spherical Optics (PTY) Ltd. is our local distributor in South Africa. Through Spherical we hold 25% of Optispeed Laboratory (PTY) Ltd., a local laboratory.

— Shamir Portugal, LDA. is our optical laboratory and distributor in Portugal, which also serves our European subsidiaries.

— Shamir UK Limited a distributor in the United Kingdom. Following recent changes in the structure of our European subsidiaries Shamir UK Limited is the holding company of most of our European subsidiaries.

— Shamir Special Optical Products Ltd. is an optical laboratory and a manufacturer of semi finished polycarbonate lenses located in Kibbutz Shamir.

32

— Shamir Israel Optical Marketing Ltd. is our local distributor to the Israeli market.

— Centro Integral Optico S.A. de C.V. is a laboratory and one of our distributors in Mexico.

— Shalens S.A. de C.V. is one of our distributors in Mexico.

— Siam Optical Technology Company Ltd. is a company through which we operate a local laboratory in Thailand.

4.D PROPERTIES, PLANT AND EQUIPMENT

        Our principal executive offices and our primary manufacturing facilities are located in Kibbutz Shamir in northern Israel and in Kibbutz Eyal in central Israel. At these facilities we produce molds, finished lenses and semi-finished glass, plastic and polycarbonate lenses. See “—Manufacturing Operations.” We sublease the facilities in Shamir from Kibbutz Shamir. See “Item 7. Major Shareholders and Related Party Transactions.” Together, the Shamir group facilities in Israel, in Kibbutz Eyal and in Kibbutz Shamir, cover approximately 17,483 square meters of manufacturing, warehouses and office space.

        We also own optical laboratories in Portugal, Turkey and Mexico, which occupy approximately 4,000 square meters, 1,496 square meters and 2,758 square meters of owned and leased manufacturing and office space, respectively. Our distributors in France, Germany, Spain, United Kingdom and South Africa also lease or own storage and office facilities in which they conduct their operations.

The following table gives an overview of our material properties, plants and facilities:

Name/Location	Company	Primary Use	Size	Leased/Owned
			(in sq meters)
Kibbutz Shamir, Israel	Shamir Optical Industry Ltd.; Shamir Special Optical Products Ltd.; Shamir Israel Optical Marketing Ltd.; Shamir Or Ltd.	Headquarters; Administration; Marketing; Research and Development; Optical Laboratory; Manufacturing	13,486	Leased
Kibbutz Eyal, Israel	Eyal Optical Industries (1995) Ltd.	Manufacturing; Distribution warehouse	3,997	Leased
Vilar, Portugal	Shamir Portugal, LDA	Optical laboratory, Distribution	4,000	Owned
Madrid, Spain	Shamir Optical Espana S.L.	Distribution	570	Leased
Collegien, France	Shamir France S.A.R.L.	Distribution	5,782	Capital Lease
Paris, France	Interoptic S.A.R.L.	Distribution	250	Leased
Istanbul, Turkey	Altra Optik Sanayi ve Ticaret A.S.	Optical laboratory; Distribution	1,496	Owned
Niederau, Germany	Shamir Optic GmbH	Distribution warehouse	3,925	Owned
Cambridge, United Kingdom	Shamir UK Limited	Distribution	1,001	Leased
San Diego, California	Shamir Insight, Inc.	Distribution	1,687	Leased
Agoura Hills, California	Shamir USA	Distribution	133	Leased
Mexico City, Mexico	Centro Integral Optico S.A. de C.V.	Optical laboratory, Distribution	2,758	Leased
Johannesburg, South Africa	Spherical Optics (Pty) Ltd.	Distribution	450	Leased

ITEM 4A. UNRESOLVED STAFF COMMENTS

Not applicable.

33

ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS

        The following discussion and analysis should be read in conjunction with our consolidated financial statements and accompanying notes, which appear elsewhere in this annual report. This discussion contains forward-looking statements that involve risks and uncertainties. See “Forward-Looking Statements.” Our actual results could differ materially from those anticipated in these forward-looking statements, including as a result of various factors discussed below and included elsewhere in this annual report, particularly under the heading “Key Information–Risk Factors.”

        We prepare our financial statements in accordance with U.S. GAAP, and our reporting currency is the U.S. dollar. We generate revenues and incur expenses principally in dollars, Euros and NIS. Certain amounts in this annual report are subject to rounding adjustments.

Overview

        We are a leading provider of innovative products and technology to the spectacle lens market, with a particular focus on the progressive and sophisticated lens market. Utilizing our proprietary technology, we develop, design, manufacture and market progressive lenses that we sell to the ophthalmic market. In addition, we sell all kind of lenses to opticians, and utilize our capabilities to provide design services to optical lens manufacturers under service, and royalty agreements. Our leading lenses are marketed under a variety of trade names, including Shamir Genesis, Shamir Piccolo, Shamir Office, Shamir Creation, Shamir Smart and Shamir Autograph.

        We believe that we have one of the world’s preeminent research and development teams for progressive lenses, molds and complementary technologies and tools. We have developed software dedicated to the design of progressive lenses. This software is based on our proprietary mathematical algorithms that optimize designs of progressive lenses. We have also created software tools specifically designed for our research and development and production requirements.

Presentation of Financials after Reorganization

        On March 6, 2005, we changed our legal structure from an agricultural cooperative society (A.C.S.) to an Israeli corporation. As the A.C.S. was a pass-through tax entity, the tax liability in respect of our operations was not charged to the company but to the owners, pro rata to their holding in the A.C.S. For comparison purposes, we have included in the selected consolidated financial data in this annual report our pro forma net income, which reflects income taxes we would have paid during the historical periods presented, assuming we had been a tax-paying corporation during that time. See “Item 3. Key Information – Corporate Reorganization.”

5.A OPERATING RESULTS

Functional Currency and Exchange Rate Fluctuations

        The functional currency of Shamir and certain of our subsidiaries is the U.S. dollar, as the dollar is the primary currency of the economic environment in which we and certain of our subsidiaries operate and expect to continue to operate in the foreseeable future.

        The functional currency of most of our European subsidiaries is the Euro. In addition, we have certain worldwide subsidiaries with various local currencies as their functional currency. Accordingly, the assets and liabilities of these subsidiaries are translated at the year-end exchange rate, and statement of income items are translated at the average exchange rate during the reported period.

        We generate our revenues primarily in Euros and U.S. dollars, and we incur a significant portion of our expenses in Euros and NIS (the latter principally in connection with salaries and related expenses of our staff in Israel). A fluctuation in the value of the Euro compared to the U.S. dollar may have a material impact on our revenues, which is often partially offset by expenses in Euro and by price adjustments for some of our Euro-priced products to compete with competitors’ U.S. dollar-priced products. In addition, a fluctuation in the value of the NIS compared to the U.S. dollar may have a material impact on our expenses. As of December 31, 2007, the NIS exchange rate appreciated against the U.S. dollar by 9.0% and the Euro exchange rate appreciated against the U.S. dollar by 10.5%. As of December 31, 2008, the NIS exchange rate appreciated against the U.S. dollar by 1.1% and the Euro exchange rate devaluated against the U.S. dollar by 5.6%.

34

        The NIS annual average rate in 2007 and 2008 appreciated against the U.S. dollar by 7.8% and 12.7% respectively, and the Euro annual average rate appreciated against the U.S. dollar by 8.3% and 6.6%, respectively, which had an adverse effect on our results of operations.

Revenues

        We generate revenues both from selling lenses to laboratories and opticians and from providing design services to third party manufacturers. Our lenses are sold primarily under Shamir brands through distributors, including our majority-owned subsidiaries. Design services are provided under contracts with other lens manufacturers and include research and development services, production of molds for lenses, and royalties from the sale of lenses made utilizing our designs. In the last five years, we have experienced significant growth in the sale of our lenses, as we have focused our efforts on the marketing and distribution of our own lenses and as our superior designs gain greater acceptance in the market. From 2004 to 2008, revenues from the sale of lenses increased by approximately 20.4% annually while revenues from design services slightly decreased during the period. We anticipate that revenues from the sale of lenses will continue to provide the majority of our revenues.

Lenses

        Our primary source of revenues is the sale of semi-finished lenses, finished progressive lenses and other lenses. Semi-finished lenses are sold through our principal fully-owned subsidiaries in the US and Europe; finished lenses and other lenses are sold mainly in Europe through our local subsidiaries. Revenues from lenses are recognized when delivery has occurred. Our revenue from Freeform technology is steadily increasing.

Design Services

        We also generate revenues from design services that we provide to third party manufacturers. We generate revenue mainly in the period between the beginning of the project and the completion of the main prototype. Following this completion, there is a period during which we receive only limited revenue, if any, from adjustments and improvements to the prototype. Upon commencement of the production stage, we receive revenue from the sales of molds and royalties from sales of lenses made from our designs. Sometimes we produce and sell to customers semi- finished lenses based on the design which we develop for them; we recognized this as sales of lenses. Design service revenues are recognized at the time research and development services are provided, upon delivery of molds and when royalties are due.

The following table shows our revenues by product category, in thousands of dollars:

	Year Ended December 31,
	2006		2007		2008
Lenses	$	90,387	$	113,945	$	135,298
Design services		6,893		6,474		5,028
Total revenues, net	$	97,280	$	120,419	$	140,326

        The increase in our revenues from the sale of lenses was primarily due to the success of the increased marketing activities of our European subsidiaries, which increased its sales from $53.3 million in 2006 to $71.9 million in 2008. In addition, Shamir Insight, increased its sales over the same period from $23.3 million to $27.6 million. . We also sell lenses through local distributors and to other third party manufacturers in other countries, which sales increased from $13.8 million in 2006 to $35.8 million in 2008, part of this increase is attributed to the sales of our Mexican subsidiaries which are consolidated commencing February 2008.

35

The following table shows our revenues by geographic region, in thousands of dollars:

	Year Ended December 31,
	2006		2007		2008
Europe	$	50,747	$	63,230	$	70,371
United States		30,077		36,681		40,796
Asia		9,560		12,695		10,769
Israel		853		1,892		3,255
Others (1)		6,043		5,921		15,135
Total revenues, net	$	97,280	$	120,419	$	140,326

(1) Most of this increase is attributed to the sales of our Mexican subsidiaries which are consolidated commencing February 2008.

Cost of Revenues

        Our cost of revenues consists primarily of manufacturing costs incurred in the production of lenses and molds, and is comprised mainly of raw materials, salaries and other personnel expenses for employees engaged in the manufacture of our products. Other expenses include inter alia subcontractor services, depreciation on property and equipment, rent and utilities. Our cost of revenues also includes the cost of lenses purchased from other manufactures. Our cost of revenues is affected, directly or indirectly, by a number of factors, as follows: mixture of products, currency fluctuations, the establishment or purchase of new production facilities and increased focus on production technologies that have a high added value.

Gross Profit

        Our gross profit margin was approximately 55%, 54% and 54% for the years ended December 31, 2006, 2007 and 2008, respectively. Although the mixture of the product we sold was different compared to prior years we have been able to maintain our margins throughout this period. Our gross margin is affected, among other things, by the mixture of products sold, by production efficiency, by our penetration efforts to new markets and by currency fluctuations.

Research and Development

         Our research and development costs consist primarily of salaries and other personnel-related expenses of employees, principally engaged in research and development activities. We also incur external engineering fees, materials costs and other overhead expenses in connection with the design and development of our products. Research and development expenses related to our design services are included in research and development costs. We expense all our research and development costs as incurred. As we expand our operations and the development of new products and technologies, we expect our research and development expenditures to increase in absolute dollar terms.

Selling and Marketing

        Our selling and marketing expenses consist primarily of salaries, commissions and other personnel-related expenses for those of our employees principally engaged in the sale and marketing of our products. Compensation for sales managers and sales representatives is based to a significant extent on commissions related to performance. Additional expenses include advertising, trade shows, delivery, other promotional costs, and office expenses related to sales and marketing.

36

        In 2008 we continued our increased marketing efforts in areas where we established or purchased a new marketing platform in the past several years, such as in France, the United Kingdom, Turkey and Mexico. The increase in our selling and marketing expenses during 2008 was caused mainly as a result of the increase in revenues. As a percentage of revenues, our selling and marketing expenses decreased from 30.4% for the year ended December 31, 2007 to 30.2% for the year ended December 31, 2008.

        As we expand our operations, we expect our selling and marketing expenses to remain at approximately the same level as a percentage of revenues.

General and Administrative

        Our general and administrative expenses consist primarily of salaries and other personnel-related expenses for executive officers, accounting and administrative personnel, bad debts and doubtful accounts, professional fees, office expenses and other general corporate expenses. The increase in our general and administrative expenses was attributable to the increase in our management personnel worldwide as part of our global expansion of operation. We expect our general and administrative expenses to remain at approximately the same level as a percentage of our revenues.

Financial Expenses and other, Net

        Financial expenses consist of interest income from our cash, cash equivalents and short term investments offset by interest expenses on borrowings and other bank fees. Financial expenses also incorporate adjustments due to exchange rate fluctuations and gains or loses from derivatives.

Taxes on Income

        Our taxes on income consist of changes in deferred tax assets or liabilities and provisions for taxes on income resulting from the activities of our subsidiaries worldwide. Our effective tax rate may vary from period to period based on changes in estimated taxable income or loss, currency fluctuation, changes to the valuation allowance, changes to state or foreign tax laws, future expansion into geographic areas with varying country, state and local income tax rates, deductibility of certain costs and expenses by jurisdiction and as a result of acquisitions, divestitures and reorganizations.

Equity in Gains (Losses) of Affiliates, Net

        Equity in gains of affiliates is shown in our consolidated financial statements primarily to reflect our holdings in Shalens and CIO (until February 20, 2008, the date on which we acquired control in CIO and Shalens) SOT Optispeed Laboratory (PTY) Ltd. as of December 31, 2008, and our holdings in Shamir Israel (until August 15, 2007, the date on which we purchased the remaining 50% interest in Shamir Israel), Shalens, CIO and SOT as of December 31, 2007.

Minority Interests in Losses of Subsidiaries

        Minority interests are reflected in our consolidated financial statements in order to reflect our non-wholly owned subsidiaries in Shalens and CIO (from February 20, 2008, the date on which we acquired control of 51% in CIO and Shalens), Spherical Optics (Pty) Ltd. (which we have a 49% minority holding) and Shamir GMBH (until July 1, 2008, the date on which we purchased the remaining 49% interest in Shamir GMBH), and the minority interest in Shamir Insight (until July 2007, the date on which we purchased the remaining 10% interest in Shamir Insight).

37

Operating Results

        The following table sets forth certain operating data as a percentage of total revenues for the periods indicated:

	Year Ended December 31,
	2006			2007			2008
Revenues, net		100.00			100.00			100.00
Cost of revenues		45.3			46.4			45.9
Gross profit		54.7			53.6			54.1
Operating expenses:
Research and development		2.4			2.1			2.4
Selling and marketing		33.7			30.3			30.2
General and administrative		11.3			11.3			12.0
Total operating expenses		47.4			43.7			44.6
Operating income		7.3			9.9			9.5
Financial income (expenses) and other, net		(0.2	)		(0.2	)		(1.4	)
Income before taxes on income		7.1			9.7			8.1
Taxes on income		2.2			4.2			1.6
Income after taxes on income		4.9			5.5			6.5
Equity in gains (losses) of affiliates, net		(0.3	)		0			0
Minority interest in losses of subsidiaries		2.0			1.3			0
Net income		6.6			6.8			6.5

Year Ended December 31, 2008 Compared To Year Ended December 31, 2007

        Revenues, Net. Total revenues were $140.3 million for the year ended December 31, 2008, an increase of $19.9 million or 16.5% compared to total revenues of $120.4 million for the year ended December 31, 2007. The increase was primarily attributable to the increase of sales of lenses to the rest of the world and to other third-party manufacturers. The sale of lenses to the rest of the world and to other third-party manufacturers in 2008 increased by $14.0 million compared to 2007, mainly due to the sales of our newly consolidated operation in Mexico. Increased demand in the United States through Shamir Insight resulted in $3.3 million increase of sales and our European subsidiaries that contributed approximately $4.0 million in sales growth mostly attributed to currency fluctuation. Revenues generated from services to third-party manufacturers, including design services, mold production and royalties, decreased by $1.4 million between these periods.

        Cost of Revenues. Cost of revenues was $64.4 million for the year ended December 31, 2008, an increase of $8.6 million or 15.3% compared to cost of revenues of $55.9 million for the year ended December 31, 2007. The increase in cost of revenues was primarily due to an increase in the number of lenses produced. As a percentage of revenues, our cost of revenues slightly decreased from 46.4% for 2007 to 45.9% for 2008.

        Research and Development. Research and development costs were $3.4 million for the year ended December 31, 2008, an increase of $0.8 million or 31.4% compared to research and development costs of $2.6 million for the year ended December 31, 2007, mainly due to the increase in manpower and the appreciation of the NIS versus the U.S. dollar.

        Selling and Marketing. Selling and marketing expenses were $42.4 million for the year ended December 31, 2008, an increase of $5.8 million or 15.9% compared to selling and marketing expenses of $36.6 million for the year ended December 31, 2007. Selling and marketing expenses increased primarily due to the increase in sales efforts and the Euro versus dollar exchange rate fluctuation. As a percentage of revenues, sales and marketing expenses slightly decreased from 30.3% for 2007 to 30.2% for 2008.

38

        General and Administrative. General and administrative expenses were $16.8 million for the year ended December 31, 2008, an increase of $3.3 million compared to general and administrative expenses of $13.5 million for the year ended December 31, 2008. As a percentage of revenues, general and administrative expenses increased from 11.3% for 2007 to 12.0% for 2008. The increase in the general and administrative expenses in U.S. dollar terms in attributed mainly to the general and administrative expenses of our newly consolidated activity in Mexico, compensation to our former chief executive officer , and the Euro versus U.S. dollar and NIS versus U.S. dollar exchange rates fluctuations.

        Financial Expenses and other, Net. Net financial expenses and other was $2.1 million for the year ended December 31, 2008, an increase of $1.9 compared to Net financial expenses and other of $0.2 million for the year ended December 31, 2007. This was primarily due to the fact that our financial income from cash and cash equivalents and short term investments decreased while the financial expenses on our borrowings increased due to the global credit crisis and from foreign exchange translation expenses.

        Taxes on Income. Taxes on income were $2.2 million for the year ended December 31, 2008, a decrease of $2.8 million compared to taxes on income of $5.0 million for the year ended December 31, 2007. Taxes on income decreased as a percentage of revenues from 4.2% for 2007 to 1.6% for 2008. The effective tax rate for 2008 was 19.7% compared to 43.0% for the fiscal year 2007. This decrease was mainly attributable to re-measuring in 2008 our taxable income in Israel for the year 2007 in NIS instead of in U.S. dollar and the valuation allowance on the deferred tax assets related to our European subsidiaries that we made in 2007.

        Equity in Gains of Affiliates, Net. Equity in gains of affiliates, net remain constant at approximately $0.04 million for the year ended December 31, 2008 and 2007. These gains were related to our affiliates, Shamir Israel (until August 15, 2007, from which time we held a 100% interest), SOT, CIO and Shalens (until February 20, 2008, from which time we held a 51% interest), and Optispeed Laboratory (PTY) Ltd.

        Minority Interests in Losses of Subsidiaries. Minority interests in losses were $0.02 million for the year ended December 31, 2008, a decrease of $1.49 million compared to minority interests in losses of $1.5 million for the year ended December 31, 2007, this decrease attributed to our purchase of the minority share in Shamir GMBH on July 1, 2008.

Year Ended December 31, 2007 Compared To Year Ended December 31, 2006

        Revenues, Net. Total revenues were $120.4 million for the year ended December 31, 2007, an increase of $23.1 million or 23.8% compared to total revenues of $97.3 million for the year ended December 31, 2006. The increase was primarily attributable to the increase of sales in Europe through our European subsidiaries and the sales of lenses to the rest of the world and to other third-party manufacturers. Increased demand in the United States through Shamir Insight resulted in $1.0 million increase of sales, while increased marketing activities of European subsidiaries contributed approximately $14.6 million in sales growth. The sale of lenses to the rest of the world and to other third-party manufacturers in 2007 increased by $8.0 million compared to 2006. Revenues generated from services to third-party manufacturers, including design services, mold production and royalties, decreased by $0.4 million between these periods.

        Cost of Revenues. Cost of revenues was $55.9 million for the year ended December 31, 2007, an increase of $11.9 million or 26.8% compared to cost of revenues of $44.0 million for the year ended December 31, 2006. The increase in cost of revenues was primarily due to an increase in the number of lenses produced. As a percentage of revenues, our cost of revenues increased from 45.3% for 2006 to 46.4% for 2007 mainly due to the devaluation of the U.S. dollar versus the NIS and Euro.

        Research and Development. Research and development costs were $2.6 million for the year ended December 31, 2007, an increase of $0.2 million or 8.1% compared to research and development costs of $2.4 million for the year ended December 31, 2006.

        Selling and Marketing. Selling and marketing expenses were $36.6 million for the year ended December 31, 2007, an increase of $3.8 million or 11.4% compared to selling and marketing expenses of $32.8 million for the year ended December 31, 2006. Selling and marketing expenses increased primarily due to the increase in sales efforts and the Euro versus dollar exchange rate fluctuation. As a percentage of revenues, sales and marketing expenses decreased from 33.7% for 2006 to 30.3% for 2007.

39

        General and Administrative. General and administrative expenses were $13.5 million for the year ended December 31, 2007, an increase of $2.5 million compared to general and administrative expenses of $11.0 million for the year ended December 31, 2006. As a percentage of revenues, general and administrative expenses remained constant at approximately 11.3% for 2006 and 2007. The increase in the general and administrative expenses in U.S. dollar terms in attributed to increases in management personnel worldwide, an increase in the doubtful accounts provisions and the Euro versus U.S. dollar and NIS versus U.S. dollar exchange rates fluctuations.

        Financial Expenses and other, Net. Net financial expenses and other remain constant at $0.2 million for the year ended December 31, 2007 and 2006. This was primarily due to the fact that the increase in the expenses on loans was offset by income from derivatives and foreign exchange translation.

        Taxes on Income. Taxes on income were $5.0 million for the year ended December 31, 2007, an increase of $2.8 million compared to taxes on income of $2.2 million for the year ended December 31, 2006. Taxes on income increased as a percentage of revenues from 2.2% for 2006 to 4.2% for 2007. The effective tax rate for 2007 was 43.0% compared to 31.5% for the fiscal year 2006. This increase was attributable to an increase in the valuation allowance on the deferred tax assets related to our European subsidiaries.

        Equity in Gains (Losses) of Affiliates, Net. Equity in gains of affiliates, net was $0.04 million for the year ended December 31, 2007, an increase of $0.29 compared to equity in losses of affiliates, net of $0.25 million for the year ended December 31, 2006. These gains were related to our affiliates, Shamir Israel (until August 15, 2007, from which time we held a 100% interest), SOT, CIO and Shalens.

        Minority Interests in Losses of Subsidiaries. Minority interests in losses were $1.5 million for the year ended December 31, 2007, a decrease of $0.5 million compared to minority interests in losses of $2.0 million for the year ended December 31, 2006. This decrease of minority interest in losses was primarily attributable to the decrease in losses of our European subsidiaries.

Critical Accounting Policies

        The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Our estimates, judgments and assumptions are continually evaluated based on available information and experience; however, actual amounts could differ from those estimates. Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements.

Revenue Recognition

        We recognize revenues in accordance with Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 104 (SAB 104), Revenue Recognition in Financial Statements. Revenues include sales of lenses to laboratories.

        Revenues from lens sales, net of rebates and returns, are recognized when delivery of the related goods has occurred, as our significant obligations have been satisfied, title and risk of loss has passed to the customer and collectability is probable.

        We have various programs that allow opticians to earn rebates on their accumulated purchases. These rebates are recognized as a reduction of revenues based on the rebates earned and the estimated future payments in accordance with EITF 01-9, “Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor’s Products).”

40

        Design services are provided to third party manufacturers and include research and development services, production of molds for lenses and royalties from sales of lenses by third party manufacturers. Revenues from research and development services are recognized at the time the services are provided. Revenues from production of molds are recognized upon delivery of the molds and when other criteria of SAB No. 104 are met. Revenues from minimum royalties are recognized when the royalties become due. Other royalties are recognized quarterly, upon the receipt of sales reports from the third-party manufacturer customers.

        We do not have post shipment obligations, customer acceptance or price protection. Our accounting for revenues is consistently applied across all of our distribution channels.

Inventory Valuation

        At each balance sheet date, we evaluate our inventory balance for excess quantities and obsolescence. This evaluation includes analyses of sales levels by product line and projections of future demand. In addition, we write off inventories that are considered obsolete. Remaining inventory balances are adjusted to the lower of cost or market value. If future demand or market conditions are less favorable than our projections, additional inventory write-downs may be required and would be reflected in cost of revenues in the period the revision is made. Significant unanticipated changes in demand could have a material and significant impact on the future value of our inventory and reported operating results. To date, we have not experienced any significant inventory write-offs.

Impairment of Long-lived Assets

        In accordance with SFAS No. 144, we assess potential impairments to our long-lived assets, comprised of property, plant and equipment and other intangible assets, when there is evidence that events or changes in circumstances indicate that the carrying value may not be recoverable. We recognize an impairment loss when the undiscounted cash flow expected to be generated by an asset (or group of assets) is less than its carrying value. Any required impairment loss is measured as the amount by which the asset’s carrying value exceeds its fair value, and is recorded as a reduction in the carrying value of the related asset and charged to results of operations. During the fiscal years 2006, 2007 and 2008, no impairment losses were identified in accordance SFAS No. 144.

Income Taxes

        We record income taxes using the asset and liability approach. Deferred income tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and net operating loss and tax credit carry-forwards.

        Our effective tax rate may vary from period to period based on changes in estimated taxable income or loss, currency fluctuations, changes to the valuation allowance, changes to state or foreign tax laws, future expansion into geographic areas with varying country, state and local income tax rates, deductibility of certain costs and expenses by jurisdiction and as a result of acquisitions, divestitures and reorganizations.

        Management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We have considered future taxable income, prudent and feasible tax planning strategies and other available evidence in determining the need for a valuation allowance. We evaluate all of these factors to determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. If the realization of deferred tax assets in the future is considered more likely than not, an adjustment to the deferred tax assets would increase net income in the period in which this determination was made.

        On January 1, 2007, we adopted FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes, an Interpretation of FASB Statement No. 109” (FIN 48). FIN 48 contains a two-step approach to recognizing and measuring uncertain tax positions accounted for in accordance with SFAS No. 109. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.

41

        As a result of the implementation of FIN No. 48, we recognized a $0.5 million increase in liability for unrecognized tax benefits, which was accounted for as a decrease to the January 1, 2007 balance of retained earnings.

Goodwill

        Under Statement of Financial Accounting Standard No.142, “Goodwill and Other Intangible Assets” (“SFAS No, 142”), goodwill is not amortized. SFAS No.142 requires goodwill to be tested for impairment at least annually or between annual tests in certain circumstances, and written down when impaired. SFAS No. 142 prescribes a two-phase process for impairment testing of goodwill. In the first phase of impairment testing, goodwill attributable to each of the reporting units is tested for impairment by comparing the fair value of each reporting unit with its carrying value. If the carrying value of the reporting unit exceeds its fair value, the second phase is then performed. The second phase of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess.

        We compare the fair value of our single reporting unit as defined under SFAS No. 142, to its carrying value. Fair value is determined using our market capitalization. We perform the impairment tests during the fourth fiscal quarter of each year. In addition, in accordance with the provisions of SFAS No. 142, as a result of the global credit crisis, we performed an additional impairment test as of December 31, 2008. During 2008, 2007 and 2006, no impairment losses were identified.

Valuation of investment in marketable securities

        Fair values of marketable securities are estimated using quoted market prices. As of December 31, 2008, we had no investments in illiquid markets. Based on our intent with respect to a particular investment at the time of investment, we are generally required to classify our investments into one of three investment categories under GAAP: (i) trading; (ii) held to maturity; or (iii) available for sale. The classification of the investment may affect our reported results. We classify the investments as available for sale. Available for sale investments are carried at fair value. Changes in the fair value of investments classified as available for sale are not recognized to income during the period, but rather are recognized as a separate component of equity until realized. We regularly review our investments for factors that may indicate that a decline in the fair value of an investment below its cost or amortized cost is other than temporary. Some factors considered in evaluating whether or not a decline in fair value is other than temporary include:

–        Our ability and intent to retain the investment for a period of time sufficient to allow for a recovery in value;

–        The duration and extent to which the fair value has been less than cost; and

–        The financial condition and prospects of the issuer.

        Such reviews are inherently uncertain in that the value of the investment may not fully recover or may decline further in future periods resulting in realized losses. During 2008, 2007 and 2006 no impairment losses were identified.

42

Contingencies

        From time to time, we are defendant or plaintiff in various legal actions, which arise in the normal course of business. We are required to assess the likelihood of any adverse judgments or outcomes to these matters as well as potential ranges of probable losses. A determination of the amount of reserves required for these contingencies, if any, which would be charged to earnings, is made after careful and considered analysis of each individual action together with our legal advisors. The required reserves may change in the future due to new developments in each matter or changes in circumstances, such as a change in settlement strategy. A change in the required reserves would affect our earnings in the period the change is made.

Recent Accounting Pronouncements

Impact of recently issued accounting standards

        In December 2007, the FASB issued SFAS No. 141 (revised 2007), “Business Combinations” (“SFAS 141R”). SFAS 141R establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, any non controlling interest in the acquiree and the goodwill acquired. SFAS 141R also establishes disclosure requirements to enable the evaluation of the nature and financial effects of the business combination. SFAS 141R is effective for fiscal years beginning after December 15, 2008. Earlier adoption is prohibited. We believe that the adoption of SFAS 141R could have an impact on our consolidated financial statements; however, the impact would depend on the nature, terms and magnitude of acquisitions it consummates in the future.

        In December 2007, the FASB issued SFAS 160 (“SFAS No. 160”), Noncontrolling Interests in Consolidated Financial Statements. SFAS 160 amends Accounting Research Bulletin 51, Consolidated Financial Statements, to establish accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. It also clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements. SFAS 160 also changes the way the consolidated income statement is presented by requiring consolidated net income to be reported at amounts that include the amounts attributable to both the parent and the noncontrolling interest. It also requires disclosure, on the face of the consolidated statement of income, of the amounts of consolidated net income attributable to the parent and to the noncontrolling interest. SFAS 160 requires that a parent recognize a gain or loss in net income when a subsidiary is deconsolidated and requires expanded disclosures in the consolidated financial statements that clearly identify and distinguish between the interests of the parent owners and the interests of the noncontrolling owners of a subsidiary. SFAS 160 is effective for fiscal periods, and interim periods within those fiscal years, beginning on or after December 15, 2008. The adoption of SFAS 160 is not expected to have a material effect on accounting for Shamir’s current subsidiaries.

        In February 2008, the FASB issued FASB Staff Position (“FSP”) FAS No. 157-2, “Effective Date of FASB Statement No. 157” (“FSP 157-2”), to delay the effective date of FASB Statement 157 for one year for certain nonfinancial assets and nonfinancial liabilities, excluding those that are recognized or disclosed in financial statements at fair value on a recurring basis (that is, at least annually).  For purposes of applying the FSP 157-2, nonfinancial assets and nonfinancial liabilities include all assets and liabilities other than those meeting the definition of a financial asset or a financial liability in FASB Statement 159.  FSP 157-2 defers the effective date of Statement 157 to fiscal years beginning after November 15, 2008, and interim periods within those fiscal years for items within the scope of this FSP 157-2. We do not expect the adoption of FSP 157-2 to have a material impact on its financial position, results of operations or cash flows.

        In April 2008, the FASB issued FSP 142-3, “Determination of the Useful Life of Intangible Assets” (FSP 142-3). FSP 142-3 amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under SFAS No. 142, “Goodwill and Other Intangible Assets”. FSP 142-3 is effective for fiscal years beginning after December 15, 2008. We do not expect the adoption of FSP 142-3 will have a material impact on the Company’s financial position, results of operations or cash flows.

43

        In May 2008, the FASB issued SFAS No. 162, “The Hierarchy of Generally Accepted Accounting Principles”. SFAS 162 identifies the sources of accounting principles and the framework for selecting the principles to be used in the preparation of financial statements of nongovernmental entities that are presented in conformity with generally accepted accounting principles in the United States. It is effective 60 days following the SEC’s approval of the Public Company Accounting Oversight Board amendments to AU Section 411, “The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles”. We are currently evaluating the impact of SFAS No. 162 on its financial statements, and the adoption of this statement is not expected to have a material effect on the Company’s financial statements.

5.B LIQUIDITY AND CAPITAL RESOURCES

        From the commencement of our business through December 31, 2008, we have self-funded and grown our business principally from cash flow from operations and loans. As of December 31, 2004, we had raised a total of $8.1 million in net proceeds from private placements of our shares, with $4.1 million in 1999 and $4.0 million in 2004. In March 2005, we raised net proceeds of $42.2 million through the initial public offering of our ordinary shares.

        As of December 31, 2008, we had working capital of $47.8 million, cash and cash equivalents and short term investments of $25.5 million and unused lines of credit of approximately $4.9 million.

        The following table sets forth elements of our cash flows for the periods indicated, in thousands of U.S. dollars:

	Year Ended December 31,
	2006			2007			2008
Net cash (used in) provided by operating activities		(1,015	)		11,745			16,617
Net cash used in investing activities		(14,550	)		(11,006	)		(1,142	)
Net cash provided by (used in) financing activities		10,936			(5,399	)		(15,673	)

        We conduct our operations primarily in three different regions: Israel, Europe and the United States. For a description of the different currencies in which we operate, see “Item 11. Quantitative and Qualitative Disclosures about Market Risk–Foreign Currency Risk.”

        We will finance acquisitions and purchases of significant fixed assets through loans, capital leases and working capital. We attempt to take these loans in the same currency in which the cash flow from the acquired assets will be generated.

        We anticipate that we will be able to meet our short-term liquidity needs through our working capital and that we will be able to meet our long-term liquidity needs, which may include investments in facilities, acquisitions and fixed assets, through long-term loans and our working capital. While we cannot predict the outcome of any legal disputes in which we may be involved or estimate the amounts of damages we may be required to pay, we do not expect that our short or long-term liquidity or our results of operations will be materially impacted by any current legal proceedings (see “Item 8. Financial Information–Legal Proceedings”).

        Our operating activities provided cash of $11.7 million and $16.6 million for the years ended December 31, 2007, and 2008, respectively. For the year ended December 31, 2006, our operating activities used cash of $1.0 million. The change in net cash provided by operating activities reflects the increase in profitability due to growth in sales and the change in our working capital.

        Our investing activities used cash of $14.6 million, $11.0 million and $1.1 million for the years ended December 31, 2006, 2007 and 2008, respectively. The 2008 figures include $7.0 million of proceeds from the sale of short term investments, net. The 2007 figures include $2.5 million of short term investments, net. Over the last three years, cash used in investing activities was primarily driven by the purchase of property and equipment, as well as the acquisition of subsidiaries and affiliates and loans given to affiliates, such as the acquisition of CIO, the acquisition of SOT and the shareholder loans we have granted it, the purchase of fixed assets for the new polycarbonate factory and laboratory of SSOP, and the expansion of our production facility in Portugal.

44

        Our financing activities used cash of $5.4 million and $15.7 million for the years ended December 31, 2007 and 2008, respectively. For the year ended December 31, 2006, our financing activities provided cash of $10.9 million. In 2008, we used the cash primarily for loans repayment in the net amount of $11.7 million and dividend in the amount of $4.0 million.

        In 2006, we received long-term loans and short-term bank credit totaling $12.3 million and $4.0 million, respectively. The receipt of long-term loans was due to our financing of our operations through our subsidiary in Turkey, France and the United Kingdom, and for the expansion of the production facility in Portugal due to the increase of our European activities.

        In 2007, we received long-term loans of $3.1 million for financing the expansion of our production facility in Portugal.

        In 2008, we received long-term loans of $2.9 million for financing the expansion of our production facility in Portugal and finance of our operations through our subsidiary in France.

45

Borrowings

	Weighted Average Interest Rate			December 31,2008 (U.S. dollar in thousands)
Short-term bank credit and loans
Mainly denominated in Euro		5.1	%		11,597
Minority shareholders in subsidiaries:
Mainly denominated in Mexican Peso		4.0	%		1,116
Long-term loans:
Dollars		2.5	%		229
Euro		4.2	%		15,702
NIS		3.8	%		659
					16,590
Total bank credit and loans					29,303

        As of December 31, 2008, we had aggregate short-term bank credit, short-term loans and long-term loans of $3.8 million, $7.8 million and $17.7 million, respectively ($1.6, $14.3 and $22.8, respectively, in 2007). As of December 31, 2008 and 2007, we had aggregate capital leases of $5.9 million and $6.7 million, respectively. These borrowings are divided between our subsidiaries and us as follows: $33.2 million are held by European subsidiaries, $0.4 million are held by Shamir, and $0.5 million from other subsidiaries. In addition, there are $1.1 million in loans from minority shareholders. The decrease in borrowings is attributed to the loans repayment mainly in our European subsidiaries. The change in the exchange rate of the Euro versus the U.S. dollar was reflected in a decrease of our outstanding bank credit and loans as of December 31, 2008, compared to December 31, 2007.

5.C RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES, ETC.

        We are focused on research and development, and the success of our business depends substantially on the results of our R&D activities. We conduct research and development both to enhance our existing proprietary technologies and to develop new technologies.

        We believe that we have one of the world’s preeminent research and development teams for progressive lenses, molds and complementary technologies and tools. Through our research and development team, we have continually enhanced our capabilities and resources to develop new, innovative products and design tools with superior characteristics.

        We have developed software dedicated to the design of progressive lenses. This software is based on our proprietary mathematical algorithms that optimize designs of progressive lenses for a variety of activities and environments. We have also created software tools specifically designed for our research and development and production requirements, including our Eye Point Technology software that simulates human vision. We believe that these proprietary tools, and in particular our optical design software and our Eye Point Technology, provide us with a competitive advantage in our market. To maintain this advantage, we have pursued investments in new technologies in the ophthalmic field and are developing product technologies in fields such as lens development, lens production and optical measurement and simulation.

46

        For a more detailed discussion of our research and development activities, see “Item 4. Information on the Company–Competitive Strengths–Research and Development Expertise” and “–Research and Development.”

        Research and development spending for fiscal years ended December 31, 2008, 2007, and 2006 was $3.4 million, $2.6 million and $2.4 million, respectively.

5.D TREND INFORMATION

        For a discussion of trend information, see “Item 4. Information on the Company–Industry Overview–Market Growth.”

5.E OFF- BALANCE SHEET ARRANGEMENTS

        None

5.F CONTRACTUAL OBLIGATIONS AND COMMERCIAL COMMITMENTS

        The following table summarizes our contractual and commercial obligations and commitments as of December 31, 2008, in thousands of U.S. dollars:

	Payments Due In
	Total		2009		2010		2011		2012		2013 and Thereafter
Contractual obligations:
Long-term debt (without loans from minority shareholders in subsidiaries) (1)	$	16,590	$	7,906	$	3,719	$	2,526	$	1,005	$	1,434
Capital lease		5,890		2,497		1,328		850		360		855
Operating lease obligations		15,594		1,552		1,553		1,573		1,604		9,312
Loans from minority shareholders in subsidiaries (2)		1,116		-		-		-		-		-
Tax reserve related to FIN 48 (3)		1,251		-		-		-		-		-
Other long-term liabilities (4)		1,033		457		156		237		100		83
Total contractual obligations	$	41,474	$	12,412	$	6,756	$	5,186	$	3,069	$	11,684

(1) Does not include interest due.

(2) No repayment date was set in connection with such loans.

(3) See note 15 in our attached financial statements.

(4) Mainly related to liabilities for long-term payments for an acquisition and intangible assets.

47

ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

6.A DIRECTORS, SENIOR MANAGEMENT

        The following table lists the current members of our board of directors and our executive officers. The address for our directors is c/o Shamir Optical Industry Ltd, Kibbutz Shamir, Upper Galilee, 12135 Israel. Giora Ben-Ze’ev and Rami Ben-Ze’ev are brothers. Other than the above mentioned, there are no other family relationships among members of our board or our executive officers.

Name	Age	Position/Principal Occupation
Eyal Hayardeny(6)	39	President and Chief Executive Officer
Amos Netzer(6)	53	President and Chief Executive Officer (effective July 1, 2009)
Dan Katzman	54	Chief Technology Officer and Vice President of R&D
Dagan Avishai (1) (2)	49	Vice President of Marketing
Yagen Moshe	39	Chief Financial Officer
Rami Ben-Ze'ev (1) (2)	59	Vice President Business Management
Noam Shamir	47	Vice President of Global Operations
Ra'anan Naftalovich	44	Chief Executive Officer of Shamir Insight, Inc.
Ron Sonnenschein	59	Managing Director of our European operations
Uzi Tzur (1) (4)	69	Director and Chairman of the Board
Giora Ben-Ze'ev (1) (2)	66	Director
Efrat Cohen (2)	41	Director
Ami Samuels (5)	50	Director
Giora Yanay (5)	71	Director
Israel Oz (3)	53	Director

(1) Member of Kibbutz Shamir.

(2) Member of the management board of Kibbutz Shamir.

(3) Independent board member.

(4) Chairman of the management board of Kibbutz Shamir.

(5) External and independent board member.

(6) On April 30, 2009, our board of directors resolved that Mr. Netzer shall replace Mr. Hayardeny who has resigned from his position as our President and Chief Executive Officer as of July 1, 2009.

        Eyal Hayardeny. Mr. Hayardeny was appointed as our President and Chief Executive Officer effective as of April 2, 2008. Mr. Hayardeny joined our company as an Executive Vice President and Vice President of Business Development in 2005. From 1994 to 1998, he worked at Somekh Chaikin’s (KPMG) economic department. From 1991 to 1994, he served as a budget officer in the IDF’s chief of staff financial consultant unit. He holds a BA degree in accounting and economics and an MBA degree from Bar-Ilan University. Mr. Hayardeny resigned from his position as our President and Chief Executive Officer as of July 1, 2009.

        Amos Netzer, Mr. Netzer serves as the chief executive officer of Spirit Economic Consultants Ltd. He served as an external director of our board of directors until April 26, 2007. Since July 2000 and until September 2007 he served as the managing director of Palram Industries Ltd., a public company traded on the Tel Aviv Stock Exchange. From 1998 until 2000 he was the managing director of SMS, a private company engaged in the production and distribution of plastic products to world markets. Between 1993 and 1997, he was president of Suntuf, Inc., a U.S.-based and responsible for the establishment of the North and south American marketing and distribution network of Palram-Paltough Ltd. He serves as a board member of Palram Industry Ltd., SZP Ltd., Al Baad Ltd., and as the chairman of the board of directors of Bio Bee Ltd., and Polyrit Ltd. He holds a B.Sc. degree in industry and administrative engineering from the Technion Institute in Haifa and an MS degree in public policy from Tel Aviv University. Mr. Netzer was appointed by our board of directors to serve as our President and Chief Executive Officer starting July 1, 2009.

48

        Dan Katzman. Mr. Katzman joined our Company in 1981 as an engineer and became Chief Technology Officer and Vice President of R&D in 1985. An internationally recognized expert in optical research and development, he has headed our research and development teams since then. He holds a BSc degree in mechanical engineering from the Technion Israel Institute of Technology.

        Dagan Avishai. Mr. Avishai has been our Vice President of Marketing since 2003. Prior to joining the Company in 1997, he served as financial manager of Kibbutz Shamir for three years. He is a director at Shalag Industries, Ltd. and a member of the management board of Kibbutz Shamir. He holds a BA degree in management and economics from the Ruppin Academic Center and serves as a Lieutenant Colonel in the Israeli reserve armed forces.

        Yagen Moshe. Mr. Moshe has been our Chief Financial Officer since July 2006. Prior to this position he served as our Vice President of Finance since March 2005. He served from 2001 to 2005 as the Chief Financial Officer of Comsec Ltd., an Israeli public company that is listed on the Tel Aviv Stock Exchange, and he worked as a Senior Manager in Ernst & Young Israel from 1996 to 2000. Mr. Moshe holds a BA degree in accounting and management from the College of Management in Tel-Aviv, he is a certified public accountant in Israel, and holds a MA in law from Bar-Ilan University in Ramat-Gan.

        Rami Ben-Ze’ev. Mr. Ben-Ze’ev joined our Company as business manager and Vice President in 2001. Previously, he served as Chief Financial Officer of Tel Hay Rodman Regional College from 1999 to 2001 and as financial manager of Kibbutz Shamir from 1992 to 1995. He is a director at Shalag Industries, Ltd. and a member of the management board of Kibbutz Shamir. He holds a BA degree in economics from the Hebrew University of Jerusalem and an Executive MBA from Tel Aviv University.

        Noam Shamir. Mr. Shamir joined our Company in 2008 and as of September 2008 has served as Vice President of Global Operations. Previously, he served as Vice President Supply Chain at Taro Pharmaceuticals. From 2001 to 2004 he served as Chief Information Officer at Cyoptics, Inc., and from 1991 to 2001 he served as Plant Manager and Production Planning and Control Manager at Delta Galail Industry. He holds a B.Sc in Industrial Engineering from the Israel Institute of Technology.

        Ra’anan Naftalovich. Mr. Naftalovich has been the Chief Executive Officer of Shamir Insight, Inc. since 1999. Prior to this position he served in various positions in Shamir Insight, Eyal and Shamir such as Marketing Vice President of Shamir Insight from 1997 until 1999, and Product Manager, Marketing Director, and International Regional Export Manager of Shamir and Eyal from 1994 to 1997. Mr. Naftalovich holds a BA degree in business administration from the College of Management in Tel-Aviv.

        Ron Sonnenschein. Mr. Sonnenschein has been the Chief Executive Officer of Shamir Optic GmbH since 2002 and since than he is the manager of our European operations. Prior to this position he served as the Executive Vice President of Altra. Prior to its acquisition by us Mr. Sonnenschein served as the President and Chief Executive Officer of Eyal Optical Industries (1995) Ltd. from 1982 to 1989. Previously, he served as the treasurer of Kibbutz Eyal between the years 1975 and 1979. Mr. Sonnenschein holds a BA degree in political science and international relations from Tel Aviv University.

        Uzi Tzur. Mr. Tzur has been a member of our board of directors since its original establishment in 1997 and the chairman of our board of directors since April 2007. He served as acting chairman of the board of directors from July 2004 until March 2005. He is also the current chairman of the management board of Kibbutz Shamir, a position he has held since 1992. Mr. Tzur is currently a member of the board of directors of Shalag Industries, Ltd., and was a board member of N.R. Spuntech Industries Ltd., two companies that are located in Kibbutz Shamir and are listed on the Tel Aviv Stock Exchange. He is also chairman of the boards of Mishkai Galil Elion, an umbrella organization of all kibbutzim in northern Israel, and of Hamashbir Hamercazi A.C.S. Ltd., an Israeli trading company. He has over twenty years of experience in different managerial positions. He holds a BA and an MBA degree in management and economics from the Ruppin Academic Center in Israel and is a retired Lieutenant Colonel of the Israeli reserve armed forces.

        Giora Ben-Ze’ev. Mr. Ben-Ze’ev has been a member of our board of directors since its original establishment in 1997. Mr. Ben-Ze’ev was our President and Chief Executive Officer from 1994 to April 2, 2008. Mr. Ben-Ze’ev is a member of the management board of Kibbutz Shamir. He holds a BSc degree from the Technion Israel Institute of Technology in industrial and management engineering.

49

        Efrat Cohen. Mrs. Cohen has been a member of our board of directors since 2001. Since 1997 she has been the Chief Financial Officer of Kibbutz Shamir. She is a director at Shalag Industries, Ltd. and a member of the management board of Kibbutz Shamir. Mrs. Cohen holds a BA degree in economics and management from the Ruppin Academic Center.

        Ami Samuels. Mr. Samuels has been a member of our board of directors since March 2005. He is currently a Senior Director, Private Equity at Poalim Capital Markets, a wholly owned subsidiary of Bank Hapoalim. From 2004 to 2006, Mr. Samuels was a Partner at Star Ventures, an international venture capital fund. From 2001 to 2003, he served as Senior Vice President and Chief Financial Officer of Satlynx, a company specializing in two-way satellite broadband services. From 1998 to 2001, he was Vice President for broadband networks at Gilat Satellite Networks, and from 1989 to 1998, he worked as an investment banker at Lehman Brothers. He holds a BA degree from Haifa University and a MA degree in Management from Yale University.

        Giora Yanai. Mr. Yanai has been elected to serve as a member of our board of directors in June 2009. He is currently the managing director of Yanai Information Resources Ltd., a consulting firm providing economic research, strategic and marketing consulting and M&A services. Between 1994 and 1995 he served as management consultant at Friedman Turbidy Inc., a New York company engaged in strategic business and management consulting and finance. Between 1988 and 1992 he served as the economic director of Kibbutz Artzi Movement, where he managed and negotiated the major debt restructuring agreement with the Israeli government and major Israeli banks for Kibbutz organizations nationwide, and designed restructuring plans for dozens of Kibbutz settlements and industries. Between 1981 and 1987 he served as managing director of Mivrag Ltd., the cold forming metal factory of Kibbutz Ein Hashofet, as well as general manager of Kibbutz Ein Hashofet between the years 1968-1971 and between 1992 and 1993. From 1977 until 1980 he served as the representative of the Israel Kibbutz Industry Association in the U.S. From 1972 until 1977 Mr. Yanai served as managing director of Eltam Ltd., a producer of electrical products, lighting and electronics. Mr. Yanai studied as a visiting scholar and completed the coursework for an M.B.A. at Columbia Business School and has studied agriculture at the Hebrew University in Jerusalem.

        Israel Oz. Mr. Oz has been elected to serve as a member of our board of directors in June 2009. He currently serves as chairman of the board of directors of the Lordan plant in Kfar Sold, Israel, which is engaged in manufacturing heat transfer equipment, and since 2003 has served as the chairman of the Administration of Kibbutzim Agreement Ltd. From 1996 until 2006, he served as the chairman of the board of directors of the holding company Neot Mordechai and of the Teva Neot shoe factory and the Palrig Neot plastics factory. Between 1996 and 2003, he served as a director at Bank Yahav, at Manpower, and at Blue Square Chain Investments & Properties Ltd. Between 1996 and 2003, he also served as chairman of the economic committee of Kibbutz Neot Mordechai and of Kibbutz Genosar. Between 1993 and 1995, he served as chief of staff of the Israeli Minister of Finance, Abraham Shohat. Between 1987 and 1993, he owned and served as the manager of Tmurot, a company engaged in organizational consulting. Mr. Oz holds a B.A. in economics and sociology from the Hebrew University in Jerusalem and has studied business administration and organizational behavior at the Hebrew University in Jerusalem.

Board of Directors

        As a corporation, we are managed by a single board of directors and by our executive officers. Under the Israeli Companies Law and our Articles of Association, the board of directors is responsible, among other things, for establishing the company’s policies and overseeing the performance and activities of our chief executive officer, convening shareholders’ meetings, preparing and approving our financial statements, reviewing and approving fundamental strategic, financial and organizational decisions on behalf of the company, and issuing securities and distributing dividends. The board also appoints and may remove the chief executive officer of the company.

50

        Our board of directors currently consists of six directors. Two of these directors are “External Directors” in accordance with the Israeli Companies Law. See “–External Directors.” These two External Directors and two additional directors qualify as independent directors for purposes of the listing requirements of the NASDAQ Global Market. Pursuant to an agreement among our shareholders, Kibbutz Shamir has agreed with another shareholder to vote for their respective nominees for membership on our board. See “Item 7. Major Shareholders and Related Party Transactions – Shareholders’ Agreement.”

        As of June 15, 2009, our majority shareholder, Kibbutz Shamir, holds approximately 59.04% of our outstanding shares and as a result we are considered to be a “controlled company” for the purpose of Nasdaq Listing Rules. Under these rules, a “controlled company” is a company of which more than 50% of the voting power for the election of directors is held by an individual, a group or another company. Under Nasdaq Listing Rules, a company’s board of directors must be comprised of a majority of independent directors, however, a controlled company is exempt from this requirement. Currently we do not have a majority of independent directors on our board of directors.

        Under our Articles of Association, our board of directors must have at least two members and no more than eleven. The members of our board of directors, other than the External Directors, for whom special election requirements apply (see “–External Directors”), are elected and may in certain circumstances be removed by the majority of our shareholders. Our Articles of Association provide that our board of directors, other than the External Directors, will be divided into three classes. Each class of directors will serve for a term of three years. The term of office of the directors assigned to class C will expire at the next annual meeting of shareholders, which will take place during the year of 2009, and at each third succeeding annual meeting thereafter. The term of office of the directors assigned to class A will expire at the annual meeting of shareholders, which will take place during the year of 2010, and at each third succeeding annual meeting thereafter. The term of office of the directors assigned to class B will expire at the annual meeting of shareholders, which will take place during the year of 2011, and at each third succeeding annual meeting thereafter. Giora Ben-Ze’ev and Israel Oz serve as class A directors, Efrat Cohen serves as class B director and Uzi Tzur serves as class C director. This classification of the board of directors may delay or prevent a change of control of our company or in our management.

        If a vacancy arises because of the death or resignation of a board member, the replacement can only be appointed at a general meeting of our shareholders. There is no limitation on the number of terms that a director (other than an External Director) may serve.

        The board of directors appoints its chairman from among its members in accordance with our Articles of Association. Pursuant to our Articles of Association, the chairman convenes and presides over the meetings of the board. A quorum consists of two-thirds of the members of the board, and decisions are taken by a vote of the majority of the members present. A director may appoint an alternate director to attend a meeting in his or her place, but this alternate must be approved by the board prior to the relevant meeting.

        Directors are required to comply with all applicable laws and with our Articles of Association. They may be jointly and severally liable for any actions that they take in violation of their fiduciary duty and duty of care toward the company and/or others.

        The Israeli Companies Law provides that an Israeli company can not exculpate an office holder from liability with respect to a breach of fiduciary duties, but may exculpate in advance an office holder from liability to the company, in whole or in part, with respect to a breach of duties of care. Our Articles of Association provide that, subject to any restrictions imposed by applicable law, we may enter into a contract for the insurance of the liability of any of our officers and directors with regard to an act performed by them in their capacity as such and with regard to certain actions specified in the Companies Law and in our Articles of Association.

        In March 2005, the Israeli legislature adopted certain amendments to the Companies Law (“Amendment No. 3”), including, inter alia, certain amendments to provisions relating to the Company’s ability to provide indemnification to corporate officers: (i) permitting indemnification for expenses incurred in connection with certain kinds of governmental inquiries or investigation in certain circumstances; and (ii) changing the standard of limitations imposed on the Company’s ability to indemnify officers for any financial liability imposed by a court judgment. The previous standard permitted indemnification relating to certain types of events that, in the opinion of the company’s board of directors could be anticipated at the time of granting the indemnity. Following Amendment No. 3, indemnification is limited to events that are anticipated in the opinion of the board of directors in light of the actual activities of the company at the time of granting the indemnity.

51

        On February 27, 2006, our shareholders at the annual general meeting approved an amendment of our Articles of Association, essentially making the provisions of the Articles relating to indemnification of officers consistent with Amendment No. 3.

        We have acquired directors’ and officers’ liability insurance covering our officers and directors and the officers and directors of our subsidiaries against certain claims, and we are currently in the final stages of providing our directors and officers with indemnification for liabilities or expenses incurred as a result of acts done by them in their capacity as directors and officers of our company.

External Directors

        We are subject to the Israeli Companies Law. Under the Companies Law, Israeli companies whose shares have been offered to the public in or outside of Israel are required to appoint at least two External Directors to serve on their board of directors. Each committee of the board of directors entitled to exercise any powers of the board is required to include at least one External Director. The audit committee must include all of the External Directors. See “–Board Practices” below.

        A person may not serve as an External Director if at the date of the person’s appointment or within the preceding two years, the person or his or her relatives, partners, employers or entities under the person’s control have or had any affiliation with us or with any entity controlling, controlled by or under common control with us. Under the Israeli Companies Law, “Affiliation” includes an employment relationship, a business or professional relationship maintained on a regular basis or control or service as an office holder.

        A person may not serve as an External Director if that person’s position or other activities create, or may create, a conflict of interest with the person’s service as a director or may otherwise interfere with the person’s ability to serve as a director. If at the time any External Director is appointed, all members of the board are of the same gender, then the External Director to be appointed must be of the other gender.

        External Directors are elected by a majority vote at a shareholders’ meeting, as long as either:

— the majority of shares voted for the election includes at least one-third of the shares of non-controlling shareholders voted at the meeting; or

— the total number of shares of non-controlling shareholders voted against the election of the External Director does not exceed one percent of the aggregate voting rights of the company.

        The Israeli Companies Law provides for an initial three-year term for an External Director, which may be extended for one additional three-year term and thereafter for additional three-year terms, if both the audit committee and the board of directors confirm that in light of the expertise and contribution of the External Director, the extension of such External Director’s term would be in the interest of our company. External Directors may be removed only by the same special majority required for their election or by a court, and then only if the External Directors cease to meet the statutory qualifications for their appointment or if they violate their duty of loyalty to the company. In the event of a vacancy created by an External Director, our board of directors is required under the Israeli Companies Law to call a shareholders meeting to appoint a new External Director.

52

        External Directors must be compensated in accordance with regulations adopted under the Companies Law. The regulations provide two alternatives for cash compensation to External Directors: a fixed amount within a range prescribed in the regulations or an amount that is not higher than the average compensation of other directors who are not controlling shareholders of the company or employees or service providers of the company or its affiliates and not lower than the minimum compensation received by any such director. A company may also issue shares or options to an External Director at the average amount granted to directors who are not controlling shareholders of the company or employees or service providers of the company or its affiliates. Cash compensation at the fixed amount determined by the regulations does not require shareholder approval. Compensation determined in any other manner requires the approval of the company’s audit committee, board of directors and shareholders. The compensation of External Directors must be communicated to them prior to their consent to serve as External Directors.

6.B COMPENSATION OF DIRECTORS AND MANAGEMENT

        We have paid compensation to the members of our board of directors for their services as directors as described below. Directors are reimbursed for expenses incurred in order to attend board or committee meetings. Our executive officers who serve as directors on our board receive compensation as part of their employment agreement as executive officers but do not receive any compensation for their service as directors.

        At the annual meeting of shareholders on April 26, 2007, our shareholders resolved that each of the current and future directors, including the External Directors but excluding our chairman and our chief executive officer at the time of the resolution, Mr. Giora Ben Ze’ev, shall be entitled to an annual fee of $15,000, paid in quarterly installments of $3,750 each. Each director who is a member of a committee of the board of directors shall be entitled to an additional annual fee of $5,000, paid in quarterly installments of $1,250 each. No additional fee will be paid for membership in more than one committee. At our Special General Meetings that took place on July 18, 2005, and on August 8, 2005, our shareholders approved the issuance of options to purchase 23,540 of our ordinary shares to each of our directors serving as of the date of the options grant, including the External Directors but excluding our chairman and our chief executive officer at the date of the options grant, Mr. Yair Shamir and Mr. Giora Ben-Ze’ev, respectively.

        On October 11, 2007, our shareholders approved a proposal to grant to Mr. Uzi Tzur, the chairman of our board of directors, a monthly salary of $5,500 retroactively as of July 1, 2007. In addition, on December 5, 2007, our shareholders approved the grant of an additional 51,460 options to Mr. Tzur, following which he holds 75,000 options to purchase ordinary shares of the Company.

        The aggregate compensation we paid our directors as a group (seven persons), excluding stock-based compensation, for the year ended December 31, 2008 was $0.16 million. This amount does not include expenses we incurred for other payments, including dues for professional and business associations, business travel and other expenses, or other benefits commonly reimbursed or paid by companies in Israel, or stock-based compensation. We have also granted options to purchase our ordinary shares to our directors as part of their overall compensation. See “–Share Ownership.”

        The aggregate compensation we paid to our officers as a group (eleven persons, including officers that retire or were appointed during 2008, for the period of their appointment), excluding stock-based compensation, for the year ended December 31, 2008, either directly or through Kibbutz Shamir as part of our working services agreement with Kibbutz Shamir (see “Item 7. Major Shareholders and Related Party Transactions.”), was approximately $3.1 million, including amounts set aside or accrued to provide for pension, retirement or similar benefits. This amount also includes the accrued and partially paid special compensation to our former chief executive officer. This amount does not include expenses we incurred for other payments, including dues for professional and business associations, business travel and other expenses, or other benefits commonly reimbursed or paid by companies in Israel. We have also granted options to purchase our ordinary shares to our officers as part of their overall compensation. See “–Share Ownership.”

        As of June 15, 2009, options granted to our current and former directors and officers to purchase a total of 1,080,224 of our ordinary shares were outstanding, at exercise prices ranging from $2.46 to $13.76 with a weighted average exercise price of $8.39 per share. See “– Share Ownership” for a description of the options granted to our officers.

53

6.C BOARD PRACTICES

        Our board of directors has established three standing committees. The three committees are an audit committee, a compensation committee and a nominating and governance committee.

Audit Committee

        Under the Israeli Companies Law, the audit committee must consist of at least three directors and must include both of the External Directors. In addition, the rules of the NASDAQ Global Market require that at least one member of our audit committee have experience or background that results in such member’s financial sophistication. Our audit committee is comprised of Ami Samuels as chairman, Giora Yanai and Israel Oz. Our board of directors has determined that Giora Yanai is financially sophisticated for purposes of the NASDAQ rules. The composition and function of the audit committee meet the requirements of the Sarbanes-Oxley Act of 2002 and the rules and regulations thereunder, as well as the NASDAQ Global Market rules.

        The audit committee provides assistance to the board of directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing, financial reporting, internal control and legal compliance functions by approving the services performed by our independent accountants and reviewing their reports regarding our accounting practices and systems of internal accounting controls. The audit committee also oversees the audit efforts of our independent accountants and takes those actions it deems necessary to satisfy itself that the accountants are independent of management. Under the Israeli Companies Law, the audit committee also is required to monitor deficiencies in the administration of the company, including by consulting with the internal auditor, and to review and approve related-party transactions.

Compensation Committee

        The compensation committee recommends to the board of directors in accordance to issuance of employee share options under our share option plan, determines salaries and bonuses for our executive officers and incentive compensation for our other employees. The members of our compensation committee are Israel Oz as chairman, Giora Yanai, and Ami Samuels. The composition and functions of the compensation committee meet the requirements of the NASDAQ Global Market rules.

Nominating and Governance Committee

        The nominating and governance committee makes recommendations to the board of directors regarding candidates for directorships and the size and composition of the board. In addition, the committee is responsible for overseeing our corporate governance guidelines and reporting and making recommendations to the board regarding corporate governance matters. The members of the nominating and governance committee are Giora Yanai as chairman, Ami Samuels and Israel Oz. The composition and functions of the nominating and governance committee meet the requirements of the NASDAQ Global Market rules.

Internal Auditor

        Under the Israeli Companies Law, the board of directors of a Public Company must appoint an internal auditor following the recommendation of its audit committee. The role of the internal auditor is to examine whether a company’s actions comply with the law and proper business procedure. The internal auditor may be an employee of the company but may not be an interested party or officer in the company, or a relative of an interested party or officer, and may not be a member of the company’s independent accounting firm or its representative. The Israeli Companies Law defines an interested party as a shareholder of 5% or more of the company’s issued share capital or of voting rights, or a person or entity that has the power to appoint one or more directors or the general manager of the company, or a person who serves in the company as a director or as general manager of a company. We appointed an internal auditor in June 2005.

54

6.D EMPLOYEES

        As of June 15, 2009, our worldwide workforce consists of 1,188 people, which includes approximately 42 employees who provide services to us through our working service agreement with Kibbutz Shamir (see “Item 7. Major Shareholders and Related Party Transactions.”). The following table shows the breakdown of our workforce by main category of activity and geographic location for the past three years.

Department or location as of June 15	2007		2008		2009
Research and development		41		45		49
Marketing and sales		199		275		266
Management and administration		159		233		194
Manufacturing and warehouse		536		792		679
Total		935		1,345		1,188
Israel		385		423		364
United States		75		77		69
Europe		466		485		446
Mexico		0		350		301
South Africa		9		10		8
Total		935		1,345		1,188

        We consider the changes in the numbers of employees in our various departments or geographic regions to be in line with our expectations for our company's growth. We believe that our relations with our employees are good.

        In Israel, we are subject to the instructions of the Extension Order in the Industrial Field for Extensive Pension Insurance 2006 according to the Israeli Collective Bargaining Agreements Law, 1957 (the “Extension Order”). The Extension Order ensures the pension insurance of certain employees which fall under its criteria, including the employees of Eyal, SSOP, Shamir Israel, Shamir Or and Shamir.

        The Israeli government, as part of a program to encourage the employment in the peripheral parts of Israel, grant certain subsidies to companies to help finance salary expenses of new employees for a period of 5 years. Our subsidiary SSOP is part of this program. In order to secure this subsidy, SSOP granted the State of Israel a bank guarantee. If SSOP fails to comply with certain conditions set by the government in this program it may have to return part or all of the subsidy it received.

6.E SHARE OWNERSHIP

        Our executive officers and other certain employees, other than directors, hold options to purchase 1,380,416 of our ordinary shares.

        At our special general meetings on July 18, 2005, and August 8, 2005, our shareholders approved the issuance of 23,540 options to our directors (except for the former chairman of our board, Yair Shamir, and our former chief executive officer, Giora Ben-Ze’ev). In addition, at our special general meeting on December 5, 2007, our shareholders approved the issuance of 51,460 options to Mr. Uzi Tzur, the chairman of our board of directors. For a description of the options held by our directors, please see “–Compensation of Directors and Management.”

55

        On August 24, 2004, our board of directors granted options to purchase 683,120 of our shares to certain of our executive officers and other employees. Out of these options, the board granted options to purchase up to 301,376 of our shares to our former chief executive officer, Giora Ben-Ze’ev, and options to purchase up to 66,973 of our shares to each of our former chief financial officer, Amir Hai, and to our vice president of marketing, Dagan Avishai. The exercise price for these options was set at $10.30 per share. Also out of these options, the board granted options to purchase a total of up to 214,312 of our shares to certain employees in research and development, and options to purchase up to 33,486 of our shares to Dan Katzman, the head of the research and development department. The exercise price for these options is $12.43. The board authorized our chief executive officer to finally determine the allocation of the options among the development employees. Furthermore, the board approved options to purchase an additional 288,360 of our shares for future grants to directors or employees. On January 1, 2005, we agreed to grant 160,961 out of these 288,360 additional options to Yair Shamir, the chairman of our board of directors at the date of the grant (see “–Compensation of Directors and Management”). On August 21, 2005, the board’s compensation committee approved an additional grant to Amir Hai, our former chief financial officer, of options to purchase 33,487 shares at the exercise price of $11.55 per share. The options granted to Messrs. Shamir, Ben-Ze’ev and Hai have been terminated unexercised following their resignations from their positions at Shamir and pursuant to the terms of our 2005 General Share and Incentive Plan as detailed below.

        On June 8, 2005, Shamir Insight granted options to acquire its shares to two of its officers. On December 29, 2005, the option grant was cancelled by Shamir Insight. On May 15, 2006, we granted options to purchase 58,000 of our shares to those officers of Shamir Insight, at an exercise price of $11.07 per share. The vesting schedule is as follows: 25% immediately, 25% on May 31, 2006, 30% on January 31, 2007, and 20% on January 31, 2008. In addition, 100,000 options were granted to Eyal Hayardeny at an exercise price of $9.97 per share. On August 14, 2006 we granted Eyal Hayardeny 47,000 options with an exercise price of $8.86 per share. On August 21, 2007, we granted Eyal Hayardeny 13,000 options with an exercise price of $9.99 per share. On September 23, 2007, we granted Eyal Hayardeny 80,000 options with an exercise price of $12.29 per share. On March 10, 2008, we granted Eyal Hayardeny 61,000 options with an exercise price of $7.1 per share. On June 17, 2009, our audit committee and board of directors have approved an amendment to the terms of all of the options granted to Mr. Hayardeny following his resignation from his position in the Company. As a result of such amendment, as of July 1, 2009, Mr. Hayardeny shall hold 225,623 fully vested options with different exercise prices, as detailed above, all of which shall be terminated on March 31, 2010, if not exercised.

        On June 30, 2006, we granted Yagen Moshe, our chief financial officer, 50,000 options at an exercise price of $9.00 per share. In addition, on August 21, 2007, we granted Mr. Moshe 50,000 options with an exercise price of $9.99 per share.

        On April 30, 2007, we granted 35,000 options with an exercise price of $9.82 per share each to Youval and Zohar Katzman, employees of SSOP, in place of the options that had been granted to them as consultants on May 15, 2006, which were canceled.

        On August 21, 2007, we granted Rami Ben-Ze’ev, our vice president of business management, and Noam Bachar, our former vice president of Business and Development, 23,540 and 50,000 options each, respectively, with an exercise price of $9.99 per share. Mr. Bachar resigned from his position on March 18, 2009, and the options granted to him shall be terminated pursuant to the terms of our 2005 General Share and Incentive Plan.

        At our special general meeting on December 5, 2007, our shareholders approved the issuance of 51,460 options to Mr. Uzi Tzur, the chairman of our board of directors, with an exercise price of $8.59 per share.

        On November 30, 2008, our board of directors granted options to purchase 256,000 of our shares to certain of our executive officers and other employees all with an exercise price of $5.00 per share.

        All of the options described above are granted pursuant to our 2005 General Share and Incentive Plan that was approved and adopted by our board on February 1, 2006. The Plan provides that 25% of the shares shall vest one year after the date of grant, and the remaining 75% shall vest on a monthly basis, with 1/36 of the remaining shares vesting on each month commencing at the end of the first anniversary of the date of grant. According to the Plan, during the year 2006 we could grant 350,000 options to purchase our shares and in each following year the option pool shall increase by an additional 280,000 options. On July 31, 2008 our shareholders approved an amendment to our 2005 General Share and Incentive Plan to provide that in the event we distribute a cash dividend and the record date for such distribution is subsequent to the date of grant of an award in the form of an option to purchase shares, but prior to its exercise or expiration, the exercise price of each such award will be reduced by the dividend amount per share. Further, at the above mentioned meeting, our shareholders resolved to adjust the exercise price of the outstanding options, including outstanding options previously granted to directors and external directors in the Company, by reducing the exercise price by $0.243, the dividend per share declared by the Company in January 2008.

56

        The options that were granted prior to the adoption of the 2005 General Share and Incentive Plan during the years 2004 and 2005 will vest in four tranches of 25% per year. The first tranche vested on March 10, 2006. The options were granted and authorized pursuant to Section 102 of the Israeli Income Tax Ordinance, which grants certain tax advantages to the employee grantees of options. In order for these tax advantages to take effect, the options must be held by a trustee, and the underlying shares cannot be sold until the end of the second fiscal year after the year in which they were granted.

        On September 30, 2003, we granted options to purchase 167,226 of our shares to Dan Katzman. The exercise price of these options is less than $0.01 per share. These options were exercised in July 2007. On the same date, the board granted Mr. Katzman additional options to purchase 167,105 of our outstanding shares. The exercise price of these options is $2.46 per share. The options in both tranches are granted pursuant to our Israeli Plan for the Allotment of Shares/Options for 2003, and are exercisable for a period of ten years following the grant date and vested immediately. The options were granted pursuant to Section 102 of the Israeli Income Tax Ordinance and are subject to its holding requirements, as described above.

        On June 5, 2000, we granted options to purchase 120,480 of our ordinary shares to Michael Latzer, the President of Shamir USA, with an exercise price of $9.96 per share. On November 30, 2008, we amended the terms of such options so that 105,000 fully vested options shall remain exercisable until December 31, 2010 at an exercise price of $9.96; and 15,480 vested options were terminated on December 31, 2008.

57

ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

7.A MAJOR SHAREHOLDERS

        The following table and footnotes set forth information, as of June 15, 2009, regarding the beneficial ownership of our ordinary shares by:

— each person or entity that we know beneficially owns more than 5% of our outstanding ordinary shares; and

— each of our directors or executive officers who beneficially owns one percent or more of our shares.

        Beneficial ownership of shares is determined in accordance with the rules of the SEC and generally includes any shares over which a person exercises sole or shared voting or investment power and options currently exercisable or exercisable within 60 days of June 15, 2009.

        Except as indicated in the footnotes to this table, each shareholder in the table has sole voting and investment power for the shares shown as beneficially owned by it. All of our shareholders have the same voting rights. Percentage ownership is based on 16,423,740 ordinary shares outstanding as of June 15, 2009, Except as otherwise disclosed, the address of Kibbutz Shamir and of Dan Katzman is c/o Shamir Optical Industry, Kibbutz Shamir, Upper Galilee, 12135 Israel. FIBI’s address is FIBI Investment House Ltd., 17th Floor, Africa Israel Building, 14 Ehad Ha-Am Street, Tel Aviv, Israel. The offices of Royce & Associates, LLC, are located at 1414 Avenue of the Americas, New York, NY 10019. Other than Dan Katzman, none of our directors or executive officers beneficially owns one percent or more of our outstanding share capital.

Name of Beneficial Owner	Percent of Shares			Number of Shares
Kibbutz Shamir(1)		59.04	%		9,695,809
FIBI Investment House Ltd.(2)		8.28	%		1,360,226
Dan Katzman(3)		1.77	%		307,817
Royce & Associates, LLC(4)		9.93	%		1,631,600

(1) Based on Amendment No. 1 to Schedule 13G filed on February 13, 2008 and other information provided to us by Kibbutz Shamir, Kibbutz Shamir holds shares in our company through Shamir Optica Holdings A.C.S. Ltd. The management board of Kibbutz Shamir manages the economic activities and strategy of Kibbutz Shamir and makes the voting and investment decisions of Kibbutz Shamir (by majority vote) with regard to our shares. The management board of Kibbutz Shamir has 16 members. Giora Ben-Ze’ev, Efrat Cohen, Dagan Avishai, Rami Ben-Ze’ev and Uzi Tzur are directors or officers of our company and also members of the management board of Kibbutz Shamir, and our shares held by Kibbutz Shamir may be attributed to them. The other members of the management board of Kibbutz Shamir are Edy Kudlash, Nili Van Der Meer, Yitzchak Cahana, Nir Shmueli, Geva Aharon, Eyal Meron, Ze’ev Markman, Ilan Pickman, Yossi Michaeli, Maya Segal and Omry Rotem. The number of ordinary shares held by Kibbutz Shamir excludes additional ordinary shares of Shamir that Kibbutz Shamir, through Shamir Optica, may be deemed to beneficially hold as a result of the shareholders agreement entered into with certain other shareholders of Shamir relating to, among other things, the voting of nominees to our board of directors, as further described in “Related Party Transactions–Shareholders Agreement.” Kibbutz Shamir and Shamir Optica disclaim beneficial ownership in the shares owned by the other parties to the shareholders agreement.

(2) Based on information provided to us by the chief financial officer of FIBI the voting and investment decisions for FIBI Investment House Ltd., or FIBI, are made by the chief executive officer of FIBI. The chief executive officer may also request the approval of the board of FIBI with regard to unusually important votes. In case of a disposition of all or substantially all of our shares by FIBI, a decision regarding this disposition will be taken by the board of directors of FIBI. The chief executive officer of FIBI is Kobi Sitt. The members of the board of directors of FIBI are Zadik Bino, Gil Bino, Garry Stock and Kobi Sitt. The members of the board of directors of FIBI Holdings Ltd. are Zadik Bino, Gil Bino, Garry Stock, Harry (Hersh) Cooper, Yossef Alchech, Gabriel Roter and Nilli Even-Chen.

58

FIBI is an affiliate of a broker-dealer. FIBI has represented to us that it purchased the shares being registered for resale in the ordinary course of business and that, at the time of the purchase, it had no agreements or understandings, directly or indirectly, with any person to distribute the securities.

Based on Amendment No. 1 to Schedule 13G filed on April 2, 2007, the number of ordinary shares held by FIBI excludes additional ordinary shares of Shamir that FIBI and FIBI Holdings Ltd. each may be deemed to beneficially hold as a result of the shareholders agreement entered into by FIBI with certain other shareholders of Shamir relating to, among other things, the voting of nominees to our board of directors, as further described in “Related Party Transactions–Shareholders Agreement.” FIBI and FIBI Holdings Ltd. each disclaim beneficial ownership in the shares owned by the other parties to the shareholders agreement.

(3) Consists of 107,226 ordinary shares and currently exercisable options to acquire 200,591 ordinary shares. The percentages of shares held by Dan Katzman are based on the number of our shares outstanding at the relevant time, partially diluted to include the number of shares corresponding to the options held by Dan Katzman.

(4) Based solely on information contained in Amendment No. 3 to Schedule 13G filed with the SEC by Royce & Associates, LLC on January 30, 2009.

There are no registered holders of our ordinary shares who are, to our knowledge, U.S. persons.

7.B RELATED PARTY TRANSACTIONS

        We have, from time to time, entered into agreements with our shareholders and affiliates. We describe these relationships and related party transactions below.

Relationship with Kibbutz Shamir

        Our majority shareholder is Kibbutz Shamir, a small communal society with approximately 300 members and approximately 600 total residents located in upper Galilee, in northern Israel. Established in 1944, Kibbutz Shamir is a largely self-governed community of members who share certain social ideals and professional interests and who live in a distinct geographic area, which they own and develop on a communal basis. Initially, the social idea behind the formation of the kibbutzim in Israel was to create a communal society in which all members share equally in all of the society’s resources and which provides for the needs of the community. Over the years, the structure of the kibbutzim has evolved, and today there are a number of different economic and social arrangements adopted by various kibbutzim. Kibbutz Shamir has moved toward more private ownership and voluntary participation in communal activities, although each member continues to own an equal part of the assets of Kibbutz Shamir. The members of Kibbutz Shamir are engaged in a number of economic activities, from farming to research and development of progressive spectacle lenses. In addition to being our majority shareholder, Kibbutz Shamir is the majority shareholder of Shalag Industries, Ltd., a company that, like us, is located on the grounds of Kibbutz Shamir. Shalag Industries, Ltd. is engaged in the manufacture and sale of non-woven cloth and is listed on the Tel Aviv Stock Exchange. The kibbutz community holds in common all land, buildings and production assets of these companies.

        Most of the members of Kibbutz Shamir work in one of the production activities of Kibbutz Shamir, according to the requirements of the Kibbutz and the career objectives of the individual concerned. Some other members work outside of Kibbutz Shamir in businesses owned by other entities. Each member receives an income based on the position the member holds and his or her economic contribution to the community, as well as the size and composition of his or her family. Each member’s income depends on the income of Kibbutz Shamir from its economic activities. Each member has a personal pension fund that is funded by Kibbutz Shamir, and all accommodation, educational, health and old age care services, as well as social and municipal services, are provided either by or through Kibbutz Shamir and are subsidized by Kibbutz Shamir.

59

        The economic activities and strategy of Kibbutz Shamir are managed by an elected management board. This board is the key economic decision-making body of Kibbutz Shamir. Its members are elected by the members of the council of Kibbutz Shamir for terms of three years. The chairman of the management board is elected for a term of four years directly by the members of Kibbutz Shamir. The council may remove a member of the management board by a simple majority vote. The boards of directors of Kibbutz Shamir’s companies operate independently from the management board of Kibbutz Shamir itself. The chairman of our board of directors, Uzi Tzur, is also the chairman of the management board of Kibbutz Shamir and a member of Kibbutz Shamir. Two of our board members, Giora Ben-Ze’ev and Efrat Cohen, and two of our company’s executive officers, Dagan Avishai and Rami Ben-Ze’ev, are also members of Kibbutz Shamir and of the management board of Kibbutz Shamir. Ms. Efrat Cohen is a member of the management board of Kibbutz Shamir but not a member of Kibbutz Shamir itself. As of June 15, 2009, approximately 42 members of our workforce in Israel are also members of Kibbutz Shamir. Our headquarters and main production facilities, which we lease from Kibbutz Shamir, are located on the premises of Kibbutz Shamir, and we have entered into several professional agreements with Kibbutz Shamir that are described below. While these agreements have been negotiated on an arm’s length basis, they may contain terms that are different from the terms that would have been included had these agreements been negotiated with unaffiliated third parties.

Working Service Agreement with Kibbutz Shamir

        We entered into a working service agreement with Kibbutz Shamir in February 2005. On July 19, 2007, we entered into a new working service agreement with Kibbutz Shamir which replaces the agreement from February 2005. The terms of the new working service agreement are substantially similar to the terms of the agreement from February 2005. Under the working service agreement Kibbutz Shamir undertakes on a best efforts basis (but is not strictly obligated) to provide us with individuals to fill the relevant positions for which we request staffing. In addition, we are obligated to grant Kibbutz Shamir a first opportunity to provide such individuals for any positions for which we seek staffing. Pursuant to the agreement, our chief executive officer at the time, Giora Ben-Ze’ev, and our executive vice president at the time, Dagan Avishai, each entered into individual employment agreements with the Company and are not part of the working service agreement.

        We are entitled to determine, with respect to all kibbutz members who provide services to us, the type of position to be filled by kibbutz members, the number of positions, the scope of each position, as well as, with respect to new workers provided by Kibbutz Shamir, the fees to be paid in consideration for the member’s services. We may, for reasonable cause, refuse to accept workers referred to us by Kibbutz Shamir or demand the replacement of existing workers. The agreement sets the reimbursement rights of the Company for any liabilities that may arise under an imputed employer-employee relationship between us and the members of Kibbutz Shamir who provide the services. In addition, the Company is entitled to determine at its discretion with respect to new workers provided by Kibbutz Shamir and current workers whose scope of position has changed since the date of the new working service agreement, the consideration to be paid by the Company. The agreement includes a non-disclosure undertaking by Kibbutz Shamir on its own behalf and on behalf of Kibbutz Shamir members through whom services are provided to us.

        The agreement specifies that Kibbutz Shamir will indemnify us for any liabilities that might arise under an imputed employer-employee relationship between us and the members of Kibbutz Shamir who provide the services.

        The initial term of the agreement expires on March 10, 2010, with subsequent automatic extensions for additional periods of five years, unless one party notifies the other, in writing, at least 180 days before the end of the then current effective period.

        In 2008, we paid a total of approximately $1.3 million to Kibbutz Shamir under the working service agreement.

60

        In addition, from time to time we pay bonuses to our employees. These bonuses are not governed by the working services agreement. Employees who are members of the kibbutz receive these bonuses on the same terms as non-member employees.

        On January 18, 2007, Kibbutz Shamir granted approval for our subsidiaries SSOP and Eyal Optical Industries (1995) Ltd. to employ directly (i.e. not through the working service agreement) local members of Kibbutz Shamir.

Service Agreement with Kibbutz Shamir

        In February 2005, we entered into a service agreement with Kibbutz Shamir, pursuant to which Kibbutz Shamir provides us with catering, laundry, switchboard and communications, maintenance and landscaping, trash removal services and water usage.

        The fee for all of these services except water usage was initially fixed at NIS 92,000 per month. The fee is linked to the consumer price index and reviewed every five years. In the event that the cost to Kibbutz Shamir of providing these services increases or decreases during the final year of the agreement’s five-year cycle as compared to the effective date of the agreement, the service fee shall be adjusted accordingly. If the costs increase or decrease by 30% or more in any particular year during the term of the agreement, the service fee will be adjusted for the following year. If Kibbutz Shamir provides additional services to us, the fee shall be adjusted accordingly. The fee for catering services is adjusted continuously based on the actual number of employees using these services.

        The initial term of the agreement expires on March 10, 2010, with automatic renewal for periods of five years, unless terminated earlier by either party upon 12 months written notice.

        On July 19, 2007, we entered into an additional arrangement with Kibbutz Shamir. Under the additional service arrangement between the Company and Kibbutz Shamir, we and our subsidiaries will be entitled to purchase additional services not covered by the current service agreement. The consideration for a single transaction will be no greater than $7,000 (plus VAT, if required by law), and the aggregate consideration for services purchased by us and our subsidiaries during any calendar year will be no greater than $300,000 (plus VAT, if required by law). At least one additional proposal in writing from an unaffiliated third party shall be obtained prior to each service order.

        In 2008, we paid a total of approximately $0.6 million to Kibbutz Shamir under the service agreement.

        On March 8, 2007, our shareholders at a special shareholders meeting approved a new service agreement between Kibbutz Shamir and our subsidiary, Shamir Special Optical Products Ltd., or SSOP, for the period commencing upon the acceptance of the new factory that is being built in Kibbutz Shamir for SSOP and ending on February 9, 2010, pursuant to which Kibbutz Shamir will provide administrative and maintenance services to SSOP to maintain the factory. SSOP shall pay Kibbutz Shamir a monthly fee of NIS 25,000 linked to the Consumer Price Index. In the event that the actual cost of services in any year is higher or lower by 30% or more compared to the service fee paid in the preceding calendar year, not taking into account extraordinary expenses not in the ordinary course of business, the service fee for the following year will be adjusted accordingly. The term of the service agreement will be extended automatically for additional periods of five years each unless either of the parties terminates the service agreement by giving 12-months’ advance notice prior to the scheduled expiration date. The service fee will be adjusted at the end of the initial term of the service agreement and then every five years, assuming that the service agreement is extended, based on the actual cost of services in the year preceding the adjustment date.

Lease and Sublease Agreements with Kibbutz Shamir

        Our principal offices, manufacturing and research and development facilities are located on the premises of Kibbutz Shamir and include a building of approximately 4,786 square meters, and a yard of approximately 2,287 square meters (the “Facilities”). The Facilities are subleased from Kibbutz Shamir, which has a long-term lease on the property from the Israel Lands Administration, or ILA.

61

        The lease agreement between Kibbutz Shamir and the ILA was signed on December 27, 1990 for a term of 49 years, with an option to extend for an additional 49 years. Pursuant to the lease, Kibbutz Shamir may use the lands for agricultural and residential purposes and services to members of Kibbutz Shamir and for commercial purposes, including the Company’s factory.

        The ILA may cancel the lease in certain circumstances, including if Kibbutz Shamir commences proceedings to disband or liquidate or in the event that Kibbutz Shamir ceases to be a “kibbutz” as defined in the lease (i.e., a registered cooperative society classified as a kibbutz).

        Pursuant to the lease, Kibbutz Shamir may, with permission from the ILA and without additional fees, sublease the parcel to a corporation under its control.

        On January 5, 1999, we and Kibbutz Shamir signed a sublease agreement pursuant to which Kibbutz Shamir subleased to us the Facilities for a period of twenty years beginning on January 1, 1999. Annual rental payments are $1 for each square meter of yard and $4 for each square meter of building. At that time, the Facilities included a building of approximately 3,646 square meters and a yard of approximately 2,287 square meters. Kibbutz Shamir constructed an additional 1,149 square meters of an extension to our headquarters and manufacturing building at its own expense, for which we pay rent of $6 per square meter.

        The rent is paid every six months in advance. Every two years, the rent will be adjusted in accordance with market rental prices for similar properties.

        The agreement also states that any construction or changes in the building located on the property are subject to Kibbutz Shamir’s prior consent and all such construction will belong to Kibbutz Shamir. Kibbutz Shamir has the right of first refusal to carry out any construction work for us with respect to the subleased property. Kibbutz Shamir may demand that we finance the cost of the construction, and we are entitled to set off construction costs related only to buildings against our rental payments. Any additional internal construction work will be at our expense and is not subject to this offsetting. In the event of a disagreement between the parties with respect to the cost of construction, the cost shall be determined by a licensed appraiser.

        In the event of additional construction, the rental fee for the property is increased to $6 for each additional square meter of building. We have insured the Facilities and added Kibbutz Shamir as a beneficiary in the insurance policy.

        The sublease will be terminated in the event that Kibbutz Shamir holds, directly or indirectly, less than 50% of our share capital, unless the ILA agrees otherwise. We are entitled to terminate the sublease agreement by a prior written notice of 36 months.

        On February 9, 2005, we entered into an amendment to the sublease agreement with Kibbutz Shamir governing the facilities we use that are located on the premises of Kibbutz Shamir. The amendment became effective upon the listing of our securities for trading on a U.S. stock exchange. Except as noted below, the operative terms of the new agreement remain unchanged from the prior agreement.

        The term of the amended agreement is extended from 20 years to 24 years and 11 months. The base rent will be updated every five years rather than two years, to a level comparable to that of similar properties in the area. We will continue to be entitled to provide Kibbutz Shamir with a 36-month written termination notice after 10 years of lease.

        Rental payments under the amended agreement are the same as under the prior agreement, except that the amended agreement specifies that any additional construction of industrial facilities will be charged a rent of $4 per square meter, while additional construction of the new offices will be charged $6 per square meter. The rent for any other additional construction will be negotiated in good faith. In addition, the rent for a specific production area identified in the agreement is reduced from $6 to $4 per square meter.

62

        Except for these changes, we believe that the payments to be made under the amended agreement will for the foreseeable future be substantially similar to the amounts we have paid under the prior agreement. In 2008, we paid a total of approximately $0.7 million to Kibbutz Shamir under the sublease agreement.

        If the agreement is terminated for any reason other than a breach by Kibbutz Shamir, Kibbutz Shamir shall not be obligated to repay any loans that we have provided for construction unless the newly constructed parts of the building are occupied by a third party or used by Kibbutz Shamir.

        The ILA may, from time to time, change its regulations governing the lease agreement, and these changes could affect the terms of the sublease agreement, as amended, including the provisions governing its termination.

        At our special general meeting of August 8, 2005, our shareholders approved the entry of Shamir and/or a subsidiary of Shamir into a lease agreement with Kibbutz Shamir.

        On June 4, 2006, we signed a memorandum of understanding with Shalag Industries Ltd., pursuant to which we rented 120 square meters for SSOP. This memorandum of understanding provided for the same rental amounts as the sublease agreement with Kibbutz Shamir, as described above. On December 15, 2007, we terminated the memorandum of understanding with Shalag Industries Ltd.

        On November 1, 2007, in lieu of the lease with Shalag, we and Kibbutz Shamir entered into a lease agreement pursuant to which we lease a newly constructed facility in the Kibbutz for SSOP until November 30, 2023. We are entitled to terminate the lease at any time; provided, however, that we have located an alternate tenant and Kibbutz Shamir has given its consent, which consent would not be reasonably withheld. The parcel of land underlying the facility is included in the long-term lease between Kibbutz Shamir and the ILA, pursuant to which Kibbutz Shamir may, with the consent of the ILA, sublease the parcel to a corporation under its control. The consent of the ILA for the lease, though, has not been obtained. In addition, the ILA may, from time to time, change its regulations governing such lease agreements, which could affect the terms of the lease, and may trigger the termination of the lease. Under the lease, Kibbutz Shamir is responsible for any expense resulting from actions of the ILA. The annual rental fees pursuant to the lease are payable quarterly, in an amount equal to 10% of the actual construction cost of the facility, excluding VAT and grants of the Investment Center, as certified by the board of directors of SSOP, but in no event more than $500,000 per annum. The current annual lease payment to Kibbutz Shamir for the use of this facility is approximately $460,000.

Loan Agreement with Kibbutz Shamir

        In accordance with our sublease agreement with Kibbutz Shamir dated January 5, 1999 (as amended on February 9, 2005), we granted a loan of approximately $0.4 million to Kibbutz Shamir in several installments in 2004 in order to fund the construction of an extension to our premises in Kibbutz Shamir. The loan was repaid by December 31, 2008, through deductions of the rental fees we pay to Kibbutz Shamir.

        At our special general meeting of shareholders on August 8, 2005, our shareholders approved a loan to Kibbutz Shamir in an amount not greater than $4.4 million, which bears annual interest at a variable rate equal to annual LIBOR plus 1.5%. The loan provided Kibbutz Shamir with funds for the construction of a building on the Kibbutz’s grounds, for our use. At our special general meeting of shareholders on March 8, 2007, our shareholders approved the termination of the loan. The loan was fully repaid.

Shareholders Agreement

        On February 9, 2005, certain of our shareholders entered into a new shareholders agreement, which became effective upon the listing of our securities for trading on a U.S. stock exchange.

63

        The agreement gives FIBI the right to nominate one director to our board of directors. The agreement obligates Kibbutz Shamir and the other shareholders party to the agreement to vote in favor of FIBI’s nominee, and FIBI to vote in favor of the directors nominated by Kibbutz Shamir.

        In addition, the agreement gives FIBI, Scorpio BSG Ltd., Gishrei Asia Ltd. and JFJ International Trading Ltd. a tag-along right to participate in a sale (other than a transfer to an affiliate or sales to the public on the stock exchange on which our shares are listed) of our shares by Kibbutz Shamir to a third party on a pro rata basis and on the same terms as those negotiated by Kibbutz Shamir with the third party.

        Finally, the agreement gives Kibbutz Shamir a right of first offer to purchase any of our shares held by FIBI, Scorpio BSG Ltd., Gishrei Asia Ltd. and JFJ International Trading Ltd. that any one of these entities intends to offer for sale to a third party and which constitutes at least 2.5% of our share capital on the same terms as those to be offered by the selling entity to the third party. This right of first offer will not apply to transfers to affiliates or sales to the public on the stock exchange on which our shares are listed.

        The agreement terminates when the aggregate holdings of FIBI, Scorpio BSG Ltd., Gishrei Asia Ltd. and JFJ International Trading Ltd. decrease below 5% of our issued and outstanding share capital and remain below 5% for a period of at least 90 consecutive days. These four entities currently hold approximately 8.35% of our outstanding shares.

Registration Rights Agreement

        Prior to the initial public offering of our shares in March 2005, we entered into a registration rights agreement with our then shareholders. See “Item 10. Additional Information – Shares Eligible for Future Sale – Registration Rights Agreement.”

Relationship with Kibbutz Eyal

        Kibbutz Eyal held 3.95% of our shares prior to the March 2005 offering. We acquired our wholly-owned manufacturing subsidiary, Eyal Optical Industries (1995) Ltd., or Eyal, from Kibbutz Eyal in a series of transactions between 1997 and 2003. Eyal is located on the premises of Kibbutz Eyal pursuant to a lease agreement between Eyal and Kibbutz Eyal.

        In December 2003, we granted Kibbutz Eyal a call option exercisable until January 10, 2004, to purchase 4,170 of our shares in consideration for an exercise price of $2.0 million. Kibbutz Eyal exercised the call option on January 4, 2004. We also granted Kibbutz Eyal a put option to sell the shares subject to the call option to us in consideration for $3.0 million. The put option was exercisable between January 1, 2006 and January 10, 2010. It expired upon the reorganization of our company from an A.C.S. into an Israeli corporation.

        Kibbutz Eyal holds a tag-along right to join a sale of our shares by Kibbutz Shamir in certain circumstances. Kibbutz Eyal waived its right to appoint a member of our board of directors on November 27, 2004, effective as of the closing of the March 2005 offering. Kibbutz Eyal currently holds approximately 1.85% of our shares.

        Kibbutz Eyal holds our shares through Haklaei Hasharon A.C.S. Ltd., an agricultural collective society owned by Kibbutz Eyal. The options and agreements discussed in this sub-section have been granted to or entered into with Haklaei Hasharon A.C.S. Ltd.

64

Relationship with Mr. Michael Oppenheimer

        On July 1, 2008, we executed an agreement pursuant to which we purchased from Mr. Oppenheimer his entire holdings in our European operations. Under the terms of the agreement, we will pay an amount derived from our European subsidiaries consolidated net profit for the fiscal years ending December 31, 2008, 2009 and 2010, not to exceed the total amount of Euro 500,000. In addition, we have undertaken to repay the loans received from Mr. Oppenheimer from time to time in aggregate principal amount of Euro 3.6 million ($5.0 million) as of December 31, 2008. The loans will be repaid in several payments until June 30, 2011.

7.C INTERESTS OF EXPERTS AND COUNSEL

        Not applicable.

65

ITEM 8. FINANCIAL INFORMATION

8.A CONSOLIDATED STATEMENTS AND OTHER FINANCIAL INFORMATION

        See Item 18 for a list of financial statements filed as part of this annual report.

Export Sales

        In 2008, substantially, all of our mold and semi-finished lenses were produced in Israel. Production of finished lenses took place mostly outside of Israel. Most of our export sales from Israel abroad are to our subsidiaries. Our export sales from Israel abroad to external customers totaled approximately $9.7 million, which is 6.9% of our total sales volume.

Legal Proceedings

        From time to time, we and our subsidiaries may be involved in lawsuits, claims, investigations or other legal or arbitral proceedings that arise in the ordinary course of our business. These proceedings may include general commercial disputes, claims regarding intellectual property or labor disputes with former employees. We are involved in two disputes concerning allegations of breach of third parties’ intellectual property, as described below.

        In September 2003, we received a notice from a large lens manufacturer regarding a claim of patent infringement relating to lenses produced using our software. We have denied any such infringement, and numerous discussions between the companies (and counsel) have ensued and are ongoing in order to resolve the matter without resorting to litigation.

        In January 2008, we received a notice from a shareholder of one of our subsidiaries claiming unlawful use of the subsidiary’s intellectual property and unjust enrichment. We have denied any such infringement, and numerous discussions between the parties (and counsel) have ensued and are ongoing in order to resolve the matter without resorting to litigation.

        We currently cannot predict the development or ultimate outcome of the discussions with regard to these claims.

Dividend Policy

        In August 2004, we declared a special dividend totaling $9.2 million in order to take advantage of certain tax benefits for our shareholders. We paid $4.0 million of this dividend in December 2004, and $5.2 million in 2005. On June 27, 2007, we declared a dividend of $4.0 million, which was paid in July 2007. On January 14, 2008, we declared a dividend of $4.0 million, which was paid in February 2008.

        We may decide not to maintain the level of dividend payments made during prior years, or not to make any dividend payments at all. Any future decisions regarding the distribution of dividends will depend on our net income, our investment policy and our dividend policy at that time.

8.B SIGNIFICANT CHANGES

        See Note 20 to our consolidated financial statements included elsewhere in this annual report.

66

ITEM 9. THE LISTING

9.A LISTING DETAILS

        Our ordinary shares began trading publicly on March 11, 2005. Prior to that date, there was no public market for our ordinary shares. The table below shows the high and low sales prices of our ordinary shares on the NASDAQ Global Market for each of periods indicated below.

Year	High		Low
2005 (for the period from March 11, 2005 through December 31, 2005)	$	16.74	$	8.45
2006	$	11.75	$	8.08
2007	$	12.75	$	7.60
2008	$	9.56	$	2.71

2007	High		Low
First Quarter	$	9.06	$	7.60
Second Quarter	$	10.64	$	8.83
Third Quarter	$	12.75	$	9.84
Fourth Quarter	$	12.12	$	7.94

2008	High		Low
First Quarter	$	9.56	$	6.61
Second Quarter	$	7.80	$	6.38
Third Quarter	$	6.89	$	5.83
Fourth Quarter	$	6.20	$	2.71

2009	High		Low
First Quarter	$	3.24	$	2.66
Second Quarter (through June 15, 2009)	$	5.30	$	3.07

Month	High		Low
December 2008	$	3.60	$	2.76
January 2009	$	3.15	$	2.78
February 2009	$	3.24	$	2.93
March 2009	$	3.20	$	2.66
April 2009	$	4.08	$	3.07
May 2009	$	4.81	$	4.13
June 2009 (through June 15, 2009)	$	5.30	$	4.72

        Our ordinary shares began trading publicly on the Tel-Aviv Stock Exchange on May 2, 2005. The table below shows the high and low sales prices of our ordinary shares on the Tel Aviv Stock Exchange for each of the periods indicated below.

Year	High		Low
2005 (for the period from May 2, 2005 through December 31, 2005)	NIS	76.42	NIS	41.40
2006	NIS	54.00	NIS	35.92
2007	NIS	52.77	NIS	31.78
2008	NIS	39.00	NIS	10.70

67

2007	High		Low
First Quarter	NIS	37.57	NIS	32.30
Second Quarter	NIS	42.77	NIS	35.17
Third Quarter	NIS	52.77	NIS	41.57
Fourth Quarter	NIS	48.42	NIS	31.78

2008	High		Low
First Quarter	NIS	39.00	NIS	22.31
Second Quarter	NIS	27.09	NIS	21.40
Third Quarter	NIS	24.89	NIS	19.35
Fourth Quarter	NIS	22.81	NIS	10.70

2009	High		Low
First Quarter	NIS	13.46	NIS	11.11
Second Quarter (through June 15, 2009)	NIS	20.36	NIS	13.52

Month	High		Low
December 2008	NIS	13.58	NIS	10.70
January 2009	NIS	12.47	NIS	11.11
February 2009	NIS	13.46	NIS	11.80
March 2009	NIS	13.46	NIS	11.90
April 2009	NIS	16.95	NIS	13.52
May 2009	NIS	19.80	NIS	18.12
June 2009 (through June 15, 2009)	NIS	20.36	NIS	19.04

9.B PLAN OF DISTRIBUTION

         Not applicable.

9.C MARKETS

        Our ordinary shares have been listed on the NASDAQ Global Market since March 11, 2005, under the symbol "SHMR". Our ordinary shares have also been listed on the Tel Aviv Stock Exchange since May 2, 2005. The address of the website of the Tel Aviv Stock Exchange is www.tase.co.il.

9.D SELLING SHAREHOLDERS

        Not applicable.

9.E DILUTION

        Not applicable.

9.F EXPENSES OF THE ISSUE

        Not applicable.

68

ITEM 10. ADDITIONAL INFORMATION

10.A SHARE CAPITAL

        Not applicable

10.B ARTICLES OF ASSOCIATION

        Our registration number with the Israeli registrar of companies is 51-365956-5.

        The purpose of the Company is to engage, directly or indirectly, in any lawful business activity or occupation whatsoever; provided, however, that the Company may donate reasonable amounts to worthy causes, as our board of directors may determine at its discretion, even if such donations are not within the framework of business considerations. See Article 3 of our Articles of Association, which sets forth our purposes.

        The following sections, to the extent they refer to our Articles of Association are qualified in their entirety by the articles themselves, filed as an exhibit to this annual report.

        For a summary of the provisions of our Articles of Association and bylaws with respect to the board of directors, see "Item 6. Directors Senior Management and Employees - Board of Directors."

Transfer of Shares and Notices

        Our fully paid ordinary shares are issued in registered form and are freely transferable under our Articles of Association. Under the Companies Law and our Articles of Association, shareholders' meetings require prior notice of at least 21 days.

Anti-Takeover Provisions; Mergers and Acquisitions under Israeli Law

        The Israeli Companies Law regulates mergers where the target company is dissolved into the acquiring company and allows such a merger to be effected if the merger receives the approval of the boards of directors of each of the merging companies and a majority of the shareholders present and voting at the general shareholders’ meeting of each of the merging companies, or by a majority of 75% of the shareholders present and voting on the proposed merger in case a company was incorporated under the Israeli Companies Ordinance. However, an approval of the general shareholders’ meeting of any of the following is not required: (a) in a target company wholly owned and controlled by the acquiring company; (b) in the acquiring company provided all of the following conditions are fulfilled: (i) the acquiring company is not required as a result of the merger to amend its articles and memorandum of association; and (ii) the acquiring company will not issue, as part of the merger, more than 20% of the voting rights in the acquiring company, and as a result of the issuance no shareholder becomes a holder of a controlling party as defined in the Companies Law. In addition to the approval of the merger by the requisite majority at the shareholders’general meeting, in case the other party to the merger or a person holding 25% or more of the shares of the other party to the merger, then the majority must include a majority of the shares held by those shareholders participating in the vote (abstaining votes shall not be taken into account) who do not have an interest in the other party. Upon petition by a creditor of a merging company, the court may delay or prevent the consummation of the merger, if it deems there to be a reasonable concern that as a result of the merger, the surviving company will not be able to meet the obligation to creditors of either of the merging companies. A merger may not be completed until 30 days have passed from the time that the general shareholders’ meetings of each of the merging companies have approved the merger and 50 days have passed from the time that the merger proposal has been filed with the Israeli Registrar of Companies, including all approvals necessary for its completion.

69

        The Israeli Companies Law also provides that an acquisition of shares in a public company such as us must be made by means of a tender offer if, as a result of the acquisition, the purchaser would become a 25% shareholder of the company. This rule does not apply if there is already another 25% shareholder of the company. Similarly, the Israeli Companies Law provides that an acquisition of shares in a public company must be made by means of a tender offer if as a result of the acquisition the purchaser would become more than a 45% shareholder of the company, unless there is already a shareholder holding more than 45% of the voting rights of the company. These rules do not apply if: (a) the acquisition is made by way of a private issue, provided that the acquisition was approved by the general shareholders’ meeting as a private issue which will grant the offeree 25% or more of the shares of the company, if there is not a person holding 25% or more of the shares of the company, or as a private issue which will grant the offeree 45% of the voting rights of the company, provided there is no person holding 45% of the voting rights in the company; (b) the acquisition is from a person holding more than 25% of the voting rights in the company, and as a result of the acquisition the purchaser will hold 25% or more of the voting rights in the company; (c) the acquisition is from a person holding more than 45% of the voting rights of the company, and as a result of the acquisition the purchaser will hold more than 45% of the voting rights of the company. In order to be accepted, the special tender offer must be accepted by a majority of the offerees and result in the acquisition of no less than 5% of the voting rights in the company. These restrictions do not apply if according to the laws of the country where the securities are registered for trading there are restrictions in respect of an acquisition of certain control rights or the acquisition of certain control rights obligates the purchaser to also make a tender offer to the public.

        An acquisition of shares following which the purchaser would become a holder of more than 90% of a public company’s shares must be made by a tender offer for the purchase of all the remaining shares (a full tender offer); if a full tender offer is accepted by holders to the extent that non-accepting holders hold less than 5% of the company’s issued shares, then the holders of the remaining shares must sell their shares to the acquirer on the terms of the tender offer. However, if the acquirer is unsuccessful in completing a full tender offer, the acquirer will not be permitted to acquire tendered shares to the extent that the acquisition of those shares would bring the acquirer’s holdings to more than 90% of the target company’s shares. Offerees of a successful full tender offer may petition the courts to raise the purchase price on the basis that it is an “unfair”price.

        In addition, a shareholder who holds more than 90% of the shares of a public company may not purchase additional shares as long as the shareholder holds more than 90%. Shares acquired in violation of these provisions become dormant and cease to confer any rights upon their holder as long as they are held by the acquirer.

Dividend and Liquidation Rights

        Our board of directors may, without seeking shareholder approval, declare a dividend to be paid to the holders of ordinary shares out of our retained earnings or our earnings derived over the two most recent years, whichever is higher, as reflected in the last audited or reviewed financial report for a period ending less than six months prior to distribution (the “Profit Requirement”), provided that there is no reasonable concern that a payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due. If we do not meet the Profit Requirement, a court may allow us to distribute a dividend, as long as the court is convinced that there is no reasonable concern that a distribution might prevent us from being able to meet our existing and anticipated obligations as they become due. Dividends are distributed to shareholders in proportion to the nominal value of their respective holdings.

        In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of ordinary shares in proportion to the nominal value of their respective holdings. This right may be affected by the grant of preferential dividend or distribution rights to the holders of any class of shares with preferential rights that may be authorized in the future. Our shareholders would need to approve any class of shares with preferential rights.

Tax Law

        Israeli tax law treats some acquisitions, particularly stock-for-stock swaps between an Israeli company and aforeign company, less favorably than U.S. tax law. Israeli tax law may, for example, subject a shareholder who exchanges our shares for shares in a foreign corporation to immediate Israeli taxation. See “–Israeli Taxation.”

70

Modification of Class Rights

        Unless otherwise provided by the Articles of Association, an amendment to the Articles of Association that prejudices the rights of a particular class of shares may be adopted by a resolution of the holders of a 75% majority of the shares of that class present at a separate class meeting, in addition to the approval of the general meeting of all classes of shares.

Election of Directors

        Our ordinary shares do not have cumulative voting rights in the election of directors. Therefore, the holders of ordinary shares representing more than 50% of the voting power at the general meeting of the shareholders, in person or by proxy, have the power to elect all of the directors whose positions are being filled at that meeting, to the exclusion of the remaining shareholders. External Directors are elected by a majority vote at a shareholders’meeting, provided that either: (i) the majority of shares voting for the election includes at least one-third of the shares of non-controlling shareholders participating in the vote (abstaining votes shall not be taken into account); or (ii) the total number of shares of non-controlling shareholders voting against the election of the External Director does not exceed one percent of the aggregate voting rights in the company. Our Articles of Association contain provisions providing for staggered terms for the members of our board of directors.

Voting, Shareholders’ Meetings and Resolutions

        Holders of ordinary shares have one vote for each ordinary share held on all matters submitted to a vote of the shareholders. These voting rights may be affected by the grant of special voting rights to the holders of any class of shares with preferential rights that may be authorized in the future; however, currently no holders of our shares have any special voting rights.

        An annual meeting of the shareholders must be held every year, and not later than 15 months following the last annual meeting. A special meeting of the shareholders may be convened by the board of directors at its discretion or upon the demand of any of: (1) two of the directors or 25% of the then serving directors, whichever is fewer; (2) shareholders owning at least 10% of the issued share capital and at least 1% of the voting rights in the company; or (3) shareholders owning at least 10% of the voting rights in the company. If the board does not convene a meeting upon a valid demand of any of the above, then whoever made the demand, and in the case of shareholders, those shareholders holding more than half of the voting rights of the persons making the demand, may convene a meeting of the shareholders to be held within three months of the demand. Alternatively, upon petition by the individuals making the demand, a court may order that a meeting be convened.

        The quorum required for any general meeting of shareholders consists of at least two shareholders present in person or by proxy who hold or represent between them at least 33 (1)/3% of the voting rights. A meeting adjourned for lack of a quorum generally is adjourned to the same day in the following week at the same time and place or to a later date specified in the summons or notice of the meeting. At the reconvened meeting, the required quorum consists of any number of shareholders present. In any shareholders’ meeting, a shareholder can vote either in person or by proxy. General meetings of shareholders will be held in Israel, unless decided otherwise by our board.

        Under Israeli law, unless otherwise provided in the Articles of Association or applicable law, all resolutions of the shareholders require a simple majority. Under our Articles of Association, resolutions requiring special voting procedures include any amendments of a provision in our Articles of Association, which requires the approval of the holders of 75% of the voting rights represented at the meeting and voting on the resolution.

        Under the Israeli Companies Law, a shareholder has a duty to act in good faith and in a customary manner in exercising his rights and duties towards the company and other shareholders, to refrain from prejudicing the rights of other shareholders and to refrain from abusing his power in the company. The rights and duties apply, among other things, to voting at the general meeting of the shareholders on any of the following matters: (1) amendments to the Articles of Association, (2) increasing our registered share capital, (3) a merger, or (4) an approval of those related party transactions that require shareholder approval.

71

        In addition, shareholders who are one of the following are under a duty to act fairly toward the company: (1) a controlling shareholder; (2) a shareholder who knows that its vote will determine the outcome of a shareholder vote; or (3) a shareholder who, under the provisions of the articles, has the power to appoint or to prevent the appointment of an office holder in the company or holds other powers with respect to the company.

Transfer Agent and Registrar

        We have appointed American Stock Transfer & Trust Company as the transfer agent and registrar for our ordinary shares.

Israeli Securities Law Requirements

        According to the Israeli Securities Law, the publication of this annual report does not require the approval of the Israeli Securities Authority.

Listing

        Our ordinary shares are listed on the NASDAQ Global Market under the symbol "SHMR" and on the Tel Aviv Stock Exchange.

10.C MATERIAL CONTRACTS

        For a description of material contracts other than the one described below, see “Item 7. Major Shareholders and Related Party Transactions–Related Party Transactions.”

Registration Rights Agreement

        On February 9, 2005, we entered into a registration rights agreement with our shareholders, according to which these shareholders, who held a total of 12,711,332 shares prior to the offering and currently hold a total of 11,371,919 shares, have the right, subject to some limited conditions, to demand that we file a registration statement on their behalf to register their shares under the U.S. Securities Act of 1933. Each of the shareholders has the right to make two such demands, with the exception of Vision Capital LLC, which had the right to make one such demand. To out knowledge, Vision Capital LLC does not hold any of our ordinary shares that are subject to the registration agreement. According to the agreement, we will bear the registration fees, filing fees and certain other costs incurred in connection with the registration resulting from the first of these demands by each shareholder, while the shareholders will bear the costs resulting from a second such demand. Under the agreement, the shareholders also have the right to demand that we include their shares in a registration statement that we file on our behalf or on behalf of other shareholders. These rights became effective in September 2005 and will terminate either in February 2011, or with respect to any shareholder, at such a time as that shareholder either disposes of its shares or will be able to sell all of the registrable securities it holds without registration and without restrictions in compliance with Rule 144.

10.D EXCHANGE CONTROLS AND OTHER LIMITATIONS AFFECTING SECURITY HOLDERS

        There are currently no Israeli currency control restrictions on payments of dividends or other distributions with respect to our ordinary shares or the proceeds from the sale of the shares, except for the obligation of Israeli residents to file reports with the Bank of Israel regarding some transactions. However, legislation remains in effect under which currency controls can be imposed by administrative action at any time.

72

        The ownership or voting of our ordinary shares by non-residents of Israel, except with respect to citizens of countries which are in a state of war with Israel, is not restricted in any way by our memorandum of association or Articles of Association or by the laws of the State of Israel.

10.E TAXATION

United States Taxation

        The following discussion is a summary of certain material U.S. federal income tax considerations applicable to the ownership and disposition of shares by U.S. holders. In general for purposes of this summary you will be a “U.S. holder” if:

— you are the beneficial owner of shares;

— you are either (i) an individual resident or citizen of the United States, (ii) a corporation or other entity treated as a corporation for U.S. federal income tax purposes created in or organized under the laws of the United States or any state thereof, (iii) an estate whose income is subject to U.S. federal income taxation regardless of its source, or (iv) a trust if a U.S. court can exercise primary supervision over the administration of the trust and one or more U.S. persons are authorized to control all substantial decisions of the trust;

— you own our shares as capital assets;

— you own directly or indirectly less than 10% of our outstanding voting stock;

— you are fully eligible for benefits under the Limitation on Benefits article of the Income Tax Treaty between the United States of America and the State of Israel, which entered into force on December 30, 2004 (the “Treaty”); and

— you are not also a resident of Israel for Israeli tax purposes.

        The Treaty benefits discussed below generally are not available to holders who hold shares in connection with the conduct of business through a permanent establishment, or the performance of personal services through a fixed base, in Israel.

        If a partnership holds shares, the tax treatment of a partner generally will depend upon the status of the partner and the activities of the partnership. If you are a partner in a partnership that holds shares, you are urged to consult your own tax advisor regarding the specific tax consequences of owning and disposing of your shares.

        The summary does not purport to be a comprehensive description of all of the tax considerations that may be relevant to any particular holder, including tax considerations that arise from rules of general application or that are generally assumed to be known by U.S. holders. This summary is based on provisions of the Internal Revenue Code of 1986, as amended (the “Code”), existing and proposed U.S. Treasury Regulations, rulings, administrative pronouncements and judicial decisions in effect as of the date of this annual report. All of the authorities are subject to change, possibly with retroactive effect, and to differing interpretations. In addition, this summary does not discuss all aspects of U.S. federal income taxation that may be applicable to investors in light of their particular circumstances or to U.S. holders who are subject to special treatment under U.S. federal income tax law, including insurance companies, dealers in stocks or securities, financial institutions, tax-exempt organizations, persons subject to the alternative minimum tax, and persons having a functional currency other than the U.S. dollar.

        U.S. holders are urged to consult with their own tax advisors regarding the tax consequences of the ownership and disposition of shares, including the effects of U.S. federal, state, local, Israeli, foreign and other tax laws with respect to their particular circumstances.

73

        This discussion assumes that we will not be considered a passive foreign investment company, as discussed below.

        Dividends

        If we make any distributions of cash or other property to you, you generally will be required to include in gross income as dividend income the amount of any distributions (including the amount of any Israeli taxes withheld in respect of such distribution as described below in the section “–Israeli Taxation”), to the extent that such distributions are paid out of our current or accumulated earnings and profits as determined for U.S. federal income tax purposes. Distributions in excess of our earnings and profits will be applied against and will reduce your tax basis in your shares and, to the extent in excess of such tax basis, will be treated as gain from a sale or exchange of such shares. Dividends paid by us will not be eligible for the dividends received deduction applicable in some cases to U.S. corporations.

        Any dividend paid in Israeli shekels, including the amount of any Israeli taxes withheld there from will be includible in your gross income in an amount equal to the U.S. dollar value of the Israeli shekels calculated by reference to the spot rate of exchange in effect on the date the dividend is received by you, regardless of whether the Israeli shekels are converted into U.S. dollars. Any gain or loss resulting from currency exchange fluctuations during the period from the date the dividend is received by you to the date such payment is converted into U.S. dollars will be treated as U.S. source ordinary income or loss.

        Any dividends paid by us to you with respect to shares will be treated as foreign source income and will be characterized as “passive income” or, in the case of some U.S. holders, “financial services income” for U.S. foreign tax credit purposes. For our taxable years beginning January 1, 2008, dividend income generally will constitute “passive category income” or, in the case of certain U.S. holders, “general category income.” Subject to the foreign tax credit limitation, you may elect to claim a foreign tax credit against your U.S. federal income tax liability for Israeli income tax withheld from dividends received in respect of shares at a rate not in excess of the U.S. tax rate. The rules relating to the determination of the foreign tax credit are complex. Accordingly, you should consult your own tax advisor to determine whether and to what extent you would be entitled to the credit. If you do not elect to claim a foreign tax credit, you may instead claim a deduction for Israeli income tax withheld, but only for a year in which you elect to do so with respect to all foreign income taxes.

        Absent an election, a U.S. holder that is an accrual method taxpayer generally must translate Israeli taxes into U.S. dollars at a rate equal to the average exchange rate for the taxable year in which the taxes accrue, but must translate taxable dividends into U.S. dollars at the spot rate on the date received. This difference in exchange rates may reduce the U.S. dollar value of the credits for Israeli taxes relative to its U.S. federal income tax liability attributable to a dividend. An accrual method U.S. holder may elect to translate Israeli taxes into U.S. dollars using the exchange rate in effect at the time the taxes were paid. Any such election will apply for the taxable year in which it is made and all subsequent years, unless revoked with the consent of the Internal Revenue Service (“IRS”).

        “Qualified dividend income” received by individuals in taxable years beginning on or before December 31, 2010, generally will be taxed at the rates applicable to capital gains (that is, a maximum rate of 15%) rather than the rates applicable to other items of ordinary income. For this purpose, “qualified dividend income” generally includes dividends paid on shares of U.S. corporations as well as dividends paid on shares of certain non-U.S. corporations if, among other things, (i) the shares of the non-U.S. corporation are readily tradable on an established securities market in the United States, or (ii) the non-U.S. corporation is eligible with respect to substantially all of its income for the benefits of a comprehensive income tax treaty with the United States which contains an exchange of information program (the Treaty has been identified by the U.S. Treasury as a qualifying treaty). Dividends paid by us with respect to the shares should constitute “qualified dividend income” for U.S. federal income tax purposes and therefore U.S. holders who are individuals should, subject to applicable limitations, be entitled to the reduced rates of tax.

74

        Sale or exchange of shares

        Upon the sale or other disposition of shares, you generally will recognize capital gain or loss equal to the difference between the amount realized on the disposition and your adjusted tax basis in your shares. Gain or loss upon the disposition of shares generally will be U.S. source gain or loss, and will be treated as long-term capital gain or loss if, at the time of the disposition, your holding period for the shares exceeds one year. If you are an individual, any capital gains generally will be subject to U.S. federal income tax at preferential rates if specified minimum holding periods are met. For shares held for over one year and sold or exchanged in taxable years beginning on or before December 31, 2010, the maximum rate of tax for individuals generally will be 15%. The deductibility of capital losses is subject to significant limitations.

        Passive Foreign Investment Company status

        We currently believe that we will not be treated as a Passive Foreign Investment Company (a “PFIC”) for U.S. federal income tax purposes for the taxable year ended December 31, 2008. However, this conclusion is a factual determination that must be made annually and thus may be subject to change. A non-U.S. corporation will be classified as a PFIC for any taxable year if at least 75% of its gross income consists of passive income (such as dividends, interest, rents, royalties, or gains on the disposition of certain minority interests), or at least 50% of the average value of its assets consists of assets that produce, or are held for the production of, passive income, taking into account a proportionate share of the income and assets of corporations at least 25% owned by such corporation. If we were characterized as a PFIC for any taxable year, you could suffer adverse tax consequences. These consequences may include having gains realized on the disposition of shares and certain dividends treated as ordinary income earned over your holding period for the shares taxable at maximum rates applicable during the years in which it is treated as earned and subject to certain interest charges for the deemed deferral benefit. Furthermore, dividends paid by a PFIC would not be “qualified dividend income” as discussed above.

        U.S. information reporting and backup withholding

        Dividend payments with respect to shares and proceeds from the sale, exchange, redemption, or other disposition of shares may be subject to information reporting to the IRS and possible U.S. backup withholding at a current rate of 28%. Certain exempt recipients (such as corporations) are not subject to these information reporting requirements. Backup withholding will also not apply to a holder who furnishes a correct taxpayer identification number or certificate of foreign status and makes any other required certification. U.S. persons who are required to establish their exempt status generally must provide IRS Form W-9 (Request for Taxpayer Identification Number and Certification).

        Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against a holder’s U.S. federal income tax liability, and a holder may obtain a refund of any excess amounts withheld by filing the appropriate claim for refund with the IRS and furnishing any required information in a timely manner.

        Israeli Taxation

        The following summary describes the current tax structure applicable to companies in Israel, with special reference to its effect on us. It also discusses Israeli tax consequences material to persons purchasing our ordinary shares. To the extent that the summary is based on new tax legislation yet to be judicially or administratively interpreted, we cannot be sure that the views expressed will be consistent with any future interpretation. The summary is not intended, and should not be considered, to be legal or professional tax advice and does not exhaust all possible tax considerations. Therefore, you should consult your own tax advisor about the particular tax consequences of an investment in our ordinary shares.

75

        General Corporate Tax Structure

        Israeli companies are currently subject to tax at the rate of 27% of taxable income. Beginning from 2004, there has been a gradual reduction in the Israeli corporate tax rate from 35% in 2004 to 34% in 2005, 31% in 2006, 29% in 2007, 27% in 2008, 26% in 2009 and in 2010 and thereafter – 25%. From 2010 and onward the corporate tax rate will be 25%, the capital gains subject to a tax rate of 25%. However, the effective tax rate payable by a company that derives income from an approved enterprise may be considerably less, as further discussed below.

        Until December 31, 2004, Shamir was not assessed for tax purposes and its business results were passed through to its shareholders. As a result, Shamir’s tax expenses were not included in the statements of income. Commencing January 1, 2005, Shamir became a taxable entity as a result of the change in legal status from an ACS to an Israeli limited corporation which took place in March 2005.

Tax Benefits under the Law for the Encouragement of Capital Investments, 1959

        The Law for the Encouragement of Capital Investments, 1959 (the “Investment Law”), provides that upon application to the Investment Center of the Ministry of Industry and Commerce of the State of Israel, a proposed capital investment in eligible facilities may be designated as an Approved Enterprise. Each certificate of approval for an Approved Enterprise relates to a specific investment program delineated both by its financial scope, including its capital sources, and by its physical characteristics, such as the equipment to be purchased and utilized under the program. The tax benefits derived from any certificate of approval relate only to taxable income derived from growth in manufacturing revenues attributable to the specific Approved Enterprise. If a company has more than one approval or only a portion of its capital investments are approved, its effective tax rate is the result of a weighted combination of the applicable rates. The tax benefits under the law are not available for income derived from products manufactured outside of Israel.

        According to the grant track, taxable income of a company derived from an Approved Enterprise is subject to tax exemption or reduction to a rate of 10%-25% based on the level of foreign ownership and geographic location, rather than the usual rate described above, for the benefit period . This period is seven to ten years also based on the level of foreign ownership beginning with the year in which the Approved Enterprise first generates taxable income, and the reduced tax rate period is limited to 12 years from when production begins or 14 years from the date of approval, whichever is earlier. A company owning an Approved Enterprise may elect to receive an alternative package of benefits, which allows the company to receive tax exemptions rather than grants. Under the alternative package, the company’s undistributed income derived from an Approved Enterprise will be exempt from tax for a period of between two and ten years from the first year of taxable income, depending on the geographic location of the Approved Enterprise within Israel, and the company will be eligible for the tax benefits under the law for the remainder of the benefit period.

        A company that has an approved enterprise program is eligible for further tax benefits if it qualifies as a foreign investors’ company. A foreign investors’ company is a company that more than 25% of whose share capital and combined share and loan capital is owned by non-Israeli residents. A company, which qualifies as a foreign investors’ company and has an approved enterprise program is eligible for tax benefits for a ten-year benefit period instead of the ordinary seven-year period. Income derived from the approved enterprise program will be exempt from tax for a specified period and will be taxed at a reduced rate for the rest of the period. The tax rate for the additional eight years is 25%, unless the level of foreign investment exceeds 49%, in which case the tax rate is 20% if the foreign investment is more than 49% and less than 74%, 15% if more than 74% and less than 90%, and 10% if 90% or more.

        The Investment Center bases its decision of whether to approve or reject a company’s application for designation as an Approved Enterprise on criteria described in the law and related regulations, the then prevailing policy of the Investment Center and the specific objectives and financial criteria of the applicant. Therefore, a company cannot be certain in advance whether its application will be approved. In addition, the benefits available to an approved enterprise are conditional upon compliance with the conditions stipulated in the law and related regulations and the criteria described in the specific certificate of approval. If a company violates these conditions, in whole or in part, it would be required to refund the amount of tax benefits and any grants received plus an amount linked to the Israeli consumer price index and interest.

76

        A portion of our production operations has been granted the status of an Approved Enterprises under three programs of grants track that are still active. Income arising from our Approved Enterprise facilities is exempted from tax for two years and entitled to reduced tax rates based on the level of foreign ownership for a period of five to eight years. We have derived and expect to continue to derive a certain portion of the income from our Approved Enterprise facilities. Subject to compliance with applicable requirements and assuming that more than 25% of the shares of the company are held by foreign residents, the current benefits will continue until 2008 with respect to the first approved enterprise, until 2010 with respect to the second approved enterprise program, and until 2014 with respect to the third approved enterprise program.

        A portion of the operations of Eyal has been granted the status of an Approved Enterprise under three programs of the alternative package of benefits. Income arising from our Approved Enterprise facilities in Eyal is exempted from tax for two years and entitled to reduced tax rates based on the level of foreign ownership for a period of five to eight years. The last year for reduced tax rates in the three programs are 2008, 2011, 2013, respectively. The benefits are contingent upon compliance with the terms of the approval and of the Encouragement Law.

        As of the year 2010, as detailed above, the percentage the Israeli corporate tax rate will be at the same rate of the Approved Enterprise tax rate.

        Dividends that are derived from Approved Enterprise are generally subject to 15% withholding tax rate. If we pay a cash dividend from tax-exempt income that is derived from our approved enterprise, we will be required to pay corporate tax on the amount intended to be distributed as dividends at the reduced tax rate (maximum 25%). We would also be required to withhold on behalf of the dividend recipient an additional 15% of the amount distributed as dividends. The law also provides that an Approved Enterprise is entitled to accelerated depreciation on its property and equipment that are included in an approved investment program.

        On April 1, 2005, an amendment to the Investment Law came into effect (“the Amendment”) and has significantly changed the provisions of the Investment Law. The Amendment limits the scope of enterprises which may be approved by the Investment Center by setting criteria for the approval of a facility as a Beneficiary Enterprise, such as provisions generally requiring that at least 25% of the Beneficiary Enterprise’s income will be derived from export. Additionally, the Amendment enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits.

        The operations of SSOP, the polycarbonate and the finished lenses production facilities, received a pre-ruling from the ITA, where it was declare a Privilege Enterprise (establishment), so that all of its income forms the abovementioned facilities will be exempted from tax for a period of ten years beginning with the year in which it first had taxable income. SSOP has not begun to enjoy the tax benefits in the year 2008 due to its accumulated losses. In addition, during the fiscal year 2007, a portion of Eyals’ activities have been acting under the status of a Privileged Enterprise under the amendment to the Investment Law. As stated above, Eyal’s status as a Privileged Enterprise is subject to the approval of the ITA.

        Shamir has decided not to declare dividends out of such tax-exempt income. Accordingly, no deferred income taxes have been provided on income attributable to the Company’s “Approved Enterprise” and “Privileged Enterprise”.

        Inflationary Adjustments

        In February 2008, the Israeli legislator adopted an amendment to the Income Tax (Inflationary Adjustments) Law, 1985, which limits the scope of the law starting in 2008 and thereafter. Starting in 2008, the results for tax purposes are measured in nominal values, excluding certain adjustments for changes in the Consumer Price Index carried out in the period up to December 31, 2007. The amended law includes, inter alia, the elimination of the inflationary additions and deductions and the additional deduction for depreciation starting in 2008.

77

        Dollar Regulations

        Results for tax purposes of Israeli entities are measured and reflected in real terms in accordance with the change in the Israeli Consumer Price Index (“CPI”) or changes in the exchange rate of the NIS against the dollar for a “Foreign Investors” company. Shamir and its subsidiaries Eyal and SSOP have elected to measure their results for tax purposes on the basis of the changes in the exchange rate of NIS against the U.S. dollar. During 2008, Shamir and Eyal, elected to measure its Israeli taxable income in NIS rather than in the exchange rate of NIS against the U.S. dollar. This election is applicable for a four taxable years commencing on January 1, 2007. The Company was permitted to make such change pursuant to regulations published by the Israeli Minister of Finance, which provide the conditions for such change. Therefore, the Company and Eyal re-measured their 2007 taxable income during 2008. In general, a company that elects to apply these regulations can not change its resolution for a period of three years following the fiscal year of such election.

        Tax Benefits for Research and Development

        The Israeli tax law allows a tax deduction in the year incurred for expenditures, including capital expenditures, in scientific research and development projects, if the expenditures are approved by the relevant Israeli government ministry and the research and development is for the promotion of the enterprise. Expenditures not so approved are deductible over a three-year period.

        Tax Benefits under the Law for the Encouragement of Industry (Taxes), 1969

According to the Law for the Encouragement of Industry (Taxes), 1969, an industrial company is a company resident in Israel, at least 90% of the income of which, exclusive of income from defense loans, capital gains, interest and dividends, is derived from an industrial enterprise owned by it. An industrial enterprise is defined as an enterprise whose primary activity in a given tax year is industrial production activity.

        Under the law, industrial companies are entitled to the following preferred corporate tax benefits:

— deduction of purchases of know-how and patents over an eight-year period for tax purposes;

— the option to file a consolidated tax return with related Israeli industrial corporations that satisfy conditions described in the law; and

— accelerated depreciation rates on equipment and buildings.

        Shamir and certain of its Israeli subsidiaries currently qualify as “Industrial Companies” pursuant to the Industry Encouragement Law. Currently, Shamir files consolidated tax returns together with SSOP.

        Eligibility for benefits under the Industry Encouragement Law is not subject to receipt of prior approval from any government authority. The Israeli tax authorities may determine that we do not qualify as an Industrial Company, which would entail the loss of the benefits that relate to this status. In addition, we might not continue to qualify for Industrial Company status in the future, in which case the benefits described above might not be available to us in the future.

Taxation of our Shareholders

Capital Gain

        Capital gain tax is imposed on the disposal of capital assets by an Israeli resident, as defined for Israeli tax purposes, and on the disposal of such assets by a non- Israel resident if those assets are either (i) located in Israel; (ii) are shares or a right to a share in an Israeli resident corporation (iii) represent, directly or indirectly, rights to assets located in Israel. In calculating capital gain, the Israeli Tax Ordinance distinguishes between “Real Gain” and the “Inflationary Surplus”. The Inflationary Surplus is the portion of the total capital gain equal to the increase in the relevant asset’s value that is attributable to the increase in the Israeli CPI between the date of the purchase and the date of sale. The Real Gain is the excess of the total capital gain over Inflationary Surplus. A non-resident that invests in taxable assets with foreign currency, or any individual that holds securities the price of which is stated in foreign currency, may elect calculate the amount of inflationary surplus in that foreign currency.

78

        The capital gain accrued by individuals on the sale of an asset purchased on or after January 1, 2003, will be taxed at the rate of 20%. However, if the individual shareholder is a “Controlling Shareholder” (i.e., a person who holds, directly or indirectly, alone or together with other, 10% or more of one of the Israeli resident company's means of control at the time of distribution or at any time during the preceding 12 months period) such gain will be taxed at the rate of 25%. In addition, capital gain derived by an individual claiming deduction of financing expenses in respect of such gain will be taxed at the rate of 25%. The real capital gain derived by corporation will be generally subject to tax at the rate of 25%. However, the real capital gain derived from sale of securities, as defined in Section 6 of the Inflationary Adjustment Law, by a corporation, which was subject upon December 31, 2005, to the provisions of the Inflationary Adjustment Law, will be taxed at the corporate tax rate (27% in 2008), only if such securities were held by such a corporation prior to December 31,2005.

        Individual and corporate shareholder dealing in securities in Israel are taxed at the tax rates applicable to business income (in 2008 – 27% tax rate for a corporation and a marginal tax rate of up to 47% for individual). Notwithstanding the foregoing, if the shareholder is a non-Israeli resident, then such taxation is subject to the provision of any applicable double tax treaty. Moreover, capital gain derived from the sale of the Shares by a non-Israeli shareholder may be exempt under the Israeli income tax ordinance from Israeli taxation provided the following cumulative conditions are met: (i) the Shares were purchased upon or after the registration of the Shares at the stock exchange, (ii) the seller doesn’t have a permanent establishment in Israel to which the derived capital gain is attributed, and (iii) if the seller is a corporation, less than 25% of its means of control are held by Israeli resident shareholders. In addition, the sale of the Shares may be exempt from Israeli capital gain tax under an applicable tax treaty. Thus, the U.S.-Israel Double Tax Treaty exempts U.S. resident from Israeli capital gain tax in connection with such sale, provided (i) the U.S. resident owned, directly or indirectly, less than 10% of an Israeli resident company’s voting power at any time within the 12 – month period preceding such sale; (ii) the seller, being an individual, is present in Israel for a period or periods of less than 183 days at the taxable year; and (iii) the capital gain from the sale was not derived through a permanent establishment of the U.S. resident in Israel.

        Either the seller, the Israeli stockbrokers or financial institution through which the sold securities are held are obliged, subject to the above mentioned exemptions, to withhold tax upon the sale of securities from the real capital gain at the rate of 25% in respect of a corporation and 20% in respect of an individual.

Dividends

        A distribution of dividend from income attributed to an “Approved Enterprise” and “Privileged Enterprise” will be subject to tax in Israel at the rate of 15%, subject to a reduced rate under any applicable double tax treaty. A distribution of dividend from income, which is not attributed to an “Approved Enterprise” to an Israeli resident individual, will generally be subject to income tax at a rate of 20%. However, a 25% tax rate will apply if the dividend recipient is a “Controlling Shareholder” (i.e., a person who holds, directly or indirectly, alone or together with other, 10% or more of one of the Israeli resident company’s means of control at the time of distribution or at any time during the preceding 12 months period). If the recipient of the dividend is an Israeli resident corporation, such dividend will be exempt from income tax provided the income from which such dividend is distributed was derived or accrued within Israel.

        Under the Israeli income tax ordinance, a non-Israeli resident (either individual or corporation) is generally subject to an Israeli income tax on the receipt of dividends at the rate of 20% (25% if the dividends recipient is a “Controlling Shareholder” (as defined above)); those rates are subject to a reduced tax rate under an applicable double tax treaty. Thus, under the Double Tax Treaty concluded between the State of Israel and the U.S. the following rates will apply in respect of dividends distributed by an Israeli resident company to a U.S. resident: (i) if the U.S. resident is a corporation which holds during that portion of the taxable year which precedes the date of payment of the dividend and during the whole of its prior taxable year (if any), at least 10% of the outstanding shares of the voting stock of the Israeli resident paying corporation and not more then 25% of the gross income of the Israeli resident paying corporation for such prior taxable year (if any) consists of certain type of interest or dividends – the tax rate is 12.5%, (ii) if both the conditions mentioned in section (i) above are met and the dividend is paid from an Israeli resident company’s income which was entitled to a reduced tax rate applicable to an “approved enterprise” under the Israeli Law for the Encouragement of Capital Investments of 1959– the tax rate is 15%, and (iii) in all other cases, the tax rate is 25%. The aforementioned rates under the Israel U.S. Double Tax Treaty will not apply if the dividend income was derived through a permanent establishment of the U.S. resident in Israel.

79

        An Israeli resident company whose shares are listed in a stock exchange is obligated to withhold tax, upon the distribution of a dividend attributed to an Approved Enterprise’s income, from the amount distributed, at the following rates: (i) Israeli resident corporation – 15%, (ii) Israeli resident individual – 15%, and (iii) non-Israeli resident – 15%, subject to a reduced tax rate under an applicable double tax treaty. If the dividend is distributed from an income not attributed to the Approved Enterprise, the following withholding tax rates will apply: (i) Israeli resident corporation – 0%, (ii) Israeli resident individual – 20% (iii) non-Israeli resident – 20%, subject to a reduced tax rate under an applicable double tax treaty.

Taxation of Non-Resident Shareholders

        Non-residents of Israel are subject to Israeli income tax on income accrued or derived from sources in Israel, including passive income such as dividends, royalties and interest. On distributions of dividends, other than bonus shares and stock dividends, income tax at the rate of 20% is withheld at the source, unless a different rate is provided in a treaty between Israel and the shareholder's country of residence. Under the U.S.-Israel Tax Treaty, the maximum tax on dividends paid to a holder of ordinary shares who is a Treaty U.S. Resident will be 25% or 12.5% for dividends not generated by an approved enterprise if the non-resident is a U.S. corporation and holds 10% or more of our voting power throughout a certain period; however, under the Investment Law, dividends generated by an approved enterprise are taxed at the rate of 15%.

Foreign Exchange Regulations

        Non-residents of Israel who hold our ordinary shares are able to receive any dividends, and any amounts payable upon the dissolution, liquidation and winding up of our affairs, freely reparable in non-Israeli currency at the rate of exchange prevailing at the time of conversion. However, Israeli income tax is required to have been paid or withheld on these amounts. In addition, the statutory framework for the potential imposition of exchange controls has not been eliminated, and may be restored at any time by administrative action.

10.F DIVIDENDS AND PAYING AGENTS

        Not applicable.

10.G STATEMENTS BY EXPERTS

        Not applicable.

80

10.H DOCUMENTS ON DISPLAY

        We are subject to the reporting and informational requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In accordance with these requirements, we file reports, including annual reports on Form 20-F, and other information with the U.S. Securities and Exchange Commission (SEC). However, as we are a foreign private issuer, we and our shareholders are exempt from some of the Exchange Act reporting requirements. The reporting requirements that do not apply to us or our shareholders include the proxy solicitation rules and Section 16 short-swing profit reporting for our officers and directors and for holders of more than 10% of our shares. In addition, we are not required to file annual, quarterly or current reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we will file with the SEC, as long as we are required to do so, within 180 days after the end of each fiscal year, an annual report on Form 20-F containing financial statements audited by an independent accounting firm. We also intend to file periodic reports on Form 6-K. You may read and obtain copies, at the prescribed rate, of any document we file with the SEC at its public reference room at 100 F Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information on the public reference rooms and their copy charges. Our SEC filings are also available to you on the SEC’s web site at www.sec.gov.

10.I SUBSIDIARY INFORMATION

        Not applicable.

81

ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

        We do not engage in trading market risk instruments or purchasing hedging or “other than trading” instruments that are likely to expose us to market risk, whether interest rate, commodity price or equity price risk. From time to time we purchase options or enter forward contracts to hedge our foreign currency risk. We have also entered into an interest-rate swap. We do not use derivative instruments for speculative trading purposes.

Foreign Currency Risk

        We conduct our business primarily in U.S. dollars and Euros but also in the currencies of the United Kingdom, South Africa, Turkey, Mexico, Israel and other countries as well as other currencies. Thus, we are exposed to foreign exchange movements. We monitor foreign currency exposure and, from time to time, may enter into various derivative transactions intended to protect against changes in foreign currencies. We hedge, from time to time, some of our foreign currency exposure to offset the effects of changes in exchange rates. The derivative instruments were not designated as hedging instruments in accordance with SFAS No. 133.

        Our foreign currency exposures give rise to market risks associated with exchange rate movements of the U.S. dollar, our functional and reporting currency, against the Euro and the NIS and other currencies. In 2008 we generated approximately 31.5% of our revenues in dollars and 48.3% in Euros, and we incurred approximately 18.0% of our operating expenses in NIS, 32.2% in dollars and 38.6% in Euros.

        In Europe we operate through our European subsidiaries, which has most of its assets and liabilities in Euros. In the United States we operate through our subsidiaries Shamir Insight and Shamir USA, which have assets and liabilities in U.S. dollars. Shamir and our Israeli subsidiaries operate in Israel and have assets and liabilities mainly in dollars, as well as some assets and liabilities in Euros and NIS . Commencing in 2008 our new Mexican subsidiaries have assets and liabilities in Mexican Pesos as well. We attempt to match our assets and liabilities in the same currency in order to counteract fluctuations in currency exchange rates.

        As of December 31, 2008, we had $22.7 million in monetary current assets and $29.1 million in monetary current liabilities that are denominated in Euros. Additionally, we had $5.1 million in monetary current assets and $3.9 million in monetary current liabilities that are denominated in NIS.

Interest Rate Risk

        We believe that we are not exposed to a material interest rate risk due to the fact that the majority of our liabilities are short-term and most of our long-term liabilities are at a fixed interest rate. Most of our assets are short-term assets.

Credit Risk

        Credit risk is the possibility that the value of our assets may become impaired if counterparties cannot meet their obligations in transactions involving financial instruments. Our financial instruments are potentially subject to concentrations of credit risk consist principally of cash and cash equivalents, short-term deposits, marketable securities and our customers.

        The majority of our cash and cash equivalents and short-term deposits are invested mainly in U.S. dollar and Euro instruments with major banks in Israel, Germany and the U.S. Marketable securities include investments in debentures of U.S. treasury, U.S. government agencies and corporations. Our investment policy provides for a minimum grading of debentures in which we can invest, thereby reducing credit risk.

        While we may in a small number of instances be exposed to credit risk with respect to our customers, we perform ongoing credit evaluations of our customers and believe that this risk is not material.

ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

        Not applicable

82

PART II

ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

None.

ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

        In preparation for the initial public offering of our ordinary shares in March 2005, we changed the structure of our company from an A.C.S. into an Israeli corporation. As part of this reorganization, we adopted new Articles of Association and restructured our share capital by splitting the 105,506 existing shares so that each share with a par value of NIS 1.00 was divided into 100 ordinary shares with a par value of NIS 0.01 each. In addition, we distributed to our shareholders out of our equity 2,160,732 new ordinary shares with a par value of NIS 0.01 each. With this distribution, the old shares of the A.C.S. were in effect split at a ratio of 120.48-to-one, and our total issued and outstanding share capital then amounted to NIS 127,113 consisting of 12,711,332 ordinary shares with a par value of NIS 0.01 each. We also created authorized share capital of 100,000,000 ordinary shares with a par value of NIS 0.01 each. As part of the March 2005 offering of our shares, we then issued 3,400,000 new shares with a par value of NIS 0.01 each.

        The following use of proceeds information relates to our registration statement on Form F-1 (File No. 333-122736), filed by us in connection with our initial public offering. Our shares commenced trading on the NASDAQ on March 11, 2005. William Blair & Company, L.L.C., CIBC World Markets Corp. and C.E. Unterberg, Towbin, L.L.C. acted as representatives for the underwriters.

        The following table sets forth information regarding our shares registered and sold in our initial public offering, including the exercise of the over-allotment option:

	Amount Registered And Sold		Aggregate Price of the Amount Registered and Sold to Date (US$)
Shamir		3,400,000		42,275,000
Selling Shareholders		1,200,000		15,624,000
Total		4,600,000		57,899,000

        The amount of expenses incurred by us in connection with the issuance and distribution of the registered securities totaled $6,501,000 including $4,508,000 for underwriting discounts and commissions, and approximately $1,993,000 for other expenses. None of the payments were direct or indirect payments to our directors, officers, general partners of our associates, persons owning 10% or more of any class of our shares, or any of our affiliates.

        Up to June 15, 2009, we used part of the net proceeds from the offering as follows:

— to pay approximately $2.2 million for early repayments of some of our outstanding indebtedness;

— to pay a dividend payable of $5.2 million;

— to pay approximately $2.3 million for establishing our new subsidiary in Turkey, including the purchase of facilities;

— to pay approximately $2.6 million for additional shares in our subsidiary Shamir Insight, Inc., raising our holdings to 90%;

— to pay approximately $0.8 million to acquire a 51% stake in our South Africa distributor;

— to pay approximately $12.2 million to establish the new SSOP production facilities;

— to pay approximately $1.0 million in order to establish and expand Shamir Israel's operation;

83

— to pay approximately $1.2 million for establishing our new subsidiary in France;

— to pay approximately $0.7 million to expand our marketing and distribution network in the UK;

— to pay approximately $0.4 million to expand our marketing and distribution network in the United States;

— to pay approximately $6.4 million to acquire a 51% stake in each of our Mexican distributors, including obligations to shareholders loans;

— to pay approximately $1.3 million to acquire a 40.4% stake and finance our Thai manufacture and distributor;

— to pay approximately $ 1.8 million to purchase the remaining 49% of the holdings in our European operations; and

— to pay approximately $ 4.2 million as repayment of long term loans.

ITEM 15T. CONTROLS AND PROCEDURES

    (a)        Our management, including our chief executive officer and chief financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2008. Based on such review, our chief executive officer and chief financial officer have concluded that we have in place effective controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure, and is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

    (b)        Our management, under the supervision of our chief executive officer and chief financial officer, is responsible for establishing and maintaining adequate internal control over our financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended. The Company’s internal control over financial reporting is defined as a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes policies and procedures that:

– pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and asset dispositions;

– provide reasonable assurance that transactions are recorded as necessary to permit the preparation of our financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

– provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.

        Due to its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

        Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we evaluated the effectiveness of our internal control over financial reporting as of December 31, 2008, based on the framework for Internal Control-Integrated Framework set forth by The Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management concluded that the Company’s internal controls over financial reporting were effective as of December 31, 2008.

84

        This management report on internal control over financial reporting shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended or otherwise subject to the liabilities of that Section.

        This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management’s report in this annual report.

    (c)        There were no changes in our internal controls over financial reporting identified with the evaluation thereof that occurred during the period covered by this annual report that have materially affected, or are reasonable likely to materially affect our internal control over financial reporting.

ITEM 16. [RESERVED]

ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT

        Our board of directors has determined that Giora Yanai, member of our audit committee, qualifies as an audit committee financial expert in accordance with the terms of this item. All three members of our audit committee qualify as “Independent Directors” under the listing rules of the NASDAQ Global Market. See “Item 6. Directors, Senior Management and Employees.”

ITEM 16B. CODE OF ETHICS

        We have adopted a code of ethics and business conduct that applies to our chief executive officer, our chief financial officer and our controller, as well as to the members of our board of directors, all of our other executive officers and all of our employees. This code of ethics is attached as an exhibit to this annual report and is incorporated by reference.

ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES

        The fees for professional services rendered by our auditors Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, and to other global members of Ernst & Young Global, for the fiscal years ended December 31, 2007 and 2008, are set below:

Audit Fees Shamir	2007		2008
	(in $)
Audit fees		335,680		365,935
Audit-related fees		-		-
Tax fees		51,841		104,552
Other fees		-		-
Total		387,521		470,487

        “Audit fees”consist of services that would normally be provided in connection with statutory and regulatory fillings or engagements, including services that generally only an independent auditor can reasonably provide. “Audit-related fees” relate to assurance and associated services that traditionally are preformed by an independent auditor, including: accounting consultation and consultation concerning financial accounting and reporting standards. “Tax fees” are fees that relate to tax compliance, planning and advise.

        On July 31, 2008, the annual meeting of our shareholders approved the re-nomination of Kost Forer Gabbay & Kasierer as our auditors for the period ending at the close of the next annual general meeting.

85

        Our audit committee is responsible for assisting the board of directors in its oversight of, among others, the independent auditor’s qualifications and independence and the performance of the Company’s internal audit function and independent auditors. The committee is responsible for or shall make recommendations regarding the appointment, retention, evaluation, remuneration, independence, oversight and termination of the work of the independent auditor employed by the Company (including resolution of disagreements between management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for the Company. The charter of the audit committee provides for a process with respect to the prior approval of all services, including non-audit services, to be performed by the independent auditors for Shamir.

ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

        We have not and do not expect to apply for any exemptions from the NASDAQ listing standards for audit committees.

ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

        Not applicable.

ITEM 16F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT

        Not Applicable.

ITEM 16G. CORPORATE GOVERNANCE

        There are no significant ways in which the corporate governance of our company, as a foreign private issuer, differ from those followed by domestic companies listed on the Nasdaq Global Market. For more information regarding the structure of our board of directors and the exemption available to our company as a “controlled company”, see “Item 6.A. Directors, Senior Management – Board of Directors”.

86

PART III

ITEM 17. FINANCIAL STATEMENTS

        We have responded to Item 18 in lieu of responding to this item.

ITEM 18. FINANCIAL STATEMENTS

        The following financial statements, together with the reports of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, for the fiscal years ended December 31, 2007 and 2008, are filed as part of this annual report:

	Page
Report of Independent Registered Public Accounting Firm	F-2
Consolidated Balance Sheets as of December 31, 2007 and 2008	F-3 - F-4
Consolidated Statements of Income for the years ended December 31, 2006, 2007 and 2008	F-5
Consolidated Statements of Shareholders' Equity for the years ended December 31, 2006, 2007 and 2008	F-6
Consolidated Statements of Cash Flows for the years ended December 31, 2006, 2007 and 2008	F-7 - F-10
Notes to Consolidated Financial Statements	F-11- F-46

ITEM 19. EXHIBITS

See Exhibit Index.

87

SHAMIR OPTICAL INDUSTRY LTD.
AND ITS SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS

AS OF DECEMBER 31, 2008

IN U.S. DOLLARS

INDEX

	Page
Report of Independent Registered Public Accounting Firm	F-2
Consolidated Balance Sheets	F-3 - F-4
Consolidated Statements of Income	F-5
Consolidated Statements of Shareholders' Equity	F-6
Consolidated Statements of Cash Flows	F-7 - F-10
Notes to Consolidated Financial Statements	F-11 - F-46

Kost Forer Gabbay & Kasierer
3 Aminadav St.
Tel-Aviv 67067, Israel

Tel: 972 (3)6232525
Fax: 972 (3)5622555
www.ey.com/il

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

        We have audited the accompanying consolidated balance sheets of Shamir Optical Industry Ltd. (“the Company”) and its subsidiaries (collectively – “Shamir”) as of December 31, 2008 and 2007 and the related consolidated statements of income, Shareholders’ Equity and cash flows for each of the three years in the period ended December 31, 2008. These financial statements are the responsibility of the Shamir’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

        We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

        In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Shamir as of December 31, 2008 and 2007 and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2008, in conformity with U.S. generally accepted accounting principles.

Tel-Aviv, Israel	KOST FORER GABBAY & KASIERER
June 18, 2009	A Member of Ernst & Young Global

F - 2

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

	December 31,
	2007		2008
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	18,953	$	18,276
Short-term investments		14,375		7,187
Trade receivables (net of allowance for doubtful accounts of $ 2,140 and $ 2,066
at December 31, 2007 and 2008, respectively) *)		30,719		30,331
Other accounts receivable and prepaid expenses *)		7,523		8,469
Inventory		27,972		26,063
Total current assets		99,542		90,326
LONG-TERM INVESTMENTS:
Severance pay fund		3,089		2,584
Long-term receivables		1,299		813
Investments in affiliates and others		4,437		2,085
Total long-term investments		8,825		5,482
PROPERTY, PLANT AND EQUIPMENT, NET		39,170		38,617
OTHER ASSETS		5,412		5,902
GOODWILL		7,542		9,169
Total assets	$	160,491	$	149,496

*) As for transactions with related parties, see Note 17.

The accompanying notes are an integral part of the consolidated financial statements.

F - 3

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except share and per share data)

	December 31,
	2007		2008
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Short-term bank credit and loans	$	15,950	$	11,597
Current maturities of long-term loans and capital leases		7,689		10,403
Trade payables*)		10,852		8,876
Accrued expenses and other liabilities *)		12,735		11,680
Total current liabilities		47,226		42,556
LONG-TERM LIABILITIES:
Long-term loans		17,491		9,800
Capital leases		4,303		3,393
Accrued severance pay		3,337		3,172
Other long-term liabilities		753		634
Deferred tax liabilities		1,358		1,922
Total long-term liabilities		27,242		18,921
MINORITY INTERESTS		800		1,250
COMMITMENTS AND CONTINGENT LIABILITIES
SHAREHOLDERS' EQUITY:
Share capital -
Ordinary shares of NIS 0.01 par value -
Authorized: 100,000,000 shares at December 31, 2007 and 2008; Issued and
outstanding: 16,423,740 shares at December 31, 2007 and 2008, respectively.		37		37
Additional paid-in capital		66,629		67,362
Accumulated other comprehensive income		1,628		(2,637	)
Retained earnings		16,929		22,007
Total shareholders' equity		85,223		86,769
Total liabilities and shareholders' equity	$	160,491	$	149,496

*) As for transactions with related parties, see Note 17.

The accompanying notes are an integral part of the consolidated financial statements.

F - 4

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

U.S. dollars in thousands (except per share data)

	Year ended December 31,
	2006			2007			2008
Revenues, net *)	$	97,280		$	120,419		$	140,326
Cost of revenues *)		44,038			55,856			64,415
Gross profit		53,242			64,563			75,911
Operating expenses:
Research and development		2,372			2,564			3,368
Selling and marketing		32,798			36,552			42,374
General and administrative		10,986			13,549			16,793
Total operating expenses *)		46,156			52,665			62,535
Operating income		7,086			11,898			13,376
Financial and other expenses, net *)		(159	)		(239	)		(2,142	)
Income before taxes on income		6,927			11,659			11,234
Taxes on income		2,179			5,013			2,216
Income after taxes on income		4,748			6,646			9,018
Equity in gains (losses) of affiliates, net		(245	)		46			44
Minority interest in losses of subsidiaries		1,957			1,509			16
Net income	$	6,460		$	8,201		$	9,078
Net earnings per share:
Basic	$	0.40		$	0.50		$	0.55
Diluted	$	0.39		$	0.50		$	0.55

*) As for transactions with related parties, see Note 17.

The accompanying notes are an integral part of the consolidated financial statements.

F - 5

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

U.S. dollars in thousands (except share data)

	Number of shares		Share capital		Additional paid-in capital			Deferred stock compensation			Accumulated other comprehensive income			Retained earnings			Total comprehensive income			Total shareholders' equity
Balance as of January 1, 2006		16,256,514	$	37	$	65,055		$	(882	)	$	**) 429		$	6,749					$	71,388
Compensation in respect of options to employees		-		-		(882	)		882			-			-						-
Stock based compensation related to options granted
to employees and consultants		-		-		1,426			-			-			-						1,426
Comprehensive income:
Foreign currency translation adjustments		-		-		-			-			548			-		$	548			548
Unrealized loss on short-term investments,
net of tax		-		-		-			-			(19	)		-			(19	)		(19	)
Net income		-		-		-			-			-			6,460			6,460			6,460
Total comprehensive income																	$	6,989
Balance as of December 31, 2006		16,256,514		37		65,599			-			***) 958			13,209						79,803
Cumulative impact of change in accounting for
uncertainties in income taxes (FIN 48)		-		-		-			-			-			(481	)					(481	)
Distribution of earnings to shareholders
($0.244 per share)		-		-		-			-			-			(4,000	)					(4,000	)
Stock-based compensation related to options to
employees and consultants		-		-		1,030			-			-			-						1,030
Exercise of options granted to employees		167,226		*)		-			-			-			-						*)
Comprehensive income:
Foreign currency translation adjustments		-		-		-			-			620			-		$	620			620
Unrealized gain on short-term investments, net of tax		-		-		-			-			50			-			50			50
Net income		-		-		-			-			-			8,201			8,201			8,201
Total comprehensive income																	$	8,871
Balance as of December 31, 2007		16,423,740		37		66,629			-			***) 1,628			16,929						85,223
Distribution of earnings to shareholders ($0.243 per
share)		-		-		-			-			-			(4,000	)					(4,000	)
Stock-based compensation related
to options to employees		-		-		733			-			-			-						733
Comprehensive income:
Foreign currency translation adjustments		-		-		-			-			(4,230	)		-		$	(4,230	)		(4,230	)
Unrealized gain on short-term investments, net of tax		-		-		-			-			(35	)		-			(35	)		(35	)
Net income		-		-		-			-			-			9,078			9,078			9,078
Total comprehensive income																	$	4,813
Balance as of December 31, 2008		16,423,740	$	37	$	67,362		$	-		$	***) (2,637)		$	22,007					$	86,769

*) Represent an amount lower than $ 1.

**) The full amount represents foreign currency translation adjustments.

***) Represent an amount of $ 977, $ 1,597 and $ (2,633) foreign currency translation adjustment as of December 31, 2006, 2007 and 2008 respectively, and $ (19) loss, $ 31 gain and $ (4) loss on short-term investment, net of tax as of December 31, 2006, 2007 and 2008 respectively.

The accompanying notes are an integral part of the consolidated financial statements.

F - 6

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Year ended December 31,
	2006			2007			2008
Cash flows from operating activities:
Net income	$	6,460		$	8,201		$	9,078
Adjustments required to reconcile net income to net cash provided by
(used in) operating activities:
Depreciation and amortization		6,250			6,152			9,069
Stock based compensation		1,426			1,030			733
Accrued severance pay, net		62			(52	)		254
Currency fluctuations of long-term loans		166			526			11
Decrease (increase) in deferred tax assets, net		(1,987	)		1,317			201
Equity in losses (gains) of affiliates, net		245			(46	)		(44	)
Minority interest in losses of subsidiaries		(1,957	)		(1,509	)		(16	)
Interest receivable on marketable securities		(190	)		85			108
Foreign currency translation gains		(604	)		(1,239	)		(1,006	)
Decrease (increase)in trade receivables		(4,852	)		(4,915	)		1,984
Increase in other accounts receivable and prepaid expenses and in
long term receivables		(1,598	)		(2,016	)		(1,024	)
Decrease (increase) in inventory		(6,210	)		2,825			1,573
Increase (decrease) in trade payables		(97	)		989			(2,718	)
Increase (decrease) in accrued expenses and other liabilities		1,696			184			(1,744	)
Others		175			213			158
Net cash provided by (used in) operating activities		(1,015	)		11,745			16,617
Cash flows from investing activities:
Loans granted to affiliates		(723	)		(909	)		(302	)
Loans granted to others		(240	)		-			-
Investment in affiliates		(2,356	)		(292	)		(273	)
Additional consideration on Shamir Insight Inc. ("SII") prior
acquisitions (see Note 1c)		-			(449	)		(725	)
Acquisition of Spherical Optics (a)		(849	)		-			-
Acquisition of Shamir Or		(27	)		-			-
Acquisition of Shamir Israel (b)		-			30			-
Acquisition of CIO and Shalens (c)		-			-			(2,687	)
Purchase of property, plant and equipment		(7,281	)		(13,375	)		(4,593	)
Purchase of intangible assets		-			(331	)		(100	)
Government participation in purchase of property, plant and equipment		-			-			189
Proceeds from sale of property and equipment		74			489			228
Loan granted to related party		(986	)		-			-
Repayment of loan by related party		-			1,297			90
Purchase of marketable securities and other short-term investments		(29,666	)		(20,352	)		(4,853	)
Proceeds from sale of marketable securities and other short-term
investments		27,504			22,886			11,884
Net cash used in investing activities		(14,550	)		(11,006	)		(1,142	)

The accompanying notes are an integral part of the consolidated financial statements.

F - 7

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Year ended December 31,
	2006			2007			2008
Cash flows from financing activities:
Distribution of earnings to shareholders		-			(4,000	)		(4,000	)
Short-term bank credit and loans, net		3,975			702			(3,637	)
Receipt of long-term loans		12,290			3,091			2,933
Repayment of long-term loans		(3,949	)		(3,236	)		(8,598	)
Repayment of long-term loans in capital lease		(1,380	)		(1,956	)		(2,371	)
Net cash provided by (used in) financing activities		10,936			(5,399	)		(15,673	)
Effect of exchange rate differences on cash and cash equivalents		332			408			(479	)
Decrease in cash and cash equivalents		(4,297	)		(4,252	)		(677	)
Cash and cash equivalents at beginning of year		27,502			23,205			18,953
Cash and cash equivalents at end of year	$	23,205		$	18,953		$	18,276
Supplemental information and disclosures of non-cash investing and
financing activities:
Purchase of property, plant and equipment in capital lease	$	5,343		$	1,898		$	1,776
Purchase of intangible assets to be paid in future periods	$	-		$	564		$	-
Additional consideration on SII prior acquisitions(see Note 1c)	$	449		$	566		$	307
Grant from the Portuguese government	$	-		$	611		$	-
Acquisition of minority interest in Shamir Optic GmbH (d)	$	-		$	-		$	357
Grant from the Israeli government (see Note 15 d)	$	-		$	189		$	-
Long-term loan written off	$	355		$	-		$	-
Cash paid during the period for:
Interest	$	1,646		$	1,747		$	2,498
Income taxes	$	3,666		$	5,383		$	4,140

The accompanying notes are an integral part of the consolidated financial statements.

F - 8

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

		Year ended December 31,
		2006			2007			2008
(a)	Acquisition of Spherical Optics (PTY) Ltd:
	Fair value of assets acquired at the acquisition date:
	Working capital (excluding cash and cash equivalents)	$	579
	Property and equipment		28
	Other intangible assets		652
	Goodwill		70
	Long-term deferred tax liabilities		(171	)
	Minority interest		(309	)
		$	849
(b)	Acquisition of Shamir Israel Optical Marketing Ltd:
	Fair value of assets acquired at the acquisition date:
	Working capital (excluding cash and cash equivalents)				$	96
	Long-term deferred tax assets					167
	Property and equipment					44
	Other intangible assets					153
	Goodwill					128
	Long-term loans and other long-term liabilities					(215	)
	Long-term deferred tax liabilities					(38	)
	Net assets acquired					335
	Investment in Shamir Israel Optical Marketing Ltd. prior to
	acquisition that was accounted for by the equity method and
	shareholder's loans					(365	)
					$	(30	)

The accompanying notes are an integral part of the consolidated financial statements.

F - 9

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

		Year ended December 31,
		2006	2007	2008
(c)	Acquisition of Centro Integral Optico S.A. de C.V.("CIO") and
	Shalens S.A. de C.V. ("Shalens")
	Fair value of assets acquired and liabilities assumed at the
	acquisition date:
	Working capital (excluding cash and cash equivalents)			$	1,814
	Long-term deferred tax assets				105
	Property and equipment				2,144
	Other intangible assets				2,208
	Goodwill				2,865
	Long-term loans and other long-term liabilities				(2,076	)
	Long-term deferred tax liabilities				(713	)
	Net assets acquired				6,347
	Investment in CIO and Shalens prior to acquisition that was
	accounted for by the equity method and shareholder's loans				(2,958	)
	Minority interest				(702	)
				$	2,687
(d)	Acquisition of minority interests in Shamir Optic GmbH
	(formally known as Altra Trading GMBH ("Shamir GmbH"))
	Fair value of assets acquired and liabilities assumed at the
	acquisition date:
	Property and equipment			$	1,186
	Customer relationship				346
	Goodwill adjustment				(915	)
	Other long-term liabilities				(36	)
	Long-term deferred tax liabilities, net				(224	)
				$	357

The accompanying notes are an integral part of the consolidated financial statements.

F - 10

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 1: – GENERAL

a. General:

Shamir Optical Industry Ltd. (“the Company”) was incorporated under the laws of the State of Israel in the early 1970s. Shamir and its subsidiaries (collectively –“Shamir”) design, develop, manufacture and market optical progressive and other lenses and molds. As of December 31, 2008, Shamir had 17 subsidiaries all over the world. Some of the subsidiaries engage in production of Shamir products, some are optical laboratories that process lenses for the opticians, and some engage in marketing and distributing the products.

On March 16, 2005, the Company completed an Initial Public Offering (“IPO”) on the NASDAQ stock exchange and issued 3,400,000 Ordinary shares of NIS 0.01 par value in a net consideration of approximately $ 42,275 (excluding tax benefit of $ 1,453).

Most of the raw materials used in the manufacture of lenses, including Shamir’s products, are available from a limited number of suppliers. Shamir purchases its raw materials from some of these suppliers. In addition, a certain part of the production process of Shamir’s lenses is supplied by a limited number of world wide sub-contractors. The loss of any one of these suppliers or sub-contractors, or a significant decrease in the supply of glass blanks, monomers or services, would require Shamir to obtain these raw materials or services elsewhere. If Shamir is unable to obtain glass blanks, monomers or services from its suppliers (or alternative suppliers) or sub-contractors at acceptable prices, Shamir may realize lower margins and experience difficulty in meeting its customers’ requirements.

b. Acquisition of Spherical Optics (PTY) Ltd.:

On January 2, 2006, the Company acquired 51% of the share capital of and ownership interest in Spherical Optics (PTY) Ltd. (“Spherical”), a South African optical lenses distribution company. The Company paid R 5.4 million ($ 855).

The acquisition was accounted for as a business combination by the purchase method and, accordingly, the purchase price has been allocated to the fair value of the assets acquired and liabilities assumed of Spherical with the remaining representing goodwill. The results of Spherical’s operations have been included in the consolidated financial statements of Shamir starting January 2, 2006.

With the acquisition of Spherical, Shamir expanded its customer base and its presence in South Africa.

F - 11

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 1: – GENERAL (Cont.)

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:

Current assets	$	1,249
Property and equipment		28
Long-term deferred tax assets		19
Customer relationship		633
Goodwill		70
Total assets acquired		1,999
Current liabilities		(664	)
Long-term deferred tax liability		(171	)
Total liabilities assumed		(835	)
Net assets acquired		1,164
Minority interest		(309	)
Total purchase price	$	855

Acquired other intangible assets in the amount of $ 633 with definite lives are amortized using the straight-line method at an annual rate of 14%.

c. Additional acquisition of shares in SII:

On July 31, 2005, Shamir signed an agreement to purchase an additional 31.3% stake in SII, increasing Shamir’s ownership interest in SII to 90%. Under the terms of the agreement, annual contingent cash payments will be paid, for a period of five years, if certain financial performance criteria are met in respect of future earnings of SII in that period. The additional consideration regarding this purchase in respect of 2006, 2007 and 2008 earnings is $ 449, $ 139 and $ 488 respectively, and as of December 31, 2006, 2007 and 2008, the goodwill increased accordingly.

On July 17, 2007, Shamir signed an agreement to purchase an additional 10% of the outstanding shares of SII, increasing Shamir’s ownership interest in SII to 100%. Under the terms of the agreement Shamir will pay a discounted amount of $ 346 over the next four years, and annual contingent cash payments based on SII’s revenues in the years 2007 to 2010. Therefore, as of December 31, 2007 and 2008, Shamir recorded a liability in the amounts of $ 427 and $ 180, respectively, related to this purchase.

Should any contingent payment be made under the agreement in the future, the additional consideration, when determined, will increase the purchase price and accordingly additional goodwill will be recorded.

The additional consideration regarding this purchase in respect of 2007 and 2008 earnings is $ 81 and $ 189 respectively, and as of December 31, 2007 and 2008, the goodwill increased accordingly.

F - 12

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 1: – GENERAL (Cont.)

The acquisition was accounted for by the purchase method and accordingly, the purchase price has been allocated to the estimated fair value of the identifiable assets acquired and identifiable liabilities assumed of SII, with the remaining representing goodwill. The fair values of the assets acquired, liabilities assumed and the buyout of the minority interest are not provided due to immateriality.

With the acquisition of additional shares of SII, Shamir increased its control of a critical distribution channel in the U.S.A., and obtained full control of SII.

Pro-forma information was not provided due to immateriality.

d. Acquisition of CIO and Shalens:

On August 15, 2006, a Share Acquisition Agreement was made, by and between CIO, a Mexican company, its shareholders and Shamir. Shamir acquired a 26% stake in CIO. In addition, as part of the Share Acquisition Agreement, Shamir was granted an option to increase its stake by an additional 25% to a total of 51%. On February 20, 2008, Shamir exercised its option and acquired an additional stake of 25% in CIO and Shalens (a sister company of CIO located in Mexico) for a consideration of $ 2,860.

The acquisition was accounted for by the purchase method and accordingly, the purchase price has been allocated to the estimated fair value of the assets acquired and liabilities assumed of CIO and Shalens, with the remaining representing goodwill. The results of CIO and Shalens operations have been included in the consolidated financial statements of Shamir commencing February 20, 2008.

With the acquisition of CIO and Shalens, Shamir expanded its presence in the Mexican optical market.

Based upon a valuation, the following table summarizes the fair values of the assets acquired and liabilities assumed as of the acquisition date:

Current assets	$	3,991
Property and equipment		2,144
Long-term deferred tax assets		105
Customer relationships		2,208
Goodwill		2,865
Total assets acquired		11,313
Current liabilities		(1,931	)
Long-term loans and other liabilities		(2,149	)
Long-term deferred tax liability		(713	)
Total liabilities assumed		(4,793	)
Net assets acquired		6,520
Investments in CIO and Shalens prior to acquisition that was accounted
for by the equity method and shareholder's loans		(2,958	)
Minority interests		(702	)
Total Purchase Price	$	2,860

F - 13

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 1: – GENERAL (Cont.)

Customer relationships in the amount of $ 2,208 (including $ 1,081 amortized cost of customer relationships allocated at the acquisition of the first 26% stake in CIO) with definite live are amortized using the straight-line method at an average annual rate of approximately 10%.

Pro-forma information is provided in note 1(f) bellow.

e. Acquisition of minority interests in Shamir GmbH:

On July 1, 2008 Shamir acquired the remaining 49% of the outstanding shares of Shamir GmbH, increasing Shamir’s ownership interest in Shamir GmbH and its subsidiaries to 100%. The total purchase price amounted to $357. In addition, under the terms of the agreement Shamir will pay a contingent cash payment based on Shamir GmbH consolidated net income in the years 2008 to 2010 up to a sum of 500 thousands euro (approximately $ 697) that will be paid on June 30, 2011.

Should any contingent payment be accrued under the agreement in the future, in addition to the amounts accrued until December 31, 2008, the additional consideration, when determined, will increase the purchase price and accordingly additional goodwill will be recorded.

The acquisition was accounted for by the purchase method and accordingly, the purchase price has been allocated to the estimated fair value of the identifiable assets acquired and identifiable liabilities assumed of Shamir GmbH and its subsidiaries, with the remaining representing goodwill.

With the acquisition of additional shares of Shamir GmbH, Shamir obtained full control of Shamir GmbH.

Based upon a valuation, the following table summarizes the fair values of the assets acquired and liabilities assumed as of the acquisition date:

Land and buildings	$	1,186
Customer relationships		346
Goodwill adjustment		(915	)
Long-term other liabilities		(36	)
Long-term deferred tax liability, net		(224	)
Total Purchase Price	$	357

Customer relationships in the amount of $ 346 with definite live are amortized using the straight-line method at an average annual rate of approximately 17%.

F - 14

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 1: – GENERAL (Cont.)

f. Unaudited pro-forma condensed results of operation:

The following represents the pro-forma results of operations for the years ended December 31, 2006, 2007 and 2008, assuming that the acquisition of CIO and Shalens occurred on January 1, 2006, 2007 and 2008, respectively. The pro-forma information is not necessarily indicative of the results of operations, which actually would have occurred if the acquisitions had been consummated at the beginning of each period presented, nor does it purport to represent the results of operations for future periods.

	Year ended December 31,
	2006		2007		2008
Revenues, net	$	103,944	$	130,348	$	141,390
Net income	$	6,241	$	7,755	$	8,997
Basic net earnings per share	$	0.38	$	0.47	$	0.55
Diluted net earnings per share	$	0.38	$	0.47	$	0.54

NOTE 2: – SIGNIFICANT ACCOUNTING POLICIES

The consolidated financial statements have been prepared according to U.S. generally accepted accounting principles ("U.S. GAAP").

a. Use of estimates:

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgment and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Shamir’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made.

b. Financial statements in U.S. dollars:

A majority of the revenues of the Company and certain subsidiaries are generated in United States dollars (“dollars”). The Company’s management believes that the dollar is the currency of the primary economic environment in which the Company and these certain subsidiaries operate. Thus, the functional and reporting currency of the Company and these certain subsidiaries is the U.S. dollar.

Accordingly, monetary accounts maintained in currencies other than the dollar are re-measured into dollars in accordance with SFAS No. 52, “Foreign Currency Translation”. All transaction gains and losses of the re-measured monetary balance sheet items are reflected in the statement of income as financial income or expenses, as appropriate.

For those foreign subsidiaries whose functional currency has been determined to be a currency other than the U.S. dollar, assets and liabilities are translated at year-end exchange rates and statement of income items are translated at average exchange rates prevailing during the year for that currency. Translation adjustments are recorded in accumulated other comprehensive income, a separate component of shareholders’ equity.

F - 15

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 2: – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

c. Principles of consolidation:

The consolidated financial statements include the accounts of the Company and it’s wholly and majority owned subsidiaries. Intercompany transactions and balances including profit from intercompany sales not yet realized outside Shamir, have been eliminated upon consolidation.

d. Cash equivalents:

Cash equivalents are short-term highly liquid investments that are readily convertible to cash with maturities of three months or less at the date acquired.

e. Short-term bank deposits:

Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost.

f. Investments in marketable securities:

The Company accounts for investments in marketable securities in accordance with SFAS No. 115, “Accounting for Certain Investments in Debt and Equity Securities” (“SFAS No. 115”).

Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determinations at each balance sheet date.

The Company classifies all of its securities as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in “accumulated other comprehensive income (loss)" in shareholders’ equity. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in financial income, net. Interest on securities is included in financial and other expenses, net. Realized gains and losses on sale of investments are included in earnings and are derived using the specific identifications method for determining the cost of securities.

Impairment losses are recognized as realized or when the Company has determined that other-than-temporary decline in fair value has occurred. FASB Staff Position (“FSP”) No. 115-1, “The Meaning of Other-Than-Temporary Impairment and Its Application to Certain Investment” (“FSP 115-1”) and SAB Topic 5M, “Other Than Temporary Impairment of Certain Investments in Debt and Equity Securities” provide guidance for determining when an investment is considered impaired, whether impairment is other-than-temporary, and measurement of an impairment loss. An investment is considered impaired if the fair value of the investment decreased below its cost in an other-than-temporary manner. If, after consideration of all available evidence to evaluate the realizable value of its investment, impairment is determined to be other-than-temporary, then an impairment loss should be recognized equal to the difference between the investment’s cost and its fair value. During 2008, 2007 and 2006, no impairment losses were identified in accordance with FSP 115-1.

F - 16

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 2: – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

g. Inventories:

Inventories are stated at the lower of cost or market value. Cost is determined as follows:

Raw materials and work-in-progress – using the “first in – first out”method.

Finished products – finished products that are produced by Shamir are recorded on the basis of direct manufacturing costs with the addition of allocable indirect manufacturing costs, using the “first in – first out” method. Finished products that are purchased for commercial purposes are recorded using the “first in – first out” method.

Inventory provisions are provided to cover risks arising from slow-moving items and discontinued products.

h. Investments in affiliates and others:

Affiliated companies are companies held to the extent of 20% or more (which are not subsidiaries), over whose operating and financial policies Shamir can exercise significant influence.

The investment in affiliated companies is accounted for by the equity method. Profits on inter-company sales, not realized outside Shamir, were eliminated. The excess of the purchase price over the proportional fair value of net tangible assets of the investee is attributed to goodwill and other identifiable intangible assets. Other identifiable intangible assets are amortized over a weighted averaged period of approximately 6.4 years, commencing from the acquisition date.

Investments in companies in which Shamir holds less than 20% are stated at cost, since Shamir does not have the ability to exercise significant influence over the operating and financial policies of those investees. Shamir’s investments in these companies are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an investment may not be recoverable, in accordance with Accounting Principle Board Opinion No. 18, “The Equity Method of Accounting for Investments in Common Stock” (“APB No. 18”). As of December 31, 2008, no impairment losses have been identified.

F - 17

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 2: – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

i. Property, plant and equipment:

1. Property, plant and equipment are stated at cost, net of accumulated depreciation and investment grants.

2. Materials, payroll and other costs that are direct incremental costs necessary to bring an asset to the condition of its intended use incurred during the construction are capitalized to the cost of such assets.

3. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets at the following annual rates:

	%
Machinery and manufacturing equipment	7 - 40
Office equipment and furniture	7 - 33
Motor vehicles	15 - 25
Buildings	4 - 5

Leasehold improvements are depreciated by the straight-line method over the shorter of the lease or the estimated useful life of the improvements.

Shamir has accounted for its fixed assets which are under a capital lease arrangement in accordance with SFAS 13 “Accounting for Leases”. Accordingly, fixed assets under a capital lease are stated as assets of Shamir on the basis of ordinary purchase prices (without the financing component), and they are depreciated according to the usual depreciation rates applicable to such assets. The lease payments payable in forthcoming years, net of the interest component included in them are included in liabilities. The interest in respect of such amounts is accrued on a current basis and is charged to earnings.

j. Other intangible assets, net:

Intangible assets are amortized over their useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are consumed or otherwise used, in accordance with SFAS No. 142, “Goodwill and Other Intangible Assets”.

Amortization is calculated using the straight-line method over the estimated useful lives at the following annual rates:

	Weighted average %
Technology	27
Customer relationship	15
Non competition	33
Distribution channels	20
Patents	10
Trade name	20

F - 18

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 2: – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

k. Impairment of long-lived assets:

Shamir’s long-lived assets are reviewed for impairment in accordance with SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. During 2008, 2007 and 2006, no impairment losses have been identified.

l. Goodwill:

Goodwill represents the excess of the cost of businesses acquired over the fair value of the net assets acquired in the acquisition.

Statement of Financial Accounting Standards No. 142, “Goodwill and Other Intangible Assets” (“SFAS No. 142”), prescribes a two-phase process for impairment testing of goodwill. The first phase screens for impairment, while the second phase (if necessary) measures impairment.

In the first phase of impairment testing, goodwill attributable to each of the reporting units is tested for impairment by comparing the fair value of each reporting unit with its carrying value. If the carrying value of the reporting unit exceeds its fair value, the second phase is then performed. The second phase of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess.

Goodwill attributable to Shamir’s single reporting unit as defined under SFAS No. 142, was tested for impairment by comparing its fair value with its carrying value.

Fair value is determined using the Company’s market capitalization. The Company performs the impairment tests during the fourth fiscal quarter. In addition, in accordance with the provisions of SFAS No. 142, as a result of the global credit crisis, the Company performed an additional impairment test as of December 31, 2008. During 2008, 2007 and 2006, no impairment losses were identified.

m. Revenue recognition:

Shamir derives its revenues from sales of lenses and from design services to third party lens manufacturers.

Revenues from sale of lenses are recognized in accordance with Staff Accounting Bulletin (“SAB”) No. 104, “Revenue Recognition in Financial Statements”, when delivery has occurred, persuasive evidence of an agreement exists, the vendor’s fee is fixed or determinable, no further obligation exists and collectibility is probable.

Shamir has various programs that allow opticians to earn rebates on their accumulated purchases. Rebates are recognized as a reduction of revenues, in accordance with EITF No. 01-9, “Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor’s Products)".

F - 19

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 2: – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Design services are provided to third party manufacturers and include development services, production of molds for lenses and royalties from sales of lenses by third party manufacturers. Revenues from development services are recognized at the time services are provided. Revenues from production of molds are recognized upon delivery of the molds when all other criteria of SAB No. 104 are met. Revenues from minimum royalties are recognized when due. Other royalties are recognized quarterly, upon the receipt of sales reports from the third party manufacturer customers.

Amounts billed to customers for shipping and handling costs are classified as revenues in the consolidated statements of income with the associated costs included as a component in the operating expenses.

n. Research and development costs:

Research and development costs are charged to the statement of income as incurred.

o. Income taxes:

Shamir accounts for income taxes in accordance with SFAS No. 109, “Accounting for Income Taxes”. This Statement prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Shamir provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.

On January 1, 2007, the Company adopted FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes, an Interpretation of FASB Statement No. 109" (“FIN 48”). FIN 48 contains a two-step approach to recognizing and measuring uncertain tax positions accounted for in accordance with SFAS No. 109. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.

As a result of the implementation of FIN No. 48, the Company recognized a $ 481 increase in liability for unrecognized tax benefits, which was accounted for as a decrease to the January 1, 2007 balance of retained earnings.

p. Advertising expenses:

Advertising costs are expensed as incurred. Advertising expenses for the years ended December 31, 2006, 2007 and 2008, were $ 2,964, $ 2,566 and $ 2,366, respectively.

F - 20

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 2: – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

q. Concentrations of credit risk:

Financial instruments that potentially subject Shamir to concentrations of credit risk consist principally of cash and cash equivalents, short-term deposits, marketable securities and trade receivables.

The majority of Shamir’s cash and cash equivalents and short-term deposits are invested mainly in dollar and Euro instruments with major banks in Israel, Germany and the U.S. Deposits in the U.S. may be in excess of insured limits and are not insured in other jurisdictions.

Marketable securities include investments in debentures of U.S. treasury, U.S. government agencies and corporations. Shamir’s investment policy provides for a minimum grading of debentures in which Shamir can invest, thereby reducing credit risk.

Shamir’s trade receivables are derived from sales to customers located mainly in the U.S. and Europe. Shamir performs ongoing credit evaluations of its customers and to date has not experienced any material losses. In certain circumstances, Shamir may require letters of credit or prepayments. An allowance for doubtful accounts is determined with respect to those amounts that Shamir has determined to be doubtful of collection. Provisions for doubtful accounts were recorded in general and administrative expenses.

Shamir from time to time enters into forward contracts and option strategies (together: “derivative instruments”) intended to protect against changes in foreign currencies. Shamir has also entered into interest-rate swaps. The derivative instruments were not qualified for hedge accounting under SFAS No. 133. All the derivatives are recognized on the balance-sheet at their fair value, with changes in the fair value carried to the statements of income and included in financial and other expenses, net.

r. Severance pay:

Shamir’s liability for severance pay is calculated pursuant to Israel’s Severance Pay Law based on the most recent salary of Shamir’s Israeli employees multiplied by the number of years of employment, as of balance sheet date. These employees are entitled to one month’s salary for each year of employment or a portion thereof. Shamir’s liability for these employees is fully provided by monthly deposits for insurance policies and by an accrual.

The deposited funds include profits and losses accumulated up to the balance sheet date. The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to Israel’s Severance Pay Law or labor agreements.

Shamir and its Israeli subsidiaries have entered into an agreement with certain employees implementing Section 14 of the Severance Pay Law and the General Approval of the Labor Minister dated June 30, 1998, issued in accordance to the said Section 14, mandating that upon termination of such employees’ employment, the company shall release to them all the amounts accrued in their insurance policies. The severance pay liabilities and deposits covered by these plans are not reflected in the balance sheet as the severance pay risks have been irrevocably transferred to the severance funds.

Severance expense for the years ended December 31, 2006, 2007 and 2008, amounted to $ 504, $ 535 and $ 1,050, respectively.

F - 21

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 2: – SIGNIFICANT ACCOUNTING POLICIES (CONT.)

s. Fair value of financial instruments:

The Company adopted the provisions of SFAS No. 157, “Fair Value Measurements”(“SFAS No. 157”) effective January 1, 2008. Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

In determining fair value, the Company uses various valuation approaches. SFAS No. 157 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.

The hierarchy is broken down into three levels based on the observability of inputs as follows:

— Level 1 – Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment

— Level 2 – Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

— Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The availability of observable inputs can vary from investment to investment and is affected by a wide variety of factors, including, for example, the type of investment, the liquidity of markets and other characteristics particular to the transaction.

The Company’s marketable securities are traded in markets that are not considered to be active, but are valued based on quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency and accordingly are categorized as Level 2.

Foreign currency and interest rate derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments.

F - 22

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 2: – SIGNIFICANT ACCOUNTING POLICIES (CONT.)

The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis at December 31, 2008:

	Fair value measurements using input type
	Level 1		Level 2			Level 3		Total
Marketable securities:
Corporate debentures	$	-	$	987		$	-	$	987
U.S. government agencies securities		-		1,304			-		1,304
U.S. Treasury		-		3,839			-		3,839
Derivatives:
Foreign currencies assets		-		234			-		234
Foreign currencies liabilities		-		(25	)		-		(25	)
Interest rates		-		(209	)		-		(209	)
Total	$	-	$	6,130		$	-	$	6,130

The carrying amounts of financial instruments carried at cost, including cash and cash equivalents, short-term deposits, trade receivables, other current assets, trade payables and other liabilities approximate their fair value due to the short-term maturities of such instruments.

t. Net earnings per share:

Basic net earnings per share are computed based on the weighted average number of shares outstanding during each year. Diluted net earnings per share are computed based on the weighted average number of shares outstanding during each year, plus dilutive potential shares considered outstanding during the year, in accordance with SFAS No. 128, “Earnings per Share”.

The total weighted average number of shares related to the outstanding options excluded from the calculations of diluted net earnings per share because these securities are anti-dilutive was 1,331,660, 1,392,682 and 1,493,826 for the years ended December 31, 2006, 2007 and 2008, respectively.

u. Accounting for stock-based compensation:

The Company accounts for stock-based compensation in accordance with Statement of Financial Accounting Standards No. 123 (revised 2004), “Share-Based Payment” (“SFAS 123(R)”) which requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees and directors. SFAS 123(R) requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated income statements.

Shamir estimates the fair value of stock options granted to employees and directors under SFAS No. 123(R) using the Black-Scholes option- pricing model that uses the assumption noted in the following table.

Shamir recognizes compensation expense for the value of its awards based on the straight line method over the requisite service period of each of the awards, net of estimated forfeitures at the time of grant. SFAS 123(R) requires forfeitures to be estimated and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

F - 23

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 2: – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

The fair value of Shamir’s stock options granted to employees and directors for the years ended December 31, 2007 and 2008, was estimated using the following assumptions:

	Year ended December 31, 2007	Year ended December 31, 2008
Expected volatility	24.99%-25.59%	26.72%-41.90%
Risk-free interest rate	3.28%-4.54%	1.93%-2.37%
Dividend yield	0.81%-1.36%	0%-1.23%
Forfeiture rate	4.48%	0%
Expected term (years)	3.62-6.05	4.58

A summary of option activity under Shamir’s stock option plans as of December 31, 2008, and changes during the year then ended are as follows:

	Number of options			Weighted-average exercise price		Weighted- average remaining contractual term (in years)		Aggregate intrinsic value as of December 31,2008
Outstanding at January 1, 2008		1,657,866		$	9.95
Granted		317,000		$	6.16
Exercised		-			-
Forfeited and expired		(383,830	)	$	10.11
Outstanding at December 31, 2008		1,591,036		$	8.95		4.56	$	62
Exercisable at December 31, 2008		896,630		$	9.29		3.76	$	62
Vested and expected to vest at
December 31, 2008		1,591,036		$	8.95		4.56	$	62

The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company’s closing stock price on the last trading day of the fourth quarter of fiscal 2008 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2008.

The weighted-average grant-date fair value of options granted during the years ended December 31, 2006, 2007 and 2008, was $ 3.00, $ 2.87 and $ 0.81, respectively. The total intrinsic value of options exercised during the years ended December 31, 2006, 2007 and 2008, was $ 0, $ 1,671 and $ 0, respectively.

As of December 31, 2008, there was $ 1,028 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under Shamir’s stock option plans to employees and directors. That cost is expected to be recognized over a weighted average period of 2.5 years. The total fair value of options vested during the year ended December 31, 2008, was $ 1,163.

v. Reclassification:

Certain amounts in prior years’ financial statements have been reclassified to conform to the current year’s presentation.

F - 24

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 2: – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

w. Impact of recently issued accounting standards:

In December 2007, the FASB issued SFAS No. 141 (revised 2007), “Business Combinations” (“SFAS 141R”). SFAS 141R establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, any non-controlling interest in the acquiree and the goodwill acquired. SFAS 141R also establishes disclosure requirements to enable the evaluation of the nature and financial effects of the business combination. SFAS 141R is effective for fiscal years beginning after December 15, 2008. Earlier adoption is prohibited. The Company believes that the adoption of SFAS 141R could have an impact on its consolidated financial statements; however, the impact would depend on the nature, terms and magnitude of acquisitions it consummates in the future.

In December 2007, the FASB issued SFAS 160 (“SFAS No. 160”), Noncontrolling Interests in Consolidated Financial Statements. SFAS 160 amends Accounting Research Bulletin 51, Consolidated Financial Statements, to establish accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. It also clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements. SFAS 160 also changes the way the consolidated income statement is presented by requiring consolidated net income to be reported at amounts that include the amounts attributable to both the parent and the noncontrolling interest. It also requires disclosure, on the face of the consolidated statement of income, of the amounts of consolidated net income attributable to the parent and to the noncontrolling interest. SFAS 160 requires that a parent recognize a gain or loss in net income when a subsidiary is deconsolidated and requires expanded disclosures in the consolidated financial statements that clearly identify and distinguish between the interests of the parent owners and the interests of the noncontrolling owners of a subsidiary. SFAS 160 is effective for fiscal periods, and interim periods within those fiscal years, beginning on or after December 15, 2008. The adoption of SFAS 160 is not expected to have a material effect on accounting for the Company’s current subsidiaries.

In February 2008, the FASB issued FASB Staff Position (“FSP”) FAS No. 157-2, “Effective Date of FASB Statement No. 157” (“FSP 157-2”), to delay the effective date of FASB Statement 157 for one year for certain nonfinancial assets and nonfinancial liabilities, excluding those that are recognized or disclosed in financial statements at fair value on a recurring basis (that is, at least annually).  For purposes of applying the FSP 157-2, nonfinancial assets and nonfinancial liabilities include all assets and liabilities other than those meeting the definition of a financial asset or a financial liability in FASB Statement 159.   FSP 157-2 defers the effective date of Statement 157 to fiscal years beginning after November 15, 2008, and interim periods within those fiscal years for items within the scope of this FSP 157-2. The Company does not expect the adoption of FSP 157-2 to have a material impact on its financial position, results of operations or cash flows.

In April 2008, the FASB issued FSP 142-3, “Determination of the Useful Life of Intangible Assets” (FSP 142-3). FSP 142-3 amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under SFAS No. 142, “Goodwill and Other Intangible Assets”. FSP 142-3 is effective for fiscal years beginning after December 15, 2008. The Company does not expect the adoption of FSP 142-3 to have a material impact on the Company’s financial position, results of operations or cash flows.

F - 25

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 2: – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

In May 2008, the FASB issued SFAS No. 162, “The Hierarchy of Generally Accepted Accounting Principles”. SFAS 162 identifies the sources of accounting principles and the framework for selecting the principles to be used in the preparation of financial statements of nongovernmental entities that are presented in conformity with generally accepted accounting principles in the United States. It is effective 60 days following the SEC’s approval of the Public Company Accounting Oversight Board amendments to AU Section 411, “The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles”. The Company is currently evaluating the impact of SFAS No. 162 on its financial statements, and the adoption of this statement is not expected to have a material effect on the Company’s financial statements.

NOTE 3: – SHORT-TERM INVESTMENTS

a. The following is a summary of the Shamir’s short-term investments:

	December 31,
	2007		2008
Short-term deposits	$	-	$	1,000
Marketable securities		14,375		6,187
Total short-term investments	$	14,375	$	7,187

b. The following is a summary of the Shamir’s investments in marketable securities:

	December 31, 2007
	Amortized cost		Net unrealized gain (loss)			Fair market value
Available-for-sale:
Corporate debentures	$	2,002	$	(6	)	$	1,996
U.S. government agencies securities		12,137		48			12,185
Total	$	14,139	$	42			14,181
Accrued interest							194
						$	14,375

	December 31, 2008
	Amortized cost		Net Unrealized gain (loss)			Fair market value
Available-for-sale:
Corporate debentures	$	1,000	$	(13	)	$	987
U.S. treasury		3,835		4			3,839
U.S. government agencies securities		1,301		3			1,304
Total	$	6,136	$	(6	)		6,130
Accrued interest							57
						$	6,187

As of December 31, 2008, the gross unrealized gains amounted to $ 7 and the gross unrealized losses amounted to $ 13.

F - 26

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 3: – SHORT-TERM INVESTMENTS (Cont.)

c. The amortized cost and fair value of marketable securities as of December 31, 2008, by contractual maturity, are shown below:

	December 31, 2008
	Amortized cost		Fair market value
Matures in one year	$	5,636	$	5,633
Matures after one year through five years		500		497
Total	$	6,136	$	6,130

NOTE 4: – OTHER ACCOUNTS RECEIVABLES AND PREPAID EXPENSES

	December 31,
	2007		2008
Prepaid expenses	$	1,145	$	1,633
Government authorities		3,155		4,142
Deferred tax assets		1,794		1,480
Related parties		90		-
Government grants and subsidies		270		169
Employees		160		65
Derivatives		129		234
Other		780		746
	$	7,523	$	8,469

NOTE 5: – INVENTORY

	December 31,
	2007		2008
Raw materials	$	3,372	$	4,765
Work-in-progress		985		815
Finished goods		23,615		20,483
	$	27,972	$	26,063

F - 27

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 6: – INVESTMENTS IN AFFILIATES AND OTHERS

a. Affiliated companies are as follows:

			December 31,
			2007			2008
	Note		Percentage of ownership of outstanding share capital
Centro Integral Optico S.A. de C.V.				26	%		*)
Shalens S.A. de C.V.				26	%		*)
Siam Optical Technology Company Ltd.
("SOT") **)		6c		25.8	%		40.4	%
Optispeed Laboratory (PTY) Ltd.
("Optispeed") ***)		6c		-			25	%
e-Vision LLC				****)			****)

*) On February 20, 2008, Shamir acquired an additional 25% of the ownership interest and the voting power in CIO and Shalens, following which Shamir increased its ownership to 51% in both sister companies. Since the acquisition date, these companies are consolidated.

**) On November 27, 2008, Shamir acquired an additional 14.6% of SOT Ordinary Shares and increased its holdings in SOT’s Ordinary Shares to a total of 40.4%. Shamir paid a consideration of $ 134 in cash to the selling shareholders.

***) On November 1, 2008, Shamir (through it subsidiary Spherical) acquired 25% of the ownership interest and the voting power in Optispeed, an optical laboratory in South Africa.

****) Less than 20% ownership. Shamir does not have significant influence over operating and financial policy of the affiliate. The investment is accounted for according to the cost method.

b. Composition of investments:

	December 31,
	2007		2008
CIO	$	2,785	$	-
Shalens		136		-
SOT		840		1,286
Optispeed		-		123
e-Vision LLC		676		676
	$	4,437	$	2,085

F - 28

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 6: – INVESTMENTS IN AFFILIATES AND OTHERS (Cont.)

c. Additional information – investment in SOT and Optispeed:

	SOT		Optispeed
Investment in shares and option *)	$	414	$	123
Long-term loans **)		872		-
Total investments as of December 31, 2008	$	1,286	$	123

*) Shamir has an option to increase its holdings in SOT to 49% of the ordinary shares and 51% of the voting rights. The option expires on March 31, 2010. The option price, should it be exercised in full, is an additional $ 80 in cash that would be paid to SOT and certain shareholders.

**) The loans to SOT bear no interest rate.

NOTE 7: – PROPERTY, PLANT AND EQUIPMENT, NET

	December 31,
	2007		2008
Cost:
Machinery and manufacturing equipment	$	38,599	$	42,173
Office equipment and furniture		7,085		8,182
Motor vehicles		291		819
Land, buildings and leasehold improvements		17,222		17,693
		63,197		68,867
Accumulated depreciation		24,027		30,250
Depreciated cost	$	39,170	$	38,617

Depreciation expense totaled $ 5,282, $ 5,094 and $ 7,778 for the years ended December 31, 2006, 2007 and 2008, respectively.

At December 31, 2007 and 2008, property and equipment under capital leases consisted of assets with a depreciated cost of $ 8,089 and $ 6,044, respectively.

Depreciation of property and equipment under capital leases totaled $ 1,535, $ 1,599 and $ 1,592 for the years ended December 31, 2006, 2007 and 2008, respectively.

As for pledges, see Note 14c.

F - 29

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 8: – OTHER ASSETS

a. Other assets:

	December 31,
	2007		2008
Deferred tax assets	$	1,997	$	1,852
Other intangible assets, net (b)		3,415		4,050
Total other assets	$	5,412	$	5,902

b. (1) Other intangible assets, net:

	December 31,
	2007		2008
Original amounts:
Technology	$	422	$	353
Customer relationship		2,438		4,208
Non-competition		353		335
Distribution channels		1,200		1,200
Patents		895		895
Trade name		936		936
		6,244		7,927
Accumulated amortization:
Technology		285		315
Customer relationship		1,403		1,869
Non-competition		293		335
Distribution channels		472		708
Patents		45		135
Trade name		331		515
		2,829		3,877
Total other intangible assets	$	3,415	$	4,050

(2) Amortization expense amounted to $ 968, $ 1,058 and $ 1,291 for the years ended December 31, 2006, 2007 and 2008, respectively.

(3) Estimated amortization expense for the years ended:

2009	$	962
2010		840
2011		516
2012		433
2013 and thereafter		1,299
	$	4,050

F - 30

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 9: – GOODWILL

The changes in the carrying amount of goodwill for the years ended December 31, 2007 and 2008, are as follows:

Balance as of January 1, 2007	$	7,178
Goodwill acquired during the year		66
Additional consideration in respect of 2007 earnings *)		220
Foreign currency translation adjustments		78
Balance as of December 31, 2007		7,542
Goodwill acquired during the year		1,950
Additional consideration in respect of 2008 earnings *)		677
Foreign currency translation adjustments		(1,000	)
Balance as of December 31, 2008	$	9,169

*) See Note 1c.

NOTE 10: – SHORT-TERM BANK CREDIT AND LOANS

Short-term bank credit and loans are classified by currencies as follows:

	Weighted average interest rate
	December 31,				December 31,
	2007		2008		2007		2008
	%
Short-term bank loans - Euro		6.5		5.5	$	14,303	$	7,843
Short-term bank credit *)		5.7		4.2		1,647		3,754
Total short-term bank credit and loans		6.4		5.1	$	15,950	$	11,597

*) Mostly denominated in Euro.

As of December 31, 2008, Shamir had authorized unused credit lines from banks in the amount of approximately $ 4,861.

NOTE 11: – ACCRUED EXPENSES AND OTHER LIABILITIES

	December 31,
	2007		2008
Employees and payroll accruals	$	4,471	$	3,992
Accrued expenses		4,743		3,500
Advances from customers		76		975
Government authorities		1,934		1,143
Related party		230		162
Former shareholders in SII		355		357
Current maturity of intangible assets long term payments		100		100
Derivatives		13		234
Others		813		1,217
	$	12,735	$	11,680

F - 31

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 12: – LONG-TERM LOANS

a. Long-term loans are classified by currencies as follows:

	Weighted average interest rate
	December 31,				December 31,
	2007		2008		2007		2008
	%
Banks:
Euro		5.0		4.0	$	15,312	$	10,752
NIS		4.4		3.8		734		659
						16,046		11,411
Minority shareholders in
subsidiaries *):
Dollar		5.2		5.2		50		50
Mexican Peso		-		4.0		-		1,066
						50		1,116
Others:
Dollar		2.7		2.5		263		229
Euro**)		4.5		4.6		6,399		4,950
						6,662		5,179
Total long-term loans						22,758		17,706
Less - current maturities						5,267		7,906
					$	17,491	$	9,800

*) No repayment date was set for the loans from minority shareholders in subsidiaries. These loans are not due in the 12 months following December 31, 2008.

**) Including a loan from a former shareholder in Shamir GmbH in the amount of $5,909 and $4,950 as of December 31, 2007 and 2008, respectively.

b. Long-term loans mature as follows (excluding loans from minority shareholders):

2009 (current maturities)	$	7,906
2010		3,719
2011		2,526
2012		1,005
2013 and thereafter		1,434
	$	16,590

c. Financial covenants

As security for various bank liabilities, Shamir’s subsidiaries undertook to comply with certain minimal financial ratios. As of the financial statements date, Shamir’s subsidiaries are in compliance with the financial covenants.

F - 32

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 13: – CAPITAL LEASES

Capital leases mature as follows:

2009 (current maturities)	$	2,497
2010		1,328
2011		850
2012		360
2013 and thereafter		855
Total	$	5,890

For the leased assets that are included as part of “Properties, plant and equipment, net.” (See Note 7)

NOTE 14: – COMMITMENTS AND CONTINGENT LIABILITIES

a. Legal proceedings:

From time to time, Shamir may be involved in lawsuits, claims, investigations or other legal or arbitral proceedings that arise in the ordinary course of our business. These proceedings may include general commercial disputes and claims regarding intellectual property or labor disputes with former employees. Shamir is involved in one dispute concerning allegations of breach of third parties’ patents, as described below.

In September 2003, Shamir received a notice from a large lens manufacturer regarding a claim of patent infringement relating to lens produced using Shamir software. Shamir has denied any such infringement, and numerous discussions between the companies (and counsel) ensued in order to resolve the matter without resorting to litigation.

In January 2008, Shamir received a notice from a shareholder of one of its subsidiaries claiming unlawful use of the subsidiaries’ intellectual property and unjust enrichment. Shamir denied any such infringement, and numerous discussions between the parties (and counsel) ensued in order to resolve the matter without resorting to litigation. Shamir currently cannot predict the development or ultimate outcome of the discussions with regard to these claims.

b. Operating lease commitments:

The land and certain of Shamir’s facilities are leased under operating lease agreements. Future minimum lease commitments under non-cancelable operating leases for the specified periods ending after December 31, 2008 are as follows:

2009	$	1,552
2010		1,553
2011		1,573
2012		1,604
2013		1,405
Thereafter		7,907
	$	15,594

Lease expenses, net for the years ended December 31, 2006, 2007 and 2008 were approximately $ 721, $ 843, and $ 1,299, respectively.

F - 33

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 14: – COMMITMENTS AND CONTINGENT LIABILITIES (Cont.)

c. Pledges and guarantees:

1. In order to secure Government grants received by the Company, under the “Approved Enterprise” programs pursuant to the Law for the Encouragement of Capital Investments, 1959, the Company granted pledges in favor of the State of Israel on all of its assets, by floating charges in an unlimited amount (see also Note 15d).

2. Certain subsidiaries of the Company pledged their land and buildings in an aggregate amount of approximately $ 6,047 to secure commitments to banks.

3. In order to secure government subsidies received by a subsidiary, the subsidiary gave the State of Israel a bank guarantee in the amount of approximately $ 104.

NOTE 15: – TAXES ON INCOME

a. Up until December 31, 2004, the Company was not assessed for tax purposes and its business results were passed through to its shareholders. As a result, the Company’s tax expenses were not included in the statements of income. Commencing January 1, 2005, the Company became a taxable entity as a result of the change in its legal status from an ACS to an Israeli limited Company which occurred in March 2005.

b. Measurement of taxable income:

The Company and its subsidiaries Eyal Optical Industries (1995) Ltd. (“Eyal”) and Shamir Special Optical Products Ltd. (“SSOP”) had elected to measure their results for tax purposes on the basis of the changes in the exchange rate of NIS against the U.S. dollar. During 2008, the Company and Eyal, elected to measure their Israeli taxable income in NIS rather than in the exchange rate of NIS against the U.S. dollar. This election is applicable for a period of four taxable years commencing on January 1, 2007. The Company was permitted to make such change pursuant to regulations published by the Israeli Minister of Finance, which provide the conditions for such change. Therefore, the Company and Eyal re-measured their 2007 taxable income during 2008. In general, a company that elects to apply these regulations can not change its resolution for a period of three years following the fiscal year of such election.

As result the Company’s and Eyal’s income for tax purposes are measured and reflected in accordance with the change in the Israeli Consumer Price Index (“CPI”) in accordance with the Income Tax (Inflationary Adjustments) Law, 1985. As explained above in Note 2(B), the consolidated financial statements are presented in U.S. dollars. The differences between the change in the Israeli CPI and in the NIS/U.S. dollar exchange rate cause a difference between taxable income and the income before taxes reflected in the consolidated financial statements. In accordance with paragraph 9(f) of SFAS No. 109, the Company has not provided deferred income taxes on the above differences resulting from changes in exchange rates and indexing for tax purposes.

In February 2008, the Knesset passed an amendment to the Income Tax (Inflationary Adjustments) Law, 1985, which limits the scope of the law starting in 2008 and thereafter. Starting in 2008, the results for tax purposes are measured in nominal values, excluding certain adjustments for changes in the Consumer Price Index carried out in the period up to December 31, 2007. The amended law includes, inter alia, the elimination of the inflationary additions and deductions and the additional deduction for depreciation starting in 2008.

F - 34

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 15: – TAXES ON INCOME (Cont.)

In accordance with paragraph 9(f) of SFAS No. 109, the Company has not provided deferred income taxes on the above difference between the reporting currency and the tax basis of assets and liabilities.

c. Tax benefits under Israel’s Law for the Encouragement of Industry (Taxation), 1969:

The Company and certain of its Israeli subsidiaries currently qualify as “Industrial Companies” pursuant to the Industry Encouragement Law. As such, the Company and these subsidiaries are entitled to certain tax benefits, including the right to deduct public issuance expenses, accelerated depreciation rates for tax purposes and the option to file a consolidated tax return with related Israeli industrial corporations that satisfy conditions described in the law. Currently, the Company files consolidated tax returns together with SSOP.

Eligibility for benefits under the Industry Encouragement Law is not subject to receipt of prior approval from any government authority, but is subject to their inspection. Shamir cannot assure that the Company or any of its Israeli subsidiaries that presently qualify as Industrial Companies will continue to qualify as such in the future, or that the benefits will be granted in the future.

d. Tax benefits under the Israel Law for the Encouragement of Capital Investments, 1959 (“the Law”):

The Law empowers the Israeli Investment Center to grant Approved Enterprise status to capital investments in production facilities that meet certain relevant criteria (“Approved Enterprise”). In general, such capital investments will receive Approved Enterprise status if the enterprise is expected to contribute to the development of the productive capacity of the economy, absorption of immigrants, creation of employment opportunities, or improvement in the balance of payments.

The tax benefits derived from any such Approved Enterprise relate only to taxable income attributable to the specific program of investment to which the status was granted. To the extent that the Company or any of its subsidiaries has been granted Approved Enterprise status and operates under more than one approval, or that their capital investments are only partly approved, the effective corporate tax rate will be the result of a weighted combination of the various rates applicable.

As of December 31, 2008, the Company has three existing programs that have been granted “Approved Enterprise” status under the Law. According to the Law, the Company is entitled to investment grants (up to 30% of investment cost) and also to a tax benefit, which grants Shamir a tax exemption for a period of two years and a reduced tax rate based on the level of foreign ownership for a period of five to eight years. Income derived from the first, second, and third programs was tax-exempt for a period of two years, commencing in 1999, 2001, and 2005, respectively, and is taxed at the reduced corporate tax rate of 10%-25% for an additional period of five to eight years (based on the percentage of foreign ownership in each tax year).

The Company’s income from sources other than “Approved Enterprises” during the benefits period will be taxable at the regular corporate tax rate.

F - 35

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 15: – TAXES ON INCOME (Cont.)

A portion of the facilities of the Company’s subsidiary Eyal has also been granted status as an “Approved Enterprise” under two programs. For these programs, Eyal has elected the alternative benefits track, waiving grants in return for tax exemptions. Income derived from the first and second programs was tax-exempt for a period of two years, commencing 2004 and 2006, respectively, and after that period will be taxed at the reduced corporate tax rate of 10%-25% (based on the percentage of foreign ownership in each tax year) for an additional period of five to eight years.

Eyal’s income from sources other than the “Approved Enterprises” during the benefits period is taxable at the regular corporate tax rate.

The period of tax benefits detailed above is subject to limits of the earlier of 12 years from the commencement of production or 14 years from receiving the approval.

The Law also entitles the Company and Eyal to claim accelerated depreciation on equipment used by an “Approved Enterprise”.

Should the Company or Eyal fail to meet such requirements in the future, income attributable to their programs could be subject to the statutory Israeli corporate tax rate and the Company could be required to refund a portion of the tax benefits and grants already received, with respect to such program. The Company’s management believes that the Company is meeting the aforementioned conditions.

On April 1, 2005, an amendment to the Investment Law came into effect (“the Amendment”) and has significantly changed the provisions of the Investment Law. The Amendment limits the scope of enterprises which may be approved by the Investment Center by setting criteria for the approval of a facility as a Beneficiary Enterprise, such as provisions generally requiring that at least 25% of the Beneficiary Enterprise’s income will be derived from export. Additionally, the Amendment enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits.

However, the Investment Law provides that terms and benefits included in any letter of approval already granted will remain subject to the provisions of the law as they were on the date of such approval.

The polycarbonate and the production of finished lenses facilities of the Company’s subsidiary SSOP received a pre-ruling from the tax authorities in Israel, according to which the Company was declared as a “Privileged Enterprise” (establishment), so that all of its income from the abovementioned facilities will be exempted from tax for a period of 10 years beginning with the year in which the Company first had taxable income. As of December 31, 2008, SSOP has not begun to enjoy the tax benefits due to its accumulated losses. In addition, during the fiscal year 2008, a portion of Eyals’activities have been acting under the status of a Privileged Enterprise under the amendment to the Investment Law. As stated above, Eyals’ status as a Privileged Enterprise is subject to the approval of the Israeli Tax Authorities.

In the event of a distribution of dividends from tax-exempt income, a reduced tax rate (currently – 25%) in respect of the amount distributed would have to be paid. As of December 31, 2008, retained earnings included approximately $ 11,156 in tax-exempt profits earned by the Company’s “Approved Enterprises” and “Privileged Enterprise”.

The Company has decided not to declare dividends out of such tax-exempt income. Accordingly, no deferred income taxes have been provided on income attributable to the Company’s “Approved Enterprise” and “Privileged Enterprise”.

F - 36

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 15: – TAXES ON INCOME (Cont.)

e. Net operating losses carryforward:

As of December 31, 2008, Shamir had carry forward tax losses in certain tax jurisdictions, most of which are derived from subsidiaries in the U.K., Turkey and France, totaling approximately $ 17,881, out of which an amount of $ 14,262 can be carried forward indefinitely. The remainder of the balance can be carried forward for a period up to five years.

f. Changes in tax rates in Israel:

On July 25, 2005, the Knesset (Israeli Parliament) approved the Law for the Amendment of the Income Tax Ordinance (No. 147), 2005, which prescribes, among other provisions, a gradual decrease in the corporate tax rate in Israel to the following tax rates: in 2006 –31%, in 2007 – 29%, in 2008 – 27%, in 2009 – 26% and in 2010 and thereafter – 25%.

g Deferred tax assets (liabilities):

Deferred taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for tax purposes. Components of Shamir’s deferred tax assets and liabilities are as follows:

	December 31,
	2007			2008
Deferred tax assets:
Unrealized gains and others	$	1,183		$	1,224
Operating losses carry forward		5,343			4,731
Total deferred tax assets before valuation allowance		6,526			5,955
Valuation allowance		(2,735	)		(2,623	)
Total deferred tax assets *)		3,791			3,332
Deferred tax liabilities:
Property and equipment		(802	)		(852	)
Other intangible assets		(584	)		(1,070	)
Total deferred tax liabilities **)		(1,386	)		(1,922	)
Net deferred tax assets	$	2,405		$	1,410

*) Deferred tax assets of $ 1,794 and $ 1,480 have been included in other accounts receivable and prepaid expenses and $ 1,997 and $ 1,852 have been included in other assets, as of December 31, 2007 and 2008, respectively (see Note 4 and Note 8a).

**) Deferred tax liabilities of $ 28 have been included in other accrued expenses and other liabilities, as of December 31, 2007.

The Company has provided valuation allowances in respect of certain deferred tax assets resulting from tax loss carry forward and other reserves and allowances due to uncertainty concerning realization of these deferred tax assets.

F - 37

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 15: – TAXES ON INCOME (Cont.)

h. A reconciliation of Shamir’s effective tax rate to the statutory tax rate in Israel is as follows:

	Year ended December 31,
	2006			2007			2008
Income before taxes on income	$	6,927		$	11,659		$	11,234
Statutory tax rate in Israel		31	%		29	%		27	%
Increase (decrease) in tax expenses resulting from:
"Approved Enterprise" benefits		(7.5	)%		(9.1	)%		(5.7	)%
Net operating losses and temporary differences
which are tax exempt or for which valuation
allowance was created		4.3	%		10.1	%		7.1	%
Subsidiaries with a different tax rate		1.2	%		3.2	%		3.6	%
Change in valuation allowance in respect of
prior years		-			9.6	%		-
Taxes in respect of prior years		-			(2.4	)%		(12.5	)%
Others		2.2	%		2.6	%		0.2	%
Effective tax rate		31.2	%		43.0	%		19.7	%
Basic and diluted net earnings per share amounts
of the benefit resulting from the "Approved
Enterprise" status	$	0.06		$	0.06		$	0.04

i. Income (loss) before taxes on income is comprised as follows:

	Year ended December 31,
	2006			2007		2008
Domestic	$	11,101		$	10,799	$	8,934
Foreign		(4,174	)		860		2,300
	$	6,927		$	11,659	$	11,234

F - 38

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 15: – TAXES ON INCOME (Cont.)

j. Taxes on income are comprised as follows:

	Year ended December 31,
	2006			2007			2008
Current taxes	$	4,166		$	3,550		$	3,496
Change in valuation allowance in respect of prior
years		-			1,128			-
Taxes in respect of prior years		-			(287	)		(1,400	)
Deferred tax benefit		(1,987	)		622			120
	$	2,179		$	5,013		$	2,216
Domestic	$	3,062		$	2,266		$	852
Foreign		(883	)		2,747			1,364
	$	2,179		$	5,013		$	2,216

k. Uncertain tax positions:

A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits is as follows:

Balance at January 1, 2008	$	845
Increases in tax positions for prior years		212
Decreases in tax positions for prior years		(171	)
Increases in tax positions for current year		365
Balance at December 31, 2008 *)	$	1,251

*) Out of the above unrecognized tax benefits an amount of $ 1,251 would result in a reduction of the company’s effective tax rate, if recognized. The unrecognized tax benefits included an immaterial accrued interest as of December 31, 2008.

l. Tax jurisdictions examination years:

Shamir files income tax returns in multiple tax jurisdictions. Final tax assessments have been received by the Company up to and including the tax year ended December 31, 2006 and by certain subsidiaries, for the years between 2003 – 2007.

F - 39

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 16: – SHAREHOLDERS’ EQUITY

a. Share rights:

Ordinary shares of the Company confer upon their holders the right to receive notice to participate and vote in the general meetings of the Company and the right to receive dividends when declared.

b. Share option plan:

In 2003 and on February 1, 2006, Shamir adopted employee share option plans (“the 2003 Option Plan” and “the 2005 General Share and Incentive Plan”, respectively). Under the 2003 Option Plan, employees and officers of Shamir may be granted options to acquire Ordinary shares. The number of options to acquire Ordinary shares and the related exercise price are determined by the Board of Directors of Shamir and its compensation committee. Grants of options to directors require the approval of Shamir’s shareholders according to the Israeli Companies Law. The 2005 General Share and Incentive Plan provides that 25% of the shares shall vest one year after the date of grant, and the remaining 75% shall vest on a monthly basis, with 1/36 of the remaining shares vesting each month commencing at the end of the first anniversary of the date of grant. According to the 2005 General Share and Incentive Plan, during 2006 the Company could grant 350,000 options to purchase Shamir’s shares and in each following year, the option pool shall increase by an additional 280,000 options. Unless otherwise stated in the relevant award agreement, awards, to the extent not previously exercised, shall terminate forthwith upon the earlier of: (i) the date set forth in the award agreement; and (ii) the expiration of the relevant period in the case of voluntarily liquidation or dissolution of Shamir, or in the events set forth in the 2005 General Share and Incentive Plan; and (iii) the lapse of seven years from the date of grant. The options granted pursuant to the 2003 Option Plan are exercisable for a period of 10 years following the grant date and were fully vested at the grant date. The options that were granted prior to the adoption of the 2005 General Share and Incentive Plan during 2004 and 2005 will vest in four trenches of 25% per year.

On July 31, 2008 the Company’s shareholders approved an amendment to the Company’s 2005 General Share and Incentive Plan to provide that in the event that the Company distributes a cash dividend and the record date for such distribution is subsequent to the date of grant of an award in the form of an option to purchase shares, but prior to its exercise or expiration, the exercise price of each such award will be reduced by the dividend amount per share.

The options outstanding as of December 31, 2008, have been separated into exercise price categories as follows:

Ranges of exercise price	Options outstanding as of December 31, 2008		Weighted average remaining contractual life		Weighted average exercise price		Options exercisable as of December 31, 2008		Weighted average exercise price of exercisable options
$			(Years)		$				$
2.46		167,105		4.75		2.46		167,105		2.46
5.00-7.10		276,000		6.76		5.46		-		-
8.35-9.96		560,000		4.35		9.45		339,827		9.55
10.06-12.19		493,771		3.69		11.60		319,078		11.59
13.76		94,160		3.59		13.76		70,620		13.76
		1,591,036						896,630

F - 40

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 16: – SHAREHOLDERS’ EQUITY (Cont.)

c. Modification of options:

On July 31, 2008 the Company’s shareholders approved an adjustment to the exercise price of the outstanding options, including outstanding options previously granted to directors and external directors in the Company, by reducing the exercise price by $0.243, the dividend per share declared by the Company in January 2008. As a result, Shamir recorded an additional compensation cost in the amount of $ 63 in 2008.

d. Dividend:

On June 27, 2007, Shamir declared a dividend of $ 4,000 ($0.244 per share), which was paid in July 2007.

On January 14, 2008, Shamir declared a dividend of $ 4,000 ($0.243 per share), which was paid in February 2008.

NOTE 17: – TRANSACTIONS WITH RELATED PARTIES

a. Manpower agreement with Kibbutz Shamir (“the Kibbutz”):

On July 19, 2007, the Company entered into a new working service agreement with the Kibbutz which replaced all former engagements. The terms of the new working service agreement are substantially similar to the terms of the agreement from February 2005. The agreement sets the reimbursement rights of the Company for any liabilities that may arise under an imputed employer-employee relationship between the Company and the members of the Kibbutz who provide the services.

On January 18, 2007, the Kibbutz granted an approval to the Company’s subsidiaries, SSOP and Eyal, to employ directly (i.e. not through the working service agreement) local members of the Kibbutz.

Manpower service fees amounted to $ 1,317, $ 1,241 and $ 1,340 for the years ended December 31, 2006, 2007 and 2008, respectively

b. Services from the Kibbutz:

The Company executed a service agreement with the Kibbutz, pursuant to which the Kibbutz provides the Company with services that include catering, security, laundry, switchboard and communications, maintenance, landscaping and trash removal, and payment of local authority taxes. On February 9, 2005, the Company entered into a new agreement with the Kibbutz. Under the new agreement, the fees to be paid will be substantially similar to the amounts paid under the prior agreement. The fee for all of these services except water usage was initially fixed at NIS 92,000 per month. The fee is linked to the consumer price index and reviewed every five years. In the event that the cost to Kibbutz Shamir of providing these services increases or decreases during the final year of the agreement’s five-year cycle as compared to the effective date of the agreement, the service fee shall be adjusted accordingly. If the costs increase or decrease by 30% or more in any particular year during the term of the agreement, the service fee will be adjusted for the following year. If Kibbutz Shamir provides additional services to the Company, the fee shall be adjusted accordingly. The fee for catering services is adjusted continuously based on the actual number of employees using these services.

F - 41

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 17: – TRANSACTIONS WITH RELATED PARTIES (Cont.)

On March 8, 2007, the Company’s shareholders approved a new service agreement between the Kibbutz and SSOP for the period commencing upon the acceptance of the new facility that was built in the Kibbutz for SSOP and ending on February 9, 2010. The facility was delivered to SSOP on November 1, 2007. Pursuant to the terms of such agreement, the Kibbutz provides administrative and maintenance services to SSOP to maintain its facility. SSOP pays the Kibbutz a monthly fee of NIS 25,000 linked to the Consumer Price Index. In the event that the actual cost of services in any year is higher or lower by 30% or more compared to the service fee paid in the preceding calendar year, not taking into account extraordinary expenses not in the ordinary course of business, the service fee for the following year will be adjusted accordingly. The term of the service agreement will be extended automatically for additional periods of five (5) years each unless either of the parties terminates the service agreement by giving a 12-months’ advance notice prior to the scheduled expiration date. The service fee will be adjusted at the end of the initial term of the service agreement and then every five (5) years, assuming that the service agreement is extended, based on the actual cost of services in the year preceding the adjustment date.

On July 19, 2007, following the approval of the Company’s shareholders at their special shareholders meeting, the Company entered into a new additional arrangement with the Kibbutz. Under the new arrangement between the Company and the Kibbutz, the Company and its subsidiaries will be entitled to purchase additional services not covered by the current service agreements, as detailed above. The consideration for a single transaction will be no greater than $ 7 (plus VAT, if required by law), and the aggregate consideration for services purchased by the Company and its subsidiaries during any calendar year will be no greater than $ 300 (plus VAT, if required by law).

Shamir paid fees to the Kibbutz pursuant to the service agreement and for other services amounting to $ 338, $ 466 and $ 573 for the years ended December 31, 2006, 2007 and 2008, respectively.

c. Lease and sub-lease agreement with the Kibbutz:

The Company’s offices, manufacturing, and research and development facilities are located on the premises of the Kibbutz. The facilities are subleased from the Kibbutz, which has a long-term lease on the property from the Israel Lands Administration (the “ILA”). On January 5, 1999, the Company and the Kibbutz signed a sublease agreement, pursuant to which the Kibbutz subleased to the Company the facilities for a period of 20 years beginning on January 1, 1999. On February 9, 2005, the Company entered into an amendment to the sub-lease agreement. The term of the amended agreement was extended from 20 years to 24 years and 11 months. Rental payments under the amended agreement are the same as under the prior agreement. The ILA may cancel the lease under certain circumstances, including if the Kibbutz commences proceedings to disband or liquidate or in the event that the Kibbutz ceases to be a “kibbutz”.

F - 42

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 17: – TRANSACTIONS WITH RELATED PARTIES (Cont.)

On March 8, 2007, the Company and the Kibbutz enter into a lease agreement pursuant to which the Company will lease a facility for SSOP from the Kibbutz until November 30, 2023 commencing on the earlier of the: (i) date of occupancy, or (ii) date of the completion of the construction. On November 1, 2007, such facility was delivered to SSOP by the Kibbutz. The Company is entitled to terminate the lease at any time; provided, however, that the Company has located an alternate tenant and the Kibbutz has given its consent, which consent would not be reasonably withheld. The parcel of land underlying the facility is included in the long-term lease between the Kibbutz and the ILA, pursuant to which the Kibbutz may, with the consent of the ILA, sublease the parcel to a corporation under its control. The consent of the ILA for the lease, though, has not been obtained. In addition, the ILA may, from time to time, change its regulations governing such lease agreement, and these changes could affect the terms of the lease, and may trigger the termination of the lease. Under the lease, the Kibbutz is responsible for any expense resulting from actions of the ILA. The annual rental fees pursuant to the lease are paid quarterly and in amounts equal to 10% of the actual construction cost of the facility, excluding VAT and grants of the Investment Center, as certified by the board of directors of SSOP, but in no event more than $ 500 per annum.

Rental payments amounted to $ 301, $ 326 and $ 747 for the years ended December 31, 2006, 2007 and 2008, respectively.

d. Loan to the Kibbutz:

In accordance with the Company’s sublease agreement with the Kibbutz dated January 5, 1999 (as amended on February 9, 2005), the Company granted a loan of approximately $ 370 to the Kibbutz in several installments in 2004 in order to fund the construction of an extension to the Company’s premises in the Kibbutz. The loan was repaid by December 31, 2008, through deductions of the rental fees the Company pays to the Kibbutz. The loan bore interest at 1.5% per year.

e. Transactions with related parties:

	Year ended December 31,
	2006			2007			2008
Revenues	$	1,109		$	1,615		$	719
Cost of revenues		1,022			886			809
Research and development		130			171			288
Selling and marketing		184			245			175
General and administrative		621			839			1,457
Financial and other income, net		(50	)		(41	)		(1	)

f. Balances with related parties:

	December 31
	2007		2008
Trade receivables	$	475	$	539
Other accounts receivable and prepaid expenses (Note 4)		90		-
Trade payables		75		35
Accrued expenses and other liabilities (Note 11)		230		162

F - 43

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 18: – MAJOR CUSTOMER AND GEOGRAPHIC INFORMATION

a. Shamir manages its business on the basis of one reportable segment. The data is presented in accordance with SFAS No. 131, “Disclosure about Segments of an Enterprise and Related Information”. Total revenues are attributed to geographic areas based on the location of end customers.

The following presents total revenues and long-lived assets for the years ended December 31, 2006, 2007 and 2008 and as of December 31, 2006, 2007 and 2008, respectively:

	2006				2007				2008
	Total revenues		Long-lived assets		Total revenues		Long-lived assets		Total revenues		Long-lived assets
Israel	$	853	$	13,886	$	1,892	$	20,530	$	3,255	$	19,344
United States		30,077		5,007		36,681		5,163		40,796		5,387
Europe		50,747		19,016		63,230		23,914		70,371		21,254
Asia		9,560		-		12,695		-		10,769		-
Others		6,043		568		5,921		520		15,135		5,851
	$	97,280	$	38,477	$	120,419	$	50,127	$	140,326	$	51,836

b. Product lines:

Total revenues from external customers divided on the basis of Shamir’s product lines are as follows:

	Year ended December 31,
	2006		2007		2008
Lenses	$	90,387	$	113,945	$	135,298
Design services		6,893		6,474		5,028
	$	97,280	$	120,419	$	140,326

c. Major customer data as a percentage of total revenues:

Customer A *) 10 % 12.6 %

*) Less than 10%.

F - 44

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 19: – SELECTED SUPPLEMENTARY STATEMENTS OF INCOME DATA

		Year ended December 31,
		2006			2007			2008
a.	Financial and other income (expenses), net
	Financial expenses:
	Interest in respect of long-term loans	$	(805	)	$	(1,319	)	$	(1,417	)
	Interest in respect of short-term loans		(816	)		(818	)		(898	)
	Changes in derivatives fair value		-			-			(81	)
	Foreign currency translation, net		-			-			(136	)
	Other		(631	)		(445	)		(440	)
			(2,252	)		(2,582	)		(2,972	)
	Financial income:
	Income in respect of loans to related parties		48			55			1
	Income in respect of cash and cash equivalents,
	marketable securities and other short-term
	investments		1,577			1,359			609
	Changes in derivatives fair value		60			539			-
	Foreign currency translation, net		163			383			-
	Other		412			177			233
			2,260			2,513			843
	Other expenses, net		(167	)		(170	)		(13	)
	Financial and other expenses, net	$	(159	)	$	(239	)	$	(2,142	)

F - 45

SHAMIR OPTICAL INDUSTRY LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 19: – SELECTED SUPPLEMENTARY STATEMENTS OF INCOME DATA (Cont.)

b. Net earnings per share:

The following table sets forth the computation of basic and diluted net earnings per share:

1. Numerator:

	Year ended December 31,
	2006		2007		2008
Numerator for basic and diluted net
earnings per share -
Net income available to shareholders	$	6,460	$	8,201	$	9,078

2. Denominator (in thousands):

Denominator for basic net earnings per
share -
Weighted average shares - shareholders'
equity	16,257	16,339	16,424
Weighted average number of shares	16,257	16,339	16,424
Effect of dilutive securities:
Add - Employee stock options	291	213	98
	291	213	98
Denominator for diluted net earnings per
share - adjusted weighted average shares	16,548	16,552	16,522

c. Allowance for doubtful accounts:

The changes in the allowance for doubtful accounts for the years ended December 31, 2006, 2007 and 2008 are as follows:

	Year ended December 31,
	2006			2007			2008
Balance at the beginning of the year	$	474		$	1,053		$	2,140
Doubtful accounts provision		553			1,096			451
Bad-debts written-off		(20	)		(167	)		(113	)
Foreign currency translation adjustment		46			158			(412	)
Balance at the end of the year	$	1,053		$	2,140		$	2,066

F - 46

SIGNATURES

        The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

SHAMIR OPTICAL INDUSTRY LTD.


By: /s/ Eyal Hayardeny
——————————————
Eyal Hayardeny
Chief Executive Officer

By: /s/ Yagen Moshe
——————————————
Yagen Moshe
Chief Financial Officer

Date: June 18, 2009

EXHIBIT INDEX

Exhibit Number	Description
1.1	Articles of Association of Shamir (incorporated by reference to Exhibit 3.1 to our registration statement on Form S-8 (File 333-137628), filed with the SEC on September 28, 2006)

4.1 Lease Agreement dated December 1, 2003, between Kibbutz Eyal and Eyal Optical Industries (1995) Ltd. (incorporated by reference to Exhibit 10.1 to our registration statement on Form F-1 (File 333-122736), filed with the SEC on February 11, 2005)

4.2 Working Service Agreement dated February 9, 2005, between Shamir and Kibbutz Shamir (incorporated by reference to Exhibit 10.2 to our registration statement on Form F-1 (File 333-122736), filed with the SEC on February 11, 2005)

4.3 Service Agreement dated February 9, 2005, between Shamir and Kibbutz Shamir (incorporated by reference to Exhibit 10.3 to our registration statement on Form F-1 (File 333-122736), filed with the SEC on February 11, 2005)

4.4 Lease Agreement dated December 27, 1990, between Kibbutz Shamir and the Israel Lands Administration (incorporated by reference to Exhibit 10.4 to our registration statement on Form F-1 (File 333-122736), filed with the SEC on February 11, 2005)

4.5 Sublease Agreement dated January 1999 between Shamir and Kibbutz Shamir, including amendment (incorporated by reference to Exhibit 10.5 to our registration statement on Form F-1 (File 333-122736), filed with the SEC on February 11, 2005)

4.6 Loan Agreement between Shamir and Kibbutz Shamir (incorporated by reference to Exhibit 10.6 to our registration statement on Form F-1 (File 333-122736), filed with the SEC on February 11, 2005)

4.7 Shareholders' Agreement dated February 9, 2005,among the shareholders of Shamir (incorporated by reference to Exhibit 10.7 to our registration statement on Form F-1 (File 333-122736), filed with the SEC on February 11, 2005)

4.8 Registration Rights Agreement dated February 7, 2005, between Shamir and certain of its shareholders (incorporated by reference to Exhibit 10.8 to our registration statement on Form F-1 (File 333-122736), filed with the SEC on February 11, 2005)

4.9 Lease Agreement dated March 8, 2007, between Shamir and Kibbutz Shamir (English translation) (incorporated by reference to Exhibit 4.9 to our annual report on Form 20-F, filed with the SEC on June 26, 2007)

4.10 Service Agreement dated March 8, 2007, between Shamir Special Optical Products Ltd. and Kibbutz Shamir (English translation) (incorporated by reference to Exhibit 4.10 to our annual report on Form 20-F, filed with the SEC on June 26, 2007).

4.11 Israeli Plan For The Allotment of Shares/Options For 2003 (English translation) (incorporated by reference to Exhibit 99.1 to our registration statement on Form S-8 (File No. 333-137628), filed with the SEC on September 28, 2006)

4.12 Summary of Stock Option Grant dated June 5, 2000 (incorporated by reference to Exhibit 99.2 to our registration statement on Form S-8 (File 333-137628), filed with the SEC on September 28, 2006)

4.13* 2005 General Share and Incentive Plan, as amended

4.14 Working Service Agreement dated July 19, 2007, between Shamir and Kibbutz Shamir (English translation) (incorporated by reference to Exhibit 4.14 to our annual report on Form 20-F, filed with the SEC on June 28, 2008)

4.15* Agreement with Mr. Oppenheimer dated June 30, 2008 (English translation)

8.1* Table of subsidiaries of Shamir

11.1 Code of Ethics of Shamir (as amended) (incorporated by reference to Exhibit 11 to our annual report on Form 20-F, filed with the SEC on June 28, 2005, and on March 19, 2009)

12.1* Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

12.2* Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

13.1* Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

15.1* Consent of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global

        * filed herewith.

EX-4.13

     
     
     
     
     
     
     
     20-F

EX-4.15

Exhibit 4.15

AGREEMENT

made and entered into on the 30 day of June, 2008 (the “Effective Date”), by and among Mr. Michael Oppenheimer, Israeli ID Number 005026042 (the “Seller”), and Shamir Optical Industry Ltd., a company incorporated under the laws of the State of Israel (the “Purchaser”), and Altra Trading GmbH, a company incorporated under the laws of Germany (the “Company”).

WHEREAS the Seller is a holder of (a) 49% the Company’s issued share capital (€1,431,617.20 on the Effective Date); (b) one (1) share of Altra Optik Sanayi Ve Ticaret Anonim Sirketi, a subsidiary of the Company incorporated in Turkey (“Altra Turkey”); and (c) €21,500 of the issued capital of Shamir Portugal, LDA., a subsidiary of the Company registered in Portugal (“Shamir Portugal”, and together with Altra Turkey the “Subsidiaries”) (all together: the “Shares”); and

WHEREAS the Purchaser is a holder of 51% of the Company's issued share capital; and

WHEREAS the Seller is interested in selling the Shares and the Purchaser desires to purchase the Shares from the Seller, all on the terms and conditions set forth hereinafter in this Agreement; and

WHEREAS the Seller and/ Hanson Valley Inc., a company incorporated in the British Virgin Islands and wholly owned by the Seller, has granted the Company shareholders loans from time to time up to the total aggregate amount of €4,830,375 (four million eight hundred thirty thousand three hundred seventy-five Euros) (the “Loans”), all bearing annual interest of 4.9%;

NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

1. Sale of Shares.

1.1. Subject and according to the terms and conditions of this Agreement, the Seller hereby to sell to the Purchaser and the Purchaser hereby purchases from the Seller on an “as is” basis the Shares against the payment detailed in Section 1.2 of this Agreement (the “Purchase Price”), free and clear of all liens, mortgages, pledges, and obligations of any kind whatsoever.

1.2. On June 30, 2011, the Purchaser shall pay the Seller (along with the last repayment of the Loans, as detailed in Section 2.1.5 below) as follows:

1.2.1 A sum of(euro)23,000; and

1.2.2 An amount equivalent to 20% of the total Net Profit of the Company for the fiscal years ending on 31 December, 2008, 2009, and 2010, according to the audited consolidated financial statements prepared in accordance with the Company’s customary practices as approved by the Company.

“Net Profit” shall mean the Company’s consolidated net profit as determined in its audited consolidated financial statement approved by the Company.

1.3. Notwithstanding the provisions of Section 1.2.2 above, the parties hereto agree that the total aggregate payment detailed in Section 1.2.2 shall not in any event exceed €500,000 (E.g.: if the total net profits for the three years determined above is €5,000,000, the payment shall be €500,000).

1.4. The Seller hereby releases, subject to receipt of the consideration detailed in Section 1.2 above, the Company and the Purchaser (and their shareholders, officers, directors, employees, agents, and representatives, respectively) forever from any and all liability for claims, damages, charges, interest payments, suits, actions, demands and payments whatsoever directly or indirectly connected with the Shares. The Purchaser undertakes to ensure replacement or deletion of the Seller and/or any personal or other undertaking existing in his name regarding the Company or its Subsidiaries with respect to the Shares.

2. Repayment of Loans.

2.1. The Company shall repay the Loans (which it received over the years as a shareholder, as detailed above), to the Seller or to Hanson Valley Inc., as the case may be, as follows:

2.1.1. At the time of Closing, as defined in Section 3.1 hereinafter, the Company shall pay the Seller the sum of €285,232 (two hundred eighty-five thousand two hundred thirty-two Euros), in respect of interest accrued on the Loans up to the time of Closing;

2.1.2. At the time of Closing the Company shall pay the Seller part of the Loans in a sum of €1,230,594 (one million two hundred thirty thousand five hundred ninety-four Euros).

2.1.3. One (1) year after the time of Closing (on June 30, 2009) the Company shall pay the Seller an additional part of the Loans in a sum of €1,207,594 (one million two hundred seven thousand five hundred ninety-four Euros).

2.1.4. Two (2) years after the time of Closing (on June 30, 2010) the Company shall pay the Seller an additional part of the Loans in a sum of €1,207,594 (one million two hundred seven thousand five hundred ninety-four Euros).

2.1.5. Three (3) years after the time of Closing (on June 30, 2011) the Company shall pay the Seller an additional part of the Loans in a sum of €1,184,594 (one million one hundred eighty-four thousand five hundred ninety-four Euros) (full repayment of the Loans).

2.2. It is hereby agreed among the parties that at the time of payment of each one of the payments specified in Sections 2.1.3-2.1.5 above, the Company shall pay the Seller the annual interest (4.9%) accrued in respect of the balance of the principal of the Loans.

2.3. To avoid any doubt, any delay in the times determined in Sections 2.1.3-2.1.5 above in payment of the Loans and/or the Interest, shall bear interest at the annual rate of 4.9%.

2.4. Notwithstanding the above, the Company may pay the Seller any part of the remainder of the Loans time and/or their interest with respect thereto, prior to the times determined in Section 2.1 above, at its sole discretion, after giving prior written notice of seven (7) days.

2.5. The Purchaser shall guarantee the Company’s full repayment of the Loans to the Seller.

2.6. It is agreed among the parties that to the extend that the Purchaser holds less than 51% of the Company’s issued share capital, the balance of the Loans which has not yet been paid and the interest in respect thereof, shall be immediately payable to the Seller by the Company.

2.7. Subject to the receipt of the Loans and interest thereon in full, the Seller hereby forever releases the Company and the Purchaser (and their shareholders, officers, directors, employees, agents, and representatives, respectively) from any and all liability for claims, damages, charges, interest payments, suits, actions, demands and payments whatsoever directly or indirectly connected with the Loans and/or the interest thereon. The Purchaser undertakes to ensure the replacement and/or deletion of the Seller from any personal and/or other guarantees existing in his in respect of the Company and/or its Subsidiaries in respect of the Loans.

2

3. Time of Closing and Closing Activities.

3.1. Time of Closing. The closing of the transactions specified hereinafter shall take place at the offices of the Purchaser, on June 30, 2008 (the “Time of Closing”).

3.2. Closing Transactions. At the Time of Closing, the activities detailed hereinafter shall take place, shall be considered as taking place simultaneously, and no activity shall be considered to have been completed and no document shall be considered delivered until all these activities have been completed and all the required documents delivered, as specified hereinafter:

3.2.1. The Seller and the Purchaser shall sign a valid share transfer deed in respect of transfer of the shares in the Company to the Purchaser, in the form attached to this Agreement as Schedule 3.2.1.

3.2.2. The Seller and the Purchaser shall sign a valid share transfer deed in respect of transfer of the Sellers shares in Company’s Subsidiaries to the Purchaser, in the form attached to this Agreement as Schedule 3.2.2.

3.2.3. The Seller shall submit letters of resignation from the Board of Directors of Altra Turkey and from the Board of Directors of the Company, in the form attached to this Agreement as Schedule 3.2.3.

3.2.4. The Purchaser shall submit to the Seller a duly signed guarantee for the repayment of the Loans by the Company, in the form attached to this Agreement as Schedule 3.2.4.

3.2.5. The Seller and the consulting company owned by it shall sign a Letter of Waiver and Release, in the form attached hereto as Schedule 3.2.5.

3.2.6. The Company shall furnish the Seller documentation attesting to transfer to the bank account to which the Purchaser instructed that the payments specified in Sections 2.1.1-2.1.2 above be transferred.

4. Undertakings.

The parties to this Agreement undertake to sign any document and to take any reasonable measure required and insofar as required for realizing the transfer of the Shares, ,to register transfer of the Shares in the name of the Purchaser, all in accordance with the law and/or applicable legislation.

5. Representations and Undertakings of the Parties.

5.1. Each one of the parties to this Agreement hereby represents and undertakes to the other party, that all actions on its part necessary for the authorization, signature, delivery and implementation of this Agreement and the activities specified herein have indeed been done, and that this Agreement shall constitute the valid and legally binding obligations of each one of the parties.

5.2. Seller hereby represents and undertakes to the Purchaser that he is the sole lawful owner of the Shares and that the Shares are free and clear of any liens, claims, pledges, mortgages, charges, encumbrances, rights of first refusal or preemptive rights, or any other rights of any third party.

5.3. The parties hereto acknowledge and agree that no representations and undertakings are made with respect to the Shares, the repayment of the Loans and/or the activities specified in this Agreement, save for the representations and undertakings specified in this Section 5.

6. Miscellaneous.

6.1. Taxes. Each party will the full payment of the taxes applicable to it according to any law and regulation. In addition, each party shall submit, on its own account, all the tax returns required and any other documentation regarding all the taxes and/or levies that each party must bear according to the terms of this Agreement, to the extent required according to the law and applicable legislation, insofar as applicable. Without derogating from the above, to the extent any payment to the Seller according to Sections 1 and 2 of this Agreement is subject to a withholding tax at source liability according to the applicable law, the Purchaser shall address the Seller in order to issue it a confirmation of withholding tax at source, insofar as required, and shall act according to the confirmation.

3

6.2. Successors and Assigns. Except as otherwise warranted herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any Shares). Neither party may transfer this Agreement or any one of the rights or obligations hereunder without the prior written consent of the other parties. Nothing in this Agreement, express or implied, is intended to confer upon any third party, other than the parties mentioned above in this Agreement, or their respective successors and assigns, any rights, remedies, obligations or liabilities unless warranted specifically in this Agreement.

6.3. Governing Law and Jurisdiction. This Agreement shall be construed according to the laws of the State of Israel. Each of the parties hereto irrevocably consents to the sole and exclusive jurisdiction and venue of the competent courts of Tel Aviv, in connection with any matter based on or emanating from this Agreement or the matters contemplated herein.

6.4. Titles and Captions. The titles and captions used in this Agreement are used for convenience in reading only, and shall not alter the interpretation of this Agreement.

6.5. Amendments and Waivers. Any term of this Agreement may be amended or waived (either in future or retroactively, either generally or in a specific instance) only with the written consent of all of the parties hereto.

6.6. Nullification and/or Unenforceability. The parties declare that their joint intention is that implementation of all their undertakings according to this Agreement shall be subject to and in accordance with the provisions of any law. In the event that it becomes clear that any one of the provisions of this Agreement is void or unlawful for any reason, each party may notify the other that notwithstanding this fact, the Agreement shall be deemed wholly valid, except for the void, unlawful or unenforceable provision, as if this provision were never included, all on condition that the said provision is not a material provision of this contract.

6.7. Entire Agreement. This Agreement, the schedules and the documents referred to herein constitute the entire agreement among the parties and no party shall be liable or bound to any other party in any manner by any undertakings or representations, except for the undertakings and representations specifically set out in this Agreement.

        IN WITNESS WHEREOF, the parties have executed this Share Purchase Agreement on the Effective Date above, as follows:

______________________________________
Shamir Optical Industry Ltd. ______________________________________
Mr. Michael Oppenheimer

Name:

Title:

______________________________________
Altra Trading GmbH

Name:

Title:

4

Schedule 3.2.1

SHARE TRANSFER DEED

JUNE 30, 2008

        For consideration received, MR. MICHAEL OPPENHEIMER (the “Transferor”) transfers to SHAMIR OPTICAL INDUSTRY LTD. (the “Transferee”), 49% of the registered capital of ALTRA TRADING GMBH, a German private company (the “Company”), to be held by the Transferee, its executors, administrators, and assigns, subject to the several conditions on which the Transferor held the Company’s shares at the time this document was signed; and the Transferee agrees to accept the Company’s shares from the Transferor on such terms.

        IN WITNESS WHEREOF, the Transferor and the Transferee have executed this Share Transfer Deed as of the date first above written.

TRANSFEREE:	TRANSFEROR:
SHAMIR OPTICAL INDUSTRY LTD. By: _________________	MR. MICHAEL OPPENHEIMER _________________

Name:

Title:

5

Schedule 3.2.2

SHARE TRANSFER DEED

JUNE 30, 2008

        For consideration received, MR. MICHAEL OPPENHEIMER (the “Transferor”) transfers to SHAMIR OPTICAL INDUSTRY LTD. (the “Transferee”), one (1) share of ALTRA OPTIK SANAYI VE TICARET ANONIM SIRKETI, a Turkish private company (the “Company”), to be held by the Transferee, its executors, administrators, and assigns, subject to the several conditions on which the Transferor held the Company’s shares at the time this document was signed; and the Transferee agrees to accept the Company’s shares from the Transferor on such terms.

        IN WITNESS WHEREOF, the Transferor and the Transferee have executed this Share Transfer Deed as of the date first above written.

TRANSFEREE:	TRANSFEROR:
SHAMIR OPTICAL INDUSTRY LTD. By: _________________	MR. MICHAEL OPPENHEIMER _________________

Name:

Title:

6

Schedule 3.2.2

SHARE TRANSFER DEED

JUNE 30, 2008

        For consideration received, MR. MICHAEL OPPENHEIMER (the “Transferor”) transfers to SHAMIR OPTICAL INDUSTRY LTD. (the “Transferee”), Euro 21,500 of the registered capital of SHAMIR PORTUGAL, LDA., a private company incorporated under the laws of Portugal (the “Company”), to be held by the Transferee, its executors, administrators, and assigns, subject to the several conditions on which the Transferor held the Company’s shares at the time this document was signed; and the Transferee agrees to accept the Company’s shares from the Transferor on such terms.

        IN WITNESS WHEREOF, the Transferor and the Transferee have executed this Share Transfer Deed as of the date first above written.

TRANSFEREE:	TRANSFEROR:
SHAMIR OPTICAL INDUSTRY LTD. By: _________________	MR. MICHAEL OPPENHEIMER _________________

Name:

Title:

7

Schedule 3.2.3

June 30, 2008

To:

ALTRA OPTIK SANAYI VE TICARET ANONIM SIRKETI (the “Company”)

Re: Letter of Resignation

        I, the undersigned, hereby submit to the Company my resignation from its board of directors. My resignation shall become effective as of the date hereof.

        I hereby release the Company and its directors, officers, employees and representatives from any and all actions, debts, claims, counterclaims, demands, liabilities, damages, causes of action, costs, expenses, and compensation of every kind and nature whatsoever, in law or in equity, which I or anyone on my behalf now have or at any time heretofore have had against the Company including, without limitation, any claims related in any way to matters that might arise out of my prior relationship with the Company and the termination hereof.

Yours sincerely,

Michael Oppenheimer

8

Schedule 3.2.4

June 30, 2008

To:

Mr. Michael Oppenheimer

Dear Sir,

Re: Guarantee to Repayment of Loans

        We, Shamir Optical Industry Ltd. (“Shamir”), pursuant the terms and conditions of the Share Purchase Agreement dated June __, 2008 (the “Share Purchase Agreement”), by and between you, Shamir and Altra Trading GmbH (the “Company”), hereby undertake as follows:

1. To procure the repayment by the Company to you of the shareholders loans you have granted the Company from time to time in the total aggregate amount of Euro 4,996,000 (four million and nine hundred and ninety six thousand), all bearing interest of 4.9% (the “Loans”), as and when they properly fall due according to the terms and conditions of the Share Purchase Agreement.

2. In the event that the Company shall not repay the Loans as set forth in the Share Purchase Agreement, Shamir irrevocably undertakes to pay you any due to you at that time according to the instructions of the Share Purchase Agreement, but not exceeding the total unpaid amount of the Loans.

3. Payment(s) will be effected within seven (7) business days (“business days” being days on which banks are open for business in Israel) upon receipt of your first written demand at our offices in Kibbutz Shamir, and will be made to an account notified to us in said written demand.

4. Our obligations under this guarantee will immediate terminate upon the full repayment of the Loans by the Company or by us. After such date this guarantee shall become null and void.

5. In case of partial repayment(s) our obligation under this guarantee shall be reduced according to the paid amount(s).

6. Please return this guarantee letter to us upon the full repayment of the Loans.

7. This guarantee is subject to shall be governed by and construed under the laws of the State of Israel and the exclusive jurisdiction and venue of the competent courts of Tel Aviv.

Sincerely,

Shamir Optical Industry Ltd.

9

Schedule 3.2.5

June 30, 2008

To:

Shamir Optical Industry Ltd.

Dear Sirs,

Re: Letter of Waiver and Release

We, the undersigned, hereby, collectively and individually, acknowledge, declare and confirm the following:

1. We sign this document of our free will and after being made fully aware of all our rights. We understand that this document is a legally binding document. Prior to signing this document, we have read it carefully and we have consulted with such experts, including legal counsel, as we have deemed appropriate.

2. We hereby acknowledge and agree that we are not entitled to any consideration and/or compensation and/or right or benefit of any kind whatsoever from Shamir Optical Industry Ltd. (the “Company”), and/or its fully or partly owned subsidiaries (the “Subsidiaries”), on any grounds whatsoever including, without limitation, pursuant to the Service Agreement dated August 5, 2002, as amended from time to time (“Service Agreement”), except of the consideration in accordance with the Share Purchase Agreement between the parties thereto, dated June___, 2008 (“Share Purchase Agreement”).

3. Without derogating from the above, and to the extent applicable, we do not have any claim against or demand upon the Company and/or its Subsidiaries (and their respective shareholders, officers, directors, employees, agents, representatives and successors), and we hereby release the Company and/or its Subsidiaries (and their respective shareholders, officers, directors, employees, agents, representatives and successors) from any and all obligations towards us arising out of any agreement or custom or on by virtue of any other grounds. Neither we nor any person acting in our name or as our representative shall in the future make any claim against or demand the Company and/or its Subsidiaries (and their respective shareholders, officers, directors, employees, agents, representatives and successors) arising out of or in connection with any matter related to the Service Agreement.

4. We shall not commence, participate in or voluntarily provide assistance in connection with any grievance, action, suit or proceeding against the Company and/or its Subsidiaries before any court, administrative agency or other tribunal, nor shall directly or indirectly encourage any other person to engage in any such activities.

5. We are fully aware of all of our rights and we acknowledge, declare, confirm and agree to all that is stated above.

____________________________________
Lenshouse Ltd. ____________________________________
Mr. Michael Oppenheimer

10

EX-8.1

Exhibit 8.1

Table of subsidiaries of Shamir Optical Industry Ltd. (“Shamir”)

Name	Jurisdiction	Active/ Not active
Eyal Optical Industries (95) Ltd.	Israel	Active
Eyal Optics Holdings A.C.S. Ltd.	Israel	Not active
E. S. P. Optics Ltd.	Israel	Not active
Aspect Optics Ltd	Israel	Not active
Shamir Special Optical Products Ltd.	Israel	Active
Shamir Israel Optical Marketing Ltd.	Israel	Active
Shamir USA	USA	Active
Shamir Insight, Inc.	USA	Active
Shamir Optic GmbH	Germany	Active
Inray Ltd.	Israel	Active
Shamir Or Ltd.	Israel	Active
Interoptic S.A.R.L.	France	Active
Shamir France S.A.R.L.	France	Active
Shamir Optical Espana S.L.	Spain	Active
Shamir Portugal, LDA.	Portugal	Active
Shamir Uk Limited	UK	Active
Cambridge Optical Group Limited	UK	Not active
Altra Optik Sanayi ve Ticaret A.S.	Turkey	Active
Centro Integral Optico S.A. de C.V.	Mexico	Active
Shalens S.A. de C.V.	Mexico	Active
Spherical Optics (Pty) Ltd.	South Africa	Active

EX-12.1

Exhibit 12.1

CERTIFICATION

I, Eyal Hayardeny, certify that:

1.     I have reviewed this annual report on Form 20-F of Shamir Optical Industry Ltd.;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

4.     The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-115(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

(a)        Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)        Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)        Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)        Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

5.     The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

a.        All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

b.        Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Date: June 18, 2009

/s/ Eyal Hayardeny
——————————————
Eyal Hayardeny
Chief Executive Officer

EX-12.2

Exhibit 12.2

CERTIFICATION

I, Yagen Moshe, certify that:

1.     I have reviewed this annual report on Form 20-F of Shamir Optical Industry Ltd.;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

4.     The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-115(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

(a)        Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)        Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)        Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)        Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

5.     The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

a.        All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

b.        Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Date: June 18, 2009

/s/ Yagen Moshe
——————————————
Yagen Moshe
Chief Financial Officer

EX-13.1

Exhibit 13.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

        In connection with the Form 20-F annual report of Shamir Optical Industry Ltd. (the “Company”) for the period ending December 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “annual report”), each of the undersigned officers of the Company certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of such officer’s knowledge and belief, that:

1.     the annual report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.     the information contained in the annual report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 18, 2009

/s/ Eyal Hayardeny
——————————————
Eyal Hayardeny
Chief Executive Officer

/s/ Yagen Moshe
——————————————
Yagen Moshe
Chief Financial Officer

EX-15.1

Exhibit 15.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements (Form S-8 Registration Nos. 333-137628, 333-145945 and 333-153396) pertaining to the Israeli Plan for the Allotment of Shares/Options for 2003, Stock Option Grant dated June 5, 2000, and 2005 General Share and Incentive Plan of Shamir Optical industry Ltd. (“Shamir”), of our report dated June 18, 2009, with respect to the consolidated financial statements of Shamir and its subsidiaries, included in this Annual Report (Form 20-F) for the year ended December 31, 2008.

Tel-Aviv, Israel	KOST, FORER, GABBAY and KASIERER
June 18, 2009	A member of Ernst & Young Global